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The diacylglycerol lipases (DAGL α and β) are key enzymes in the biosynthesis of 
2-AG, the major endocannabinoid (eCB) in the brain. 2-AG acts on CB1 and/or CB2 
receptors and DAGL-dependent eCB signalling regulates a large number of 
responses including axonal growth during development, as well as neurogenesis and 
retrograde synaptic plasticity in the adult. The enzymes also play a major role in 
driving pathogenic inflammatory responses via a DAGL/MAGL pathway that 
generates arachidonic acid as a precursor to prostaglandin synthesis. DAGL 
antagonists are being developed as novel therapeutics based on their ability to 
regulate eCB-mediated signalling and/or inflammatory responses, but the 
mechanisms underlying the regulation of these enzymes is poorly understood.  
 
The DAGLs appear to display ‘on-demand’ synthesis, generating increasing amounts 
of 2-AG in response to cellular messengers. Using a bioinformatics approach, we 
have postulated that phosphorylation is key mechanism for regulation of DAGL 
function. We overexpressed each enzyme in U2OS cells that harbour the Tango 
assay system. We showed the transgenic DAGLs to be expressed at the membrane, 
and DAGLα to be active using surrogate substrates. We measured an eCB-dependent 
CB1 response in the Tango assay, with evidence for kinase activation-dependent 
eCB signalling, but only a portion of this response appeared to be DAGL-dependent. 
As a result, we are pursuing a genetic strategy to systematically ‘switch off’ 
endogenous eCB production. We first targeted the DAGLs using the CRISPR/Cas9 
system, using both wild-type and nickase Cas9. Our next strategy will be to knock-
out other eCB-producing enzymes in these cells to tease out which enzymes are 
resulting in the eCB-CB1 activation in the Tango assay. This will also provide us 
with a ‘parent’ cell line to support future mutagenesis studies to understand which (if 
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CHAPTER 1. INTRODUCTION 
 
1.1 History of Endocannabinoid Signalling 
 
The Cannabis genus of flowering plants mainly comprises the sativa and indica 
species. Indigenous to Central and South Asia, cannabis has been widely used 
recreationally and therapeutically for millennia, with the earliest reference to its 
potential as a medicine being around 2700 BC, in the pharmacopoeia of the Chinese 
emperor, Shennong also known as the ‘God of Chinese herbal medicine’ (Russo et 
al., 2008). Like very many other herbs, it has been used medically for a wide variety 
of diseases, especially throughout Asia and the Middle East, as well as a pleasure 
inducing drug. Cannabis can induce altered perception, euphoria, hallucination and 
enhanced appetite in humans, as well as reduced spontaneous motor activity, 
immobility, analgesia and  impairment of short-term memory (Sugiura et al., 2006). 
In Victorian times, it was used to promote uterine contractions in childbirth and as a 
sedative to induce sleep (Di Marzo, 2006). However, the first time the therapeutic 
effect of cannabis was assessed scientifically was by William O’Shaughnessy, an 
Irish physician who established his reputation while working in Calcutta by 
successfully treating tetanus and other convulsive disorders with a local preparation 
called ‘Hemp Resin’ and inevitably brought cannabis as a drug to the western world 
(O'Shaughnessy, 1843).   
 
In the years that followed, the active ingredients of the cannabis plant were 
discovered, with pharmacological and pharmaceutical efforts beginning in the mid- 
to late-20th century (Di Marzo, 2006) and the potential therapeutic benefit of 
cannabis has received continued interest. Although efficacy varies substantially for 
different indications, the best evidence for the benefit of cannabis therapeutically is 
for use in painful HIV-associated sensory neuropathy (Phillips et al., 2010), chronic 
pain (Martin-Sanchez et al., 2009), chemotherapy-induced nausea and vomiting 
(Machado Rocha et al., 2008; Flachenecker, 2013) and spasms in patients with 
multiple sclerosis (Flachenecker, 2013). Non-psychoactive substances of cannabis 
have also been examined for their therapeutic use. For example, cannabidiol (CBD) 
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is another constituent of cannabis plants may be a useful treatment of epilepsy and 
other neuropsychiatric disorders (Devinsky et al., 2014). Today, cannabis is the most 
commonly used drug of abuse; over 2 million people in the UK smoke cannabis and 
half of all 16 to 29 year olds have tried it at least once (Global Drug Survey, 2015). 
 
 
1.2 The Endocannabinoid System 
 
Discovery of the Receptors 
There was huge growth in the field of endocannabinoid (eCB) research that began 
with the identification of the receptors specific for the active component of cannabis. 
The mechanism of action of the plant Cannabis sativa was realised through the 
initial purification and characterisation of its active principles. The major 
psychoactive component of cannabis is Δ9-tetrahydrocannabiniol (Δ9-THC) 
(Matsuda et al., 1990; Munro et al., 1993). C. sativa contains much higher 
concentrations than indica and thus sativa strains often have more psychotropic 
effects (Watson et al., 2000). While the discovery of other plant substances like 
morphine were already well established, the identification Δ9-THC remained elusive 
until the 1960s, when the isolation and structure of this chemical compound was first 
reported (Gaoni & Mechoulam, 1964).  
 
Initial binding experiments using Δ9-THC or its natural analogues were unsuccessful 
due to the highly lipophillic properties of cannabinoids (CBs).  New classes of potent 
and selective synthetic THC analogues were developed, such as HU-210 (Figure 1.1)  
(Mechoulam et al., 1990). Labelling of HU-210 to generate [3H] HU-245, alongside 
prior development of the highly potent bi-cyclic CP-55,940 (Pfizer in 1974), led to 
the pharmacological identification of CB-sensitive sites in the brain. These 
investigations were carried out in 1988 by Howlett’s group using  radio-labelled CP-
55,940 which allowed the group to identify specific THC binding sites in cortical 
membrane preparations from rat brain (Figure 1.1) (Devane et al., 1988). Subsequent 
qualitative and quantitative radioligand-binding studies revealed the distribution of 
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CB receptors in the brain, with dense binding of [3H] CP 55,940 within the globus 
pallidus, substantia nigra and striatum of the basal ganglia, the cerebellum, the 
dentate gyrus of the hippocampus, as well as the cerebral cortex (Herkenham et al., 
1990).  
 
These discoveries were quickly followed by the molecular identification of the CB 
receptors from orphan G protein-coupled receptors (GPCRs). These 7-
transmembrane (TM) receptors were activated in response to Δ9-THC and signalled 
through the Bordetella pertussis toxin-sensitive Gi/o protein and subsequent 
inhibition of adenylate cyclase (Howlett et al., 1986). Following a report on cDNA 
from a rat brain library encoding a CB receptor, the first human CB receptor was 
discovered in 1990, consisting of 472 amino acids (Matsuda et al., 1990). The 
second was in 1993, when a second CB receptor of 360 amino acids was identified in 
human promyelocytic leukemia cell line, HL60. Rat or human CB receptor clones 
were able to hybridise with mRNA in undifferentiated HL60 cells and in those that 
had been differentiated into granulocytes and macrophages (Munro et al., 1993). 
These receptors were subsequently termed cannabinoid receptor 1 (CB1) and 
cannabinoid receptor 2 (CB2) respectively, with 48% similarity between the two 
receptors (68% identity for the TM domains) (Howlett, 2002). Phylogenetic analysis 
of the relationship of vertebrate CB receptors with other GPRCRs revealed a close 
relationship between the two CB receptors, which originated from a gene duplication 
event from a common ancestor (Elphick & Egertova, 2001). 
 
In 1999, the first CB1 knockout (KO) mouse was generated, where mutant mice 
were largely unresponsive to CB drugs. From this, the CB1 receptor was 
demonstrated to be the mediator of analgesia, hypotension and hypothermia as well 
as having an involvement in the motivational aspects of opiates (Ledent et al., 1999); 
making it an attractive target for many disease implications. The CB1 receptor is 
highly expressed throughout the mammalian nervous system, but it is also found in 
some peripheral organs such as the lungs, small intestine and reproductive machinery 
(Galiegue et al., 1995; Sugiura et al., 2002). The generation of an antibody for the 
intracellular C-terminal tail of CB1 led to immunohistochemical validation of CB1 
receptor localisation. This confirmed its expression in the olfactory system, 
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cerebellum, neocortex, hippocampus and basal ganglion and was mainly found to be 
localised in nerve fibre systems and axon terminals (Egertova & Elphick, 2000). 
CB1 is also expressed in a number of non-CNS neuronal tissues, including the dorsal 
root ganglion cells and the neuromuscular junction (Howlett et al., 2002). 
 
The creation of a CB2 receptor KO mouse followed shortly after the CB1 KO model 
(Buckley et al., 2000) and CB2 was found to be mainly expressed in immune cells,  
such as in the spleen, tonsil and lymph nodes (Munro et al., 1993; Galiegue et al., 
1995; Van Sickle et al., 2005). The initial dogma that the CB2 receptor does not 
have a role in the brain has been revised based on more recent reports showing the 
CB2 receptor to be involved in neural stem proliferation in cell culture and in the 














Figure 1.1 Chemical structure of plant-derived and synthetic cannabinoid 
receptor agonists which activate both CB1 and CB2 receptors 
Even though cannabis had been used medically for 1000s of years, it wasn’t until the 
1960s that is major active component of cannabis, Δ9-THC was purified and 
characterised. THC analogues were subsequently developed due to the hydrophobic 
nature of Δ9-THC, such as HU-210. Labelling of HU-210 to generate [3H]HU-245, 
and subsequent development of the bi-cyclic cannabinoid CP-55,940 (Pfizer) led to 
the pharmacological identification of the specific cannabinoid binding sites in the 
brain, CB1 and CB2. Neither of the synthetic compounds is more selective for one 
type of cannabinoid receptor over the other.  
 




Discovery of the Endocannabinoids 
The discovery of the CB receptors in the 1990s implied the existence of natural 
ligands in the body, thereby initiating a quest to identify the ‘endocannabinoids’ 
(eCBs) (Figure 1.2). The first to be identified was the lipid N-arachidonyl 
ethanolamine, also known as anandamide based on the Sanskrit word ananda 
meaning ‘bliss’. Because of the lipophillic nature of the chemical constituents of 
cannabis plants (phytocannabinoids), it was argued that lipid-soluble fractions of the 
brain should contain the eCB molecule, which led to the chemical identification of 
anandamide. Devane et al. (1992) tested the ability of fractionated organic solvent 
extracts from porcine brain to displace a radiolabelled probe (HU-243) from rat 
synaptosomal membranes. This enabled them to isolate and identify the first putative 
eCB. Anandamide also demonstrated cannabimimetic properties in isolated mouse 
vas deferens twitch assay in a dose-dependent manner (Devane et al., 1992). This 
group also demonstrated that anandamide can elicit other properties associated with 
cannabis, such as spontaneous motor activities, immobility, hypothermia and 
analgesia when administered to mice.  
 
However, the role of anandamide as an eCB had a few remaining issues. For 
example, anandamide is a partial agonist at the two CB receptors (unusual for an 
endogenous ligand) and is found at relatively low concentrations in the brain 
(Sugiura et al., 2002; Pertwee et al., 2010). Synthetic pathways (described below) 
were not able to generate sufficient amounts of anandamide, as precursor 
concentrations are also low (Sugiura et al., 2002). Moreover, anandamide did not 
fully recapitulate the behavioural effects of Δ9-THC (Smith et al., 1994). Therefore, 
the existence of a second eCB was postulated.  
 
Soon after the discovery of anandamide, another derivative of arachidonic acid (AA) 
was described as an eCB and this was 2-arachidonoylglycerol (2-AG) (Figure 1.2). 
2-AG is generated by the rapid hydrolysis of inositol phospholipids by 
phospholipase C (PLC) and subsequent hydrolysis of the resultant diacylglycerol 
(DAG) by DAG lipase (DAGL) activity. This was first described by Prescott and 
Majerus as a degradation pathway for AA-containing DAGs in platelets (Prescott & 
Majerus, 1983). It was observed that 2-AG was released by simulated cells, such as 
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Swiss mouse 3T3 cells stimulated by platelet-derived growth factor (PDGF) 
(Hasegawa-Sasaki, 1985) or bradykinin-stimulated rat dorsal ganglion neurons 
(Gammon et al., 1989). 2-AG was then shown to be released by other stimuli, for 
example the membrane depolarising agent, ionomycin. N18TH2 cells released 2-AG 
into the medium in a calcium-dependent fashion and in a concentration analogous to 
that released from 3T3 cells (Bisogno et al., 1997b). Calcium-induced 2-AG 
generation was revealed in rat brain homogenate, with phosphatidylinositol (PI) 
being the most preferred substrate (Kondo et al., 1998; Sugiura et al., 2006). This 
group also pointed to the role for PLC, an enzyme regulated by G proteins, in 2-AG 
generation. This followed the observation that addition of GTPγS enhanced 2-AG 
generation in brain homogenate in the presence of a low concentration of calcium. It 
was not until 2003 that the focus shifted from PLC to DAGL, where the cloning and 
characterisation of the DAGLs was first reported (Bisogno, 2003).  
 
2-AG as an eCB was first described by two separate groups. Mechoulam et al. 
isolated 2-AG from canine gut and then intravenously administered it to rats. This 
produced the tetrad of effects typically seen with Δ9-THC; antinociception, 
immobility, reduction of spontaneous activity and lowering of body temperature. 2-
AG also bound to both CB1 and CB2 in membranes from COS cells transiently 
expressing either one of the CB receptor types (Mechoulam et al., 1995). The effects 
of anandamide, 2-AG and other related compounds were then compared in 
synaptosomal membranes. Only 2-AG showed similar displacement of a 
radiolabelled ligand [3H] CP55940 in the presence of a monoacylglycerol (MAGL) 
inhibitor; that is it say, when the breakdown of 2-AG was prevented, the effects of 2-
AG were revealed. Stella et al. (1997) confirmed 2-AG as a prominent constituent of 
brain tissue that acted as a full agonist at the CB1 receptor. It has the same effect as 
CB1 synthetic agonists in the hippocampus, whereby 2-AG inhibited long-term 
potentiation (LTP), an effect blocked by CB1 antagonists (Stella et al., 1997). 
Furthermore, 2-AG can be released from cells following stimulation (Bisogno et al., 















Figure 1.2 Structure of the Endocannabinoids 
Structures of the two most well studied endocannabinoids (eCBs) – Anandamide and 
2-Arachidonylglycerol (2-AG), and two compounds that may act as eCBs, 
Virodhamine and Noladin ether, are presented above. Anandamide and Noladin ether 
exhibit greater affinity towards CB1 when compared to CB2. 2-AG exhibits similar 
affinity towards both cannabinoid receptors. Virodhamine on the other hand exhibits 
greater affinity towards the CB2 receptor. 
 




2-AG as the “true” endocannabinoid for CB1 
Although it was initially viewed as an intermediate to AA synthesis, 2-AG 
subsequently became regarded as the major eCB in the brain and has been postulated 
to be the “true” endogenous ligand for the CB1 receptor (Sugiura et al., 1999). There 
are many reasons for this belief. Anandamide is found in low amounts in mammalian 
tissues (Stella et al., 1997) and the biosynthetic pathways discovered thus far for 
anandamide are not able to produce sufficient amounts of the eCB due to low 
substrate availability (discussed in more detail below). Importantly, there is 800-fold 
more 2-AG in the rat brain than anandamide (Sugiura et al., 1999) and 2-AG is the 
most abundant eCB in the developing (Watson et al., 2008), as well as the adult 
brain (Mechoulam et al., 1995; Sugiura et al., 1995; Stella et al., 1997). This last 
study showed that the 2-AG isoform is strictly recognised by CB1 and was the most 
potent ligand, acting as a full agonist at both CB1 and CB2 receptors. Anandamide 
acted as a partial agonist at CB1 in NG108-15 neuroblastoma cells and a weak 
agonist for CB2 (Sugiura et al., 1999; Piomelli, 2003; Ross, 2003; Sugiura et al., 
2006). Several investigators have also provided evidence that anandamide interacts 
with binding sites other than the CB receptors and there is evidence that a specific 
receptor may exist for anandamide. These points are discussed below. 
 
 
Other eCBs and eCB receptors 
Since the discovery of anandamide and 2-AG, a number of other potential ligands 
and receptors have been identified as eCBs and CB receptors, respectively. The 
occurrence of several novel structural analogues of anandamide in vivo has been 
reported. Porter et al. (2002) demonstrated that an ester-linked isomer of 
anandamide, O-arachidonoyl ethanolamine, is present in the rat brain and human 
hippocampus and named this compound ‘Virodhamine’. Virodhamine acts as an 
agonist at CB2 and was found at substantial levels in rat striatum lysates, while 
anandamide was virtually undetectable (Porter et al., 2002). It is not surprising that 
virodhamine can bind CB receptors in pharmacological assays due its structural 
similarity to 2-AG (Figure 1.2). However, virodhamine as a true eCB is still in 
23 
 
debate, as it does not contain essential structural groups at the correct location for 
CB activity. For example, the hydroxyl group adjacent to the ester linkage in the 
structure of 2-AG has been shown to be ‘essential in exhibiting strong agonistic (CB) 
activity’ (Sugiura et al., 1999), which is absent in virodhamine. 
  
N-arachidonoyl dopamine (NADA) has also been shown to act as an eCB. Huang et 
al. (2002) synthesised and purified NADA and showed it could bind to both the CB 
receptors and the vanilloid receptor, inducing analgesia upon systemic administration 
and hyperalgesia when intradermally injected (Huang et al., 2002). NADA requires 
fatty amide amide hydrolase (FAAH) activity for its biosynthesis, which either 
liberates AA from anandamide or acts as a conjugation enzyme, or both (Bisogno et 
al., 2000; Hu et al., 2009). Therefore NADA’s role in the eCB system is still unclear.  
 
In terms of structural analogues of 2-AG, Hanus et al. (2001) reported that 2-AG 
ether (Noladin ether), an ether linked analog of 2-AG, is present in the pig brain and 
in small amounts in rat brain (Figure 1.2). Noladin ether could bind selectively to 
CB1 and CB2, producing behavioural effects in mouse tests (Hanus et al., 2001; 
Fezza et al., 2002). However, concentrations of noladin ether were not found in 
significant amounts in a variety of mammalian brains and doubt remains over 
whether it is a serious candidate as an eCB (Oka et al., 2003; Alexander & Kendall, 
2007).  
 
The above related lipids clearly share an ability to bind to and activate CB1 and/or 
CB2 receptors but it remains to be determined to what extent they actually drive or 
modulate physiologically relevant eCB responses in the body. More recently, reports 
have suggested that the anti-proliferative/anti-cancer effects of the ethanolamide 
derivatives docosahexaenoylethanolamide (DHEA) and eicosapentaenoyl-
ethanolamide (EPEA) may be due to their ability to bind, even with low affinity, to 
both CB1 and CB2 receptors, with DHEA thought to be produced by the same 
pathway as anandamide (De Petrocellis et al., 2000; Brown et al., 2010; Yang et al., 
2011). Therefore these lipids may also be candidate eCBs. On the other hand, these 
studies were carried out in recombinant or cancer cell lines and so their role as eCBs 




Two naturally occurring acylethanolamides: oleoylethanolamide (OEA) and 
palmitoylethanolamide (PEA), and two phytocannabinoids: cannabinol (CBN) and 
CBD, all lack affinity at CB1 / CB2 but still evoke pharmacological and / or 
cannabimmetic effects, suggesting other CB receptors may exist. Three orphan 
GPRCRs have been put forward as potential CB receptors and these are GPR119, 
GPR18 and GPR35. GPR119 is reportedly a receptor for OEA (Overton et al., 
2006). However, it is unclear whether the high concentrations of OEA required to 
activate recombinant GPR119 occur (patho-) physiologically, or whether another as-
yet unidentified ligand with greater potency might be the endogenous ligand for 
GPR119 (Brown, 2007). GPR18, a receptor cloned in 1997, has also been linked to 
the eCB system when it was shown to be activated by anandamide (Gantz et al., 
1997; Kohno et al., 2006; Pertwee, 2006b; a; Rajaraman et al., 2015) and has been 
implicated in obesity (Rajaraman et al., 2015). 
 
A second orphan GPCR, GPR55 has been suggested as a third CB receptor (Baker et 
al., 2006; Brown, 2007; Ryberg et al., 2007). The effect of CBs on GPR55 was 
shown following an in silico search on public databases, where two patents described 
how some CB agonists and antagonists act on the GPR55 receptor. GPR55 is 
sensitive to certain eCBs and is expressed in the brain, including the hippocampus, 
where the CB system is thought to play a role in memory (Sylantyev et al., 2013). 
However, [3H] CP 55,940 (the compound that mimics the action of Δ9-THC) was not 
shown to be bound in CB-receptor KO mice. There are also conflicting reports of 
this compound acting as an inverse agonist, rather than an agonist at this receptor 
(Baker et al., 2006). These observations were based on pharmacological agents that 
act on CB1/CB2 acting on the GPR55 receptor. Therefore, more physiologically 
relevant evidence is needed before determining if GPR55 is indeed a CB receptor. In 
addition, GPR55 has low sequence identity with the CB1 or CB2 receptors. 
Therefore, the nature and scope of these effects are presently unclear and they may 





Structural similarities between synthetic vanilloids and anandamide suggested 
possible interactions between CB and vanilloid signalling systems (Di Marzo et al., 
1998). The first revelations of the structural similarity of anandamide to capsaicin 
led to the discovery of anandamide’s ability to bind the transient receptor potential 
vanilloid type-1 (TRPV1) (Zygmunt et al., 1999; Smart et al., 2000). The search for 
endogenous ligands for TRPV1 suggested that anandamide may be one such 
compound (Ross, 2003), as there is ample evidence that the interaction of 
anandamide with TRPV1 receptors is specific. For example, TRPV1 actions are 
blocked by receptor-specific antagonists and not antagonists of CB1 and CB2 
receptors; desensitisation of TRPV1 via capsaicin pre-treatment blocks the effects of 
anandamide; neonatal capsaicin treatment prevents anandamide activation of 
TRPV1; anandamide-mediated TRPV1 effects are absent from untransfected cells 
that do not express TRPV1 receptors (Zygmunt et al., 1999; Smart et al., 2000; Ross 
et al., 2001). Interestingly, both TRPV1 and CB1  are found in brain regions with 
high expression of the anandamide degrading enzyme, FAAH, pointing to a role for 
anandamide in acting on the TRPV1 receptor (Egertova et al., 2003). 
 
The peroxisome proliferators activated receptor (PPAR) may serve as a receptor for 
certain actions of some CB compounds (Burstein et al., 2004; Burstein, 2005) and 
has been shown to be part of the eCB system through pharmacological methods. 2-
AG was shown to activate PPARγ receptors, as evident by PPARγ-specific luciferase 
reporter in transiently transfected 3T3-L1 cells (Rockwell et al., 2006). The putative 
role of PPARγ in IL-2 suppression could also be mediated by 2-AG and/or noladin 
ether in Jurkat T cells, the action of which was blocked by the PPARγ-specific 
antagonist, 2-chloro-5-nitro-N-(4-pyridyl)-benzamide (T0070907). Likewise, 2-AG 
suppressed the activity of two transcription factors crucial for IL-2 expression, 
nuclear factor of activated T cells and nuclear factor kappa B, in the absence but not 
in the presence of T0070907. 2-AG treatment also induced PPARγ binding to a 
PPAR response element in activated Jurkat T cells (Rockwell et al., 2006). 
Furthermore, OEA, anandamide, noladin ether and virodhamine were also found to 
bind PPARα (Sun et al., 2007). Together, these studies suggest TRPV1 receptors and 
PPARs as targets for eCBs, in a manner that is independent of CB1 and CB2. These 
26 
 
receptors systems may also exhibit a degree of cross-talk, as PPAR agonists can bind 
both CB1 and CB2 receptors (Priestley et al., 2014).  
 
In more recent studies, anandamide and 2-AG levels have been selectively elevated 
using drugs that inhibit FAAH and MAGL, respectively (Cravatt et al., 2001; 
Schlosburg et al., 2010), also showing that both anandamide and 2-AG can elicit 
cannabinoid-like effects. However these are again ‘pharmacological’ effects as the 
ligands are outside the range of their normal expression levels for considerable 
periods of time. Confounding factors include the facts that anandamide will also act 
on TRPV1 receptors (Zygmunt et al., 1999) and high levels of 2-AG can readily 
desensitise, as well as activate CB1 (Chanda et al., 2010). Due to the much greater 
pharmacological and physiological evidence available, the CB1 and CB2 receptors, 
together with anandamide and 2-AG as their endogenous ligands, remain the best 




1.3 Synthesis & Degradation Pathways of the 
Endocannabinoids 
 
In order to establish a more comprehensive understanding of eCB signalling, it is 
important to understand how and where the putative eCBs are synthesised and 
broken down. This dictates whether they have an opportunity to serve as ligands for 
the CB receptors. Unlike most other neurotransmitters (NTs), which are water 
soluble and stored in membrane-delineated vesicles before release, the eCBs are 
hydrophobic neutral lipids that appear to be biosynthesised and released at the 
moment of their intended action, using an ‘on-demand’ type of production 
(Marsicano et al., 2003). The processes that underlie the biosynthesis of eCBs have 
been extensively studied for 2-AG and anandamide. It is believed that the diversity 
of the signalling pathways in which anandamide, 2-AG and other potential eCBs 
partake implies their significant roles in various physiological conditions and 
evidence suggests that these pathways are differentially regulated in the nervous 
system (Hoover et al., 2008). These features indicate that the enzymes involved in 
eCB production and degradation are important regulators of signalling.  
 
 
Anandamide: Synthesis and Degradation 
Anandamide belongs to a class of signalling lipids called N-acyl ethanolamines 
(NAEs), which are ubiquitous trace constituents of animal and human tissues and 
cells (Schmid, 2000). Studies by Schmid and colleagues first identified NAEs as 
markers of ischemic shock in brain and heart tissues. They postulated that NAE-
phospholipids are precursors of the biologically active NAEs (Natarajan et al., 
1982). NAEs have been implicated in diverse physiological processes, including 
nociception, cognition, anxiety, appetite and inflammation (Simon & Cravatt, 2006). 
In 1992, when anandamide was identified as an eCB, there was renewed interest in 
NAEs and interest into its biosynthesis began. However a detailed understanding of 
the biosynthetic pathway(s) for NAEs and anandamide has proven hard to pin down. 
Since anandamide is usually accompanied by much larger amounts of (CB receptor-
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inactive) saturated and mono-unsaturated NAEs, it is of interest to determine to what 
extent anandamide is selectively synthesised, transported and degraded (Schmid, 
2000).  
 
Multiple synthetic pathways have been proposed for anandamide synthesis (Figure 
1.3). Originally, two possible mechanisms of anandamide formation had been 
suggested: (1) energy-dependent condensation of free arachidonate with 
ethanolamine, or (2) release by phospholipase D (PLD)-mediated cleavage of the 
phospholipid precursor arachidonyl phosphatidylethanolamine (PE). Di Marzo et 
al.(1994) suggested that because levels of free arachidonate and ethanolamine are 
low in neurons, the first pathway was unlikely to be the primary pathway for 
anandamide biosynthesis, as it would require a plethora of enzymes to be co-
activated in order to occur. For example, phospholipase 2 (PLA2) or PLC to generate 
arachidonate and PLD to generate ethanolamine and inhibitors of these enzymes had 
no effect on ionomycin-stimulated anandamide formation (Di Marzo et al., 1994). 
By using [3H] ethanolamine labelled cultured neurons, this group were able to 
demonstrate that ionomycin stimulated anandamide synthesis and that N-arachidonyl 
phosphatidylethanolamine (N-acyl PE, or NAPE) could act as an anandamide 
precursor. In one hydrolytic cleavage step, anandamide could be produced and this 
was presumably through the action of an endogenous phosphodiesterase (Di Marzo 
et al., 1994). Indeed, stimuli that enhanced formation of anandamide increased 
NAPE turnover in cultured neurons. Certain physiological stimuli may cause 
anandamide formation specifically by activating distinct biochemical pathways, in 
analogy with platelet-activating factor (Yue & Feuerstein, 1994). 
 
Calcium-stimulated anandamide synthesis was then described as a two-step process. 
First, calcium activates a (yet to be defined) transacylase which catalyses the 
formation of NAPE (Cadas et al., 1997). This NAPE intermediate is then converted 
via a hydrolytic step by PLD into an NAE and phosphatidic acid (Figure 1.3 A) 
(Schmid, 2000; Leung et al., 2006). The NAPE-specific PLD (NAPE-PLD) thought 
to be involved was then cloned (Okamoto et al., 2004) and was shown to be 
expressed in various organs in mice, including the brain and is highly conserved in 
sequence from rodents to human. It belongs to the metallo-lactamase family of 
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enzymes and could catalyse the formation of anandamide from NAPE in vitro 
(Okamoto et al., 2004). NAPE-PLD soon established itself as the likely synthetic 
enzyme for anandamide synthesis  (Ligresti et al., 2005). However none of these (or 
related studies) directly tested whether NAPE-PLD was required for anandamide 
biosynthesis in vivo.  
 
Characterisation of this enzyme was next studied by way of a NAPE-PLD KO 
mouse and measured endogenous levels of NAPEs and NAEs by LC-MS (Leung et 
al., 2006). While saturated and mono-unsaturated NAEs were decreased, 
surprisingly there were no differences in anandamide (i.e. polyunsaturated NAEs) 
levels observed in the brains of these KO mice. The fact that NAPE-PLD affected 
levels of certain NAEs while leaving others unaffected, suggested cells could exert 
significant control over NAE biosynthesis by expressing distinct NAPE-PLDs. The 
results suggested the existence of multiple biosynthetic pathways for NAEs in vivo; 
NAPE-PLD being principally responsible for generating very long chain saturated 
NAEs and other, as of yet, unidentified enzymes contributing to the production of 
long chain saturated and polyunsaturated NAEs, including anandamide. Consistent 
with this premise, brain homogenates from NAPE-PLD KO mice possessed a 
residual calcium-independent enzymatic activity equivalent to WT controls, 
converting NAPEs to NAEs, indicating that in the absence of millimolar calcium 
which is required for maximal activation of NAPE-PLD (Ueda et al., 2001), a 
significant fraction of NAE biosynthesis proceeds through an alternative pathway.  
 
At least two other pathways have since been suggested. Simon et al. (2006) reported 
that a significant amount of NAPE-PLD-independent anandamide synthesis could be 
blocked by methoxy arachidonyl fluorophosphonate (MAFP), a general inhibitor of 
the serine hydrolase class of enzymes in both NAPE-PLD (+/+) and (-/-) mice 
brains. They suggested that NAE synthesis from NAPE proceeds through a serine 
hydrolase-catalysed double deacylation of NAPE to generate glycerophospho-NAE 
(GP-NAE), followed by the phosphodiesterase-mediated cleavage of this 
intermediate to liberate NAE. This led to the cloning and identification of the serine 
hydrolase α/β-hydrolase 4 (Abh4), which can selectively deacylate both NAPEs and 
lysoNAPEs en route to generating GP-NAE (Simon & Cravatt, 2006). This was 
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subsequently demonstrated ex vivo (Simon & Cravatt, 2008). The EDTA-sensitive 
conversion of GP-NAE to anandamide was attributed to metal dependent 
glycerophosphodiester phosphodiesterase 1 (GDE1), whereby double O-deacylation 
by Abh4 to yield GP-NAE, followed by GDE1-mediated conversion of this lipid 
intermediate to anandamide (Figure 1.3 B). Both Abh4 and GDE1 are expressed in 
various tissues including the brain (Simon & Cravatt, 2008). However neither GDE1 
KO mice nor GDE1/NAPE-PLD double KO mice showed significant decrease in 
anandamide levels in the brain compared to WT control. Treatment with FAAH 
inhibitors in the double KO also resulted in the accumulation previously seen 
(Johnson et al., 2009), indicating GDE1 and NAPE-PLD together contribute towards 
NAE synthesis with potential cross-talk between the two pathways, as this was not 
seen in GDE1 KO alone (Simon & Cravatt, 2010a). Additionally, rat brain tissues 
have been shown to contain lyso-PLD activity that can generate anandamide from 
lyso-NAPE (Sun et al., 2004).  
 
A third pathway involved in the bacterial endotoxin, lipopolysaccharide (LPS)-
stimulated synthesis of anandamide in macrophages has also been described. This 
pathway involves an unidentified PLC and dephosphorylated by phosphatase 22 
(PTPN22), previously described as a tyrosine phosphatase (Figure 1.3 C). The LPS-
induced synthesis of anandamide in macrophages is mediated exclusively by the 
PLC/phosphatase pathway, which is up-regulated by LPS. Conversely, NAPE-PLD 
is down-regulated by LPS and functions as a salvage pathway of anandamide 
synthesis when the PLC/phosphatase pathway is compromised (Liu et al., 2006). 
Although it is generally accepted that NAPEs are the precursors for NAEs, the 
precise enzymatic steps leading to release of NAEs, anandamide in particular, from 




Anandamide signalling is terminated through its cellular uptake and subsequent 
catabolism by the endoplasmic reticulum-localised enzyme, FAAH (Deutsch & 
Chin, 1993; Cravatt et al., 2001). Due to the intracellular localisation of FAAH, an 
anandamide transporter has been postulated to mediate internalisation and diffusion 
across the hydrolytic cytosol. Identifying this transporter has generated interest as a 
therapeutic target and to date, several proteins capable of binding anandamide have 
been identified. For example, trafficking of anandamide from the plasma membrane 
via a non-vesicular mechanism can be mediated by cytosolic carriers, such as Hsp70 
and serum albumin (Oddi et al., 2009). Fatty acid binding proteins (FABPs) were 
also shown to mediate anandamide transport. Anandamide uptake and hydrolysis 
were significantly potentiated in N18TG2 neuroblastoma cells after overexpression 
of FABP5 or FABP7 (Kaczocha et al., 2009). Similarly, a catalytically-silent, partly 
cytosolic variant of FAAH was shown to drive anandamide transport in Neuro-2A 
cells and was termed FAAH-like anandamide transporter (FLAT) (Fu et al., 2012). 
FLAT bound anandamide with low micromolar affinity and facilitated its 
translocation into cells, an effect blocked by the known anandamide transport 
inhibitors, AM404 and OMDM-1 (Beltramo et al., 1997; Ortar et al., 2003). 
However, all of these studies used overexpressing recombinant systems and 
examined anandamide accumulation at long time points, leaving the results obtained 
open to debate. Furthermore, elevation of anandamide via AM404 can be assigned to 
inhibition of COX-1 and COX-2 activity (discussed in more detail below) (Hogestatt 
et al., 2005). Anandamide transport has subsequently been described as a diffusion 
process. More recently, a study showed that fluorescently-labelled anandamide was 
transported into endothelial cells exclusively by TRPV1 in a calcium-dependent 
manner (Hofmann et al., 2014). Therefore, anandamide transport into the cells is still 
in debate. 
 
While synthetic pathways and cellular uptake mechanisms for anandamide are still 
uncertain, there is a clear consensus that anandamide degradation in the CNS and in 
peripheral tissues is mediated by the well characterised enzyme, FAAH (Figure 1.3 
D) (Cravatt et al., 1996). FAAH KO mice had barely detectable levels of 
anandamide hydrolytic activity and 15-fold higher brain anandamide levels 
compared to WT control. FAAH KO mice also displayed cannabimimetic 
32 
 
behavioural effects that ‘rivalled THC’ in terms of efficacy and duration (Cravatt et 
al., 2001). Genetic (Cravatt et al., 2001; Lichtman et al., 2004b) and 
pharmacological (Lichtman et al., 2004a; Jhaveri et al., 2008; Ahn et al., 2009) 
disruption of FAAH not only elevates brain levels of anandamide but also produces 
CB1-dependent analgesia in multiple pain assays. These findings clearly show that 
anandamide can act at CB1 receptors, but again this has to be viewed as 
“pharmacological” activity, as the anandamide levels are substantially higher than 







(A) NAPE PLD mediated AEA synthesis (C) PLC/PTPN22 mediated AEA synthesis
(D) FAAH mediated AEA degradation(B) ABH4 mediated AEA synthesis
 
Figure 1.3 Putative pathways involved in AEA synthesis and the primary 
pathway involved in AEA degradation 
A. N-acyl transacylase (NAT) is believed to catalyse the formation of N-acyl 
phosphatidylethanolamine (NAPE) using phosphatidylethanolamine (PE) and 
phosphatidylcholine (PC). NAPE can then be hydrolysed to Anandamide (AEA) by 
a NAPE-specific phospholipase D (NAPE-PLD).  
B. The serine hydrolase α/β-hydrolase 4 (ABH4) can deacylate both NAPE to lyso-
NAPE and then lyso-NAPE to glycero-NAPE. Glycerophosphodiesterase 1 (GDE 1) 
can then convert glycerol-NAPE to AEA. Rat tissues also contain lysoPLD activity 
that can convert lyso-NAPE to AEA.  
C. A third pathway involved in lipopolysaccharide (LPS) stimulated synthesis of 
AEA in macrophages involves an unidentified phospholipase C (PLC) converting 
NAPE to phosphor-AEA and then phosphatases including protein tyrosine 
phosphatase 22 (PTPN22) that convert phosphor-AEA to AEA.  
D. Fatty acid amide hydrolase (FAAH) hydrolyses AEA to arachidonic acid (AA) 
and ethanolamine. 
Adapted with permission from Deutsch et al., 2002 and Placzek, 2008. 
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2-AG: Synthesis and Degradation 
Even though 2-AG has  been shown to be generated through combined actions of 
PLA1 and PLC (Sugiura et al., 1995) and from AA-containing lysophosphatidic acid 
in the rat brain through the action of a phosphatase (Nakane et al., 2002), the main 
synthetic pathway for formation of 2-AG is through combined actions of PLC and 
diacylglycerol lipase (DAGL). 2-AG is formed from AA-containing phospholipid 
bilayers in response to cellular stimuli. The steady-state levels as well as the ‘on-
demand’ synthesis of 2-AG are regulated by two sn-1 specific DAGLs, DAGLα and 
DAGLβ (Bisogno, 2003). This pathway consists of hydrolysis by PLC of inositol 
phopholipids containing AA at sn-2 position and further hydrolysis by DAGL of the 
resultant AA-containing DAG. PI serves as the most preferred phospholipid 
substrate for 2-AG formation in the brain (Sugiura et al., 2006). This is the 
beginning of 2-AG synthesis, consisting of hydrolysis of phosphatidylinositol 4,5-
bisphosphate (PIP2) by PLC into DAG and inositol triphosphate (IP3), and further 
hydrolysis of DAG by DAGL to 2-AG (Figure 1.4).  
 
DAG  is an essential second messenger in mammalian cells and is synthesised in 
response to the activation of a number of cellular signalling cascades, including 
activation of GPCRs (Brose et al., 2004). DAG is able to bind to C1 domains of a 
large number of proteins with diverse functions. The most prominent DAG targets 
belong to the PKC family of serine/threonine kinases. Binding of DAG, often in 
synergy with IP3 release of intracellular Ca2+ leads to the membrane translocation 
and activation of certain PKCs (Brose et al., 2004). In a second pathway, as 
mentioned above, 2-AG may be produced by sequential hydrolyses of PI via lyso PI, 
which are catalysed by PLA1 and lyso PI-specific PLC (Ueda et al., 1993). However 
since the identification and cloning of the two DAGLs, α and β, these enzymes are 
now accepted as the synthetic enzymes for 2-AG generation, and are discussed in 
more detail below.  
 
Following synthesis and release, 2-AG can be taken up through the anandamide 
transporter and metabolised by FAAH. However FLAT expression in HEK-293 cells 
did not alter [3H] 2-AG transport, nor did the FLAT inhibitor ARN272 increase 
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plasma 2-AG in mice (Fu et al., 2012). Furthermore, inactivation of FAAH by 
pharmacological or genetic intervention does not result in elevation of 2-AG (Cravatt 
& Lichtman, 2002; Deutsch et al., 2002; Di Marzo, 2008).  
 
The main degradative enzyme for 2-AG in vivo is MAGL, which hydrolyses 2-AG to 
AA and glycerol (Figure 1.4) (Beltramo & Piomelli, 2000; Piomelli et al., 2000; 
Dinh et al., 2002; Muccioli et al., 2007; Long et al., 2009a; Schlosburg et al., 2010). 
The selective MAGL inhibitor, JZL184 raises brain 2-AG concentrations by 8-10 
fold (without altering anandamide) and JZL184-treated mice exhibit the tetrad of CB 
activity (analgesia, hypothermia, hypomobility and catalepsy) and mimic much of 
the pharmacological profiles typically seen with CB1 agonists (Cravatt et al., 2001; 
Wiley & Martin, 2003). Therefore, MAGL is considered the 2-AG hydrolysing 
enzyme. However, two other serine hydrolases have also been to shown to hydrolyse 
2-AG, namely ABHD6 and ABHD12 (Blankman et al., 2007). This study showed 
that approximately 85% of brain 2-AG was hydrolysed by MAGL, while the 
remaining 15% was hydrolysed by either ABHD6 and/or ABHD12; JZL195 was 
also shown to be capable of inhibiting ABHD6, albeit at a lower potency than that 
seen for MAGL (Long et al., 2009b). Interestingly, these three 2-AG hydrolysing 
enzymes have distinct subcellular distributions, suggesting that they may control 
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Figure 1.4 On-demand Synthesis of 2-AG is regulated by the DAGLs 
2-arachidonylglycerol (2-AG) synthesis begins with activation of phospholipase C 
(PLC) following cell stimulation, which hydrolyses phosphatidylinositol 4,5-
bisphosphate (PIP2) into inositol triphosphate (IP3) and diacylglycerol (DAG) (A). 
IP3 initiates intracellular calcium release and PKC activation. DAG is further 
hydrolysed to 2-AG by DAG lipase (DAGL, both in red) which itself is activated by 
PKC. 2-AG is further hydrolysed by monoacylglycerol lipase (MAGL) to 
arachidonic acid (AA), the precursor to prostaglandin synthesis. However, it is 
believed that an increase in DAGL activity can lead to an increase in ‘on-demand’ 2-




2-AG and Anandamide as substrates for COX-2 
Oxidation is another route for eCB metabolism. Both 2-AG and anandamide have 
been found to be substrates for cyclooxygenase (COX)-2, the key enzyme required 
for the conversion of AA to prostaglandins (Kozak et al., 2004). Two COX isoforms 
have been identified, COX-1 and COX-2. In general, COX-1 is produced 
constitutively by gastric mucosa, whereas COX-2, discovered more recently, is 
inducible at sites of inflammation and also in the CNS. Several observations 
prompted investigations into the ability of COX-2 to utilise the eCBs as substrates, 
including co-localization of components of the eCB system. For example, the 
expression of COX-2 in the central nervous and immune systems parallels the 
distribution of the CB1 and CB2 receptors, respectively (Herschman, 1996; Felder & 
Glass, 1998). In addition, 2-AG is present at high levels in regions of the brain and in 
immune cells where COX-2 is expressed (Stella et al., 1997; Bisogno et al., 1999).  
 
Evidence for anandamide and 2-AG as COX-2 substrates has mainly been provided 
through in vitro studies, such as oxygenation of anandamide by recombinant COX-2 
(and not COX-1) to the prostaglandin E2 ethanolamide in cell lysates and human cell 
lines (Yu et al., 1997). COX-2 mediated 2-AG oxygenation generated the ‘novel 
lipid’ prostaglandin H (2) glycerol ester (PGH2-G) in vitro as well as in cultured 
macrophages, the production of which was prevented by inhibition of DAGL, PLC, 
as well as PGD synthase (Kozak et al., 2000). Endogenous cellular stores of 2-AG 
have been shown to support PGH2-G biosynthesis in a stimulus-induced manner 
(Kozak et al., 2000). Additionally, PGH2-G has been shown to be a substrate for 
PGD synthase, raising the possibility that the class of glyceryl PGs is as diverse as 
the well-known AA-derived metabolites, but again so far has only been shown in 
vitro (Kozak et al., 2002). There is some evidence ex vivo from isolated rabbit lung, 
where anandamide increased pulmonary hypertension via COX-2 metabolites 
following enzymatic degradation by FAAH into AA products, an effect completely 
obliterated by the FAAH inhibitor methyl arachidonyl fluorophosphanate (MAFP) 
(Wahn et al., 2005). However, this study showed anandamide as a precursor for 
COX-2 substrates, and not as a substrate itself. Finally, anti-nociceptive effects of 
eCBs were enhanced when FAAH was inhibited in a hind paw model of 
inflammatory hyperalgesia. COX-2 inhibition increased anti-nociception, 
38 
 
presumably by blocking action of COX-2 on eCBs (Jhaveri et al., 2008). These 
findings are the result of how specific polyunsaturated fatty acids, the substrate for 
eCB biosynthesis, and the signalling of the eCB system may influence COX and its 






Identification and Characterisation of DAGL signalling 
DAGL activity first came to the fore as a key enzymatic step for AA release from 
membrane phospholipids as an alternative to the established pathway involving 
PLA2 activity. AA concentrations released from thrombin-stimulated platelets 
depended on both DAGL and PLC activity, and DAGL activity could be stimulated 
by calcium. DAGL had ‘sufficient activity to provide for the burst of arachidonate 
released after platelet stimulation’, and was not due to PLA2, as previously thought 
(Bell et al., 1979). The metabolism of DAG to AA was later identified as a two-step 
mechanism. This signalling pathway involves the generation of the substrate DAG 
by PLC and subsequent hydrolysis by DAGL at the sn-1 position, leading to release 
of 2-AG  (Prescott & Majerus, 1983) which is subsequently hydrolysed by MAGL to 
AA and glycerol (Figure 1.4).  
 
Isolation of purified DAGL was first attempted from bovine brain. Its activity was 
identified to be adenosine triphosphate (ATP)-dependent, displaying a more potent 
inhibitory activity from ATP compared to ADP, while cAMP marginally increased 
activity and AMP had no effect (Farooqui et al., 1984). DAGL was subsequently 
purified from bovine brain microsomes. At low concentrations neither calcium nor 
magnesium had a direct effect on enzyme activity but a threefold increase was 
observed after phosphorylation by a cAMP-dependent protein kinase (Rosenberger 
et al., 2007). This became relevant to neuroscience, when the DAGL-MAGL 
pathway was demonstrated to release AA from cultured dorsal root ganglion neurons 
(Allen et al., 1992). 
 
Early DAGL studies relied heavily on the semi-selective DAGL inhibitor 
RHC80267 (Sutherland & Amin, 1982), which also displays a considerable efficacy 
towards other serine lipases. Comparing another DAGL inhibitor tetrahydrolipstatin 
(THL) with RHC80267, a minimal overlap of target profiles was seen, indicating 
that an effect seen by both drugs has a high likelihood to be a DAGL-dependent 
event. Furthermore, in the case of a known CB1/CB2 receptor-dependent event, 
RHC80267 remains helpful regarding the differentiation between a 2-AG- and an 
anandamide- mediated event (Hoover et al., 2008). THL, also known as orlistat, is 
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more prominently known for its inhibition of pancreatic lipase. This lipase is well 
studied in the context of weight loss (Hadvary et al., 1991). OMDM-188 (an 
analogue of THL) is very specific and promised to be the leader for the next 
generation of DAGL inhibitors (Ortar et al., 2008). More recently, relatively 
selective DAGLβ inhibitors have been developed which reduce 2-AG and AA 
synthesis in macrophages (Hsu et al., 2012) and could help differentiate between 
DAGLα and DAGLβ activities. Cloning of the DAGLs and generation of KO mice 
has highlighted the importance of these enzymes for 2-AG synthesis and that 




1.4 Identifying potential regulatory mechanisms for 
the DAGLs 
 
In order to assess the regulatory mechanisms of the DAGLs, detailed analysis of the 
structure is essential to see if there is any potential for a role of post-translational 
modifications (PTMs). Characterisation of lipases was initially driven by the food 
industry, where the lipid composition of fungi was essential for oil and fat 
processing, as well as in medicine, food additives, diagnostic reagents and cleaners. 
For example, the gene encoding for a 39 kDa enzyme that can hydrolyse mono- and 
diacylglycerides was crystalised from Penicillium camembertii, a fungus used in the 
manufacture of Camembert and Brie cheeses (Yamaguchi et al., 1991; Derewenda et 
al., 1994). Although biochemical characterisation the DAGLs was first attempted 
over 30 years ago (Farooqui et al., 1984; 1986), to date very little is known about 
how these enzymes are regulated. Due to the vast area of therapeutic implications 
associated with the DAGLs and the eCB system (discussed in more detail in section 
1.5), there is an increasing interest into how these enzymes are regulated.  
 
The DAGLs are membrane bound proteins which are notoriously difficult to 
crystallise, owing to their partially hydrophobic surfaces, flexibility and lack of 
stability (Carpenter et al., 2008) and as such the crystal structures for the DAGLs are 
not yet available. Using homology and bioinformatics to build a working model of 
the DAGLs has provided a template for developing testable hypotheses on the 
mechanisms that regulate DAGL activity and has allowed our group to identify key 
sites on the enzymes that most probably regulate function (Reisenberg et al., 2012).  
 
 
Conservation and domain structure of the DAGLs 
The DAGLs α and β were cloned in 2003, by first aligning the fungal DAGL crystal 
structure with drosophila genome, which identified a single related molecule. This 
sequence was compared to the human genome, which identified the two homologues 
designated α and β (Yamaguchi et al., 1991; Bisogno, 2003; Reisenberg et al., 
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2012). DAGLα gene product is 1, 042 amino acids in length, with a molecular 
weight of ~120 kDa. DAGLβ on the other hand is 672 amino acids long and is ~74 
kDa (SDS-PAGE) (Bisogno, 2003). The two gene products show extensive 
homology throughout, with the major difference being that the α isoform has a ‘tail’ 
region extending from the catalytic domain, which is absent in DAGLβ (Figure 1.5). 
The alpha isoforms appears to be under more tight evolutionary constraint as it 
harbours sequence stretches almost identical to those found in the fly (Gareth 
Williams, unpublished data). The α and β sequences show a high degree of 
conservation between human and mouse DAGL – 97% for DAGLα and 79% for 
DAGLβ. Homology between the two DAGLs is about 35%, which is even higher in 
the catalytic domain (Figure 1.5 and Gareth Williams, unpublished data.) 
 
The membrane topology consists of a short cytosolic N-terminus, followed by the 
transmembrane (TM) domain, consisting of 4 helices that span the cell membrane 
and are separated and linked by short loops; two extracellular and two intracellular. 
The leading N-terminus is highly conserved between drosophila and vertebrate 
DAGLα, pointing towards an important, but unknown function. However this is less 
conserved between DAGLα and DAGLβ (63% homology) (Reisenberg et al., 2012). 
The TM domains may serve as docking sites for other proteins in a functional 
complex, or form part of a channel that regulate DAG access to the catalytic domain, 
or indeed 2-AG release from cells. However deletion of the region does not impact 
on catalytic activity or 2-AG availability to CB receptors. (Won et al., 2009).  
 
Using online web search tools our group identified the two extracellular loops as 
potential sites for glycosylation (Su et al., 2014). Glycosylation is a form of PTM in 
which a glycan is attached to a hydroxyl (or other functional) group. Glycans serve a 
variety of structural and functional roles in membrane and secreted proteins and have 
an important role in protein folding. Recently, a ‘DAG-like lipase’ from Malassezia 
globose was cloned and recombinantly expressed, which was indeed shown to be 
glycosylated (Xu et al., 2015).  
 
Tetraspanins, a family of membrane-bound proteins found in all eukaryotic cells, are 
thought to act as scaffolds, anchoring multiple proteins to one area of the cell 
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membrane. In a likeness to the DAGLs, tetraspanins have 4 TMs forming a distinct 
class of membrane domains, the tetraspanin-enriched microdomains by associating 
with other transmembrane receptors and with themselves. The TM domains of the 
DAGLs might also facilitate packing of the enzymes at the membrane, in analogy 
with tetraspanins into microdomains (Yanez-Mo et al., 2009). 
 
Following from the TM domain, the second intracellular loop extends into the 
catalytic domain (followed by the carboxyl-terminal ‘tail’ domain in the case of 
DAGLα). The structure of the DAGLs’ catalytic domain is a member of the α/β 
hydrolase fold family of enzymes. The α/β hydrolase fold is a common tertiary 
protein structure to a large number of enzymes with diverse functions, yet have 
virtually no sequence similarity, and is therefore a typical example of evolution from 
a common ancestor. The family includes lipases, peptidases and esterases (Nardini & 
Dijkstra, 1999; Holmquist, 2000). The fold consists of 8 mostly parallel β strands 
(the second is anti-parallel) constituting a β sheet (Figure 1.6 A). This is surrounded 
on both sides by α helices. The catalytic residues in the family always constitute a 
triad: a nucleophile (serine, cysteine or aspartic acid), an acidic residue and an 
absolutely conserved histidine. The DAGLs’ catalytic triad consists of a serine, 
aspartic acid, and histidine (Figure 1.6 B) (Bisogno, 2003; Pedicord et al., 2011). 
Among members of this enzyme family, there may be differences in the degree of 
twisting of the β-sheet and also spatial positioning of the α helices. However, αC is 
highly conserved and is probably necessary for the appropriate position of the 















Figure 1.5 Structural features of the DAGLs 
Diagram showing the overall domain structure of DAGLα and DAGLβ. The figure 
indicates the 4TM domains (black lines crossing the membrane), the intracellular 
catalytic domain (red), containing the cysteine rich insert and regulatory loop 
(yellow and green, respectively), with the extended tail domain in case of DAGLα.  
 
Adapted from Reisenberg et al., 2012. 
  DAGLα            DAGLβ  
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The nucleophile is always located in a sharp turn, the ‘nucleophile elbow’. This 
structure plays an important role in presenting the substrate to the nucleophile and 
access of water molecule for hydrolysis (Nardini & Dijkstra, 1999). Within the α/β 
hydrolase fold family, it is located within a consensus Sm-X-Nu-X-Sm sequence 
(Sm=small residue, X=any residue and Nu=nucleophile); in the DAGLs this 
sequence is Gly-His-Ser-Leu-Gly (Figure 1.7, boxed). The catalytic residues and 
nucleophile elbow are absolutely conserved between human DAGLα and DAGLβ 
(and also in mouse), as highlighted in their primary sequence alignment in Figure 
1.7. Therefore, the α/β hydrolase fold in the DAGLs’ catalytic domain provides a 
stable scaffold for the active site. 
 
Our group exploited sequence information from the fungal MAGL/DAGL from 
Penicillium camembertii in order to gain insights into the human DAGLα/β 
structural features (Derewenda et al., 1994). In addition to the motifs conserved 
between fungus and man that we assume must define the catalytic activity of the 
enzyme, there are additional sequence stretches in the mammalian enzyme located 
within the catalytic domain. These are a cysteine-rich domain just before the 
catalytic serine residue and an intriguing domain between the catalytic aspartic acid 
and histidine residues. This latter domain is a common feature to lipase members of 
the α/β hydrolase fold family. This feature can move position and orientation 
depending on the conformational position of the enzyme, thereby regulating 
substrate access to the catalytic site (Nardini & Dijkstra, 1999; Karageorgos et al., 
2013; Xu et al., 2015). This domain is intriguing as it harbours a highly conserved 
motif of ten residues completely conserved in the alpha, beta and fly versions of 
DAGL. Both inserts within DAGLs’ catalytic domain are explored in more detail in 










Figure 1.6 The core structure to the α/β hydrolase fold compared to that 
predicted for the DAGLs 
(A) The structure of the ‘canonical’ α/β hydrolase fold consists of mostly parallel 8 β 
strands which make up the core β sheet, with only the second (β2) being anti-parallel 
(grey arrows). The β sheet is surrounded on both sides by α helices (white cylinders). 
The conserved nucleophile, acid and histidine constitute the catalytic triad (black 
dots). Insertions are tolerated amongst members of this enzyme family and can be 
found at certain locations, such as between the first two α helices and between the 7th 
and 8th β strands, as indicated by the dashed lines.  
Figure A- Adapted (with permission) from Nardini & Dijkstra, 1999. 
 
(B) The predicted structure of the DAGL catalytic domain with the canonical α/β 
hydrolase fold, consisting of a  β-sheet linked by α helices, as seen in A. The DAGLs 
contain a 20-24 amino acid long cysteine-rich insert between the first two α helices, 
which may be a palmitoylation sites (as indicated). The catalytic triad (green circles) 
is harboured by a serine, aspartic acid and histidine. There is a second, 50-60 amino 
acid insert of unknown structure between the 7th and 8th β strands. Its proximity to 
the catalytic triad mean it may act as a lid to shield the catalytic site from substrate 
























The Cysteine Rich Insert 
Aligning amino acid DAGL sequences from P. camembertii and human DAGLs 
revealed that DAGLα and DAGLβ sequences contain a 20-24 amino acid long 
cysteine rich insert within the catalytic domain (Figure 1.5, yellow; Figure 1.7, blue), 
between the first two alpha helices (Figure 1.6 B), which may contain a 
palmitoylation site (Reisenberg et al., 2012). Protein palmitoylation refers to the 
PTM involving addition of a fatty acid to the side chain of a cysteine, forming a 
covalent thioester linkage. It is estimated that ~ 5% of the proteome comprises 
enzymes that perform more than 200 types of PTMs (Gonzalez-Montelongo et al., 
2013). Palmitoylation is reversible and is a potential regulatory mechanism for 
proteins, as well as their subcellular trafficking. It increases the hydrophobity of 
proteins, thereby enhancing membrane association (reviewed in (Mitchell et al., 
2006). This insert could therefore act to regulate DAGL activity by affecting its 
localization at the membrane.  
 
Evidence for palmitoylation of both DAGLα and DAGLβ has been provided from 
three independent proteomic studies (Kang et al., 2008; Martin & Cravatt, 2009; 
Yang et al., 2010). One of these studies mapped this to cysteines 610/611 in the 
regulatory loop region within DAGLβ catalytic domain (Figure 1.7), although the 
authors did note the possibility of inaccurate localization of the palmitoylated site 
(Yang et al., 2010). One lipase known to be palmitoylated is phospholipase D 
(PLD). Palmitoylation is essential for correct membrane localization and endocytosis 
of PLD (Du et al., 2003). This process could also be important for DAGL location, 
as co-factors that collaborate with DAGL during development are also 
palmitoylated; for example the cell adhesion molecules L1 and NCAM. This might 
allow for coordinated function between these proteins and organization into 






TRANSMEMBRANE DOMAINS   
 
Intracelluar   TM1      
hDAGLα MPGIVVFRRRWSVG  SDDLVLPAIFLFLLHTTWFVILS 37 
hDAGLβ MPGMVLFGRRWAIA  SDDLVFPGFFELVVRVLWWIGIL 37 
  *** * * ***   ***** *  *       *   * 
 
Extracelluar   TM2   
hDAGLα VVLFGLVYNPHEACSLNLVD HGRGYLGILLSCMIAEMAIIWL 79 
hDAGLβ      TLYLMHRGKLDCAGGALLSS YLIVLMILLAVVICTVSAIMCV 79 
              *              *        **    
 
  Intracelluar   TM3 
hDAGLα SMRGGILYTEPRDSMQYVLY VRLAILVIEFIYAIVGIVW 118 
hDAGLβ SMRGTICNPGPRKSMSKLLY IRLALFFPEMVWASLGAAW 118 
  **** *    ** **   **  ***    *   *  *  * 
 
Extracelluar   TM4   
hDAGLα LTQYYTSCNDLTAKNV  TLGMVVCNWVVILSVCITVLCVF 157 
hDAGLβ VADGVQCDRTVVNG--  IIATVVVSWIIIAATVVSIIIVF 155 
                      **  *  *         ** 
 
Intracelluar 
hDAGLα DPTGRTFVKLRATKRRQRNLR-TYNLRHRLEEGQATSWSRRLKVF  201 
hDAGLβ DPLGGKMAPYSSAGPSHLDSHDSSQLLNGLKTAATSVWETRIKLL  200   
  ** *                     *   *       *     
 
hDAGLα LCCTRTKDSQSDAYSEIAYLFAEFFRDLDIVPSDIIAGLVLLRQR  246 
hDAGLβ CCCIGKDDHTRVAFSSTAELFSTYFSDTDLVPSDIAAGLALLHQQ  245 
   *          * *  * **   * * * ***** *** ** * 
 
hDAGLα QRAKRNAVLDEANNDILAFLSGMPVTRNTKYLDLKNSQEMLRYKE  291 
hDAGLβ QDNIR------NNQEPAQVVCHAPGSSQEADLDAELEN-------  277 
  *   *       *          *       **      
 
hDAGLα VCYYMLFALAAYGWPMYL  309 
hDAGLβ CHHYMQFAAAAYGWPLYI  295 




hDAGLα  MRKPACGLCQLARSCSCCLCPARPRFAPGVTIEEDNCCGCNAIAI  354 
hDAGLβ  YRNPLTGLCRIGGDC----CRSRTTDYDLVGGDQLNCHF------  330 
   * *  ***          *  *      *     **      
 
hDAGLa RRHFLDENMTAVDIVYTSCHDAVYETPFYVAVDHDKKKVVISIRG  399 
hDAGLβ GSILHTTGLQYRDFIHVSFHDKVYELPFLVALDHRKESVVVAVRG  375 
              *    * ** *** ** ** **    **   ** 
 
hDAGLα TLSPKDALTDLTGDAERLPVEGHHGTWLGHKGMVLSAEYIKKKLE  444  
hDAGLβ TMSLQDVLTDLSAESEVLDVECEVQDRLAHKGISQAARYVYQRLI  420 
  * *  * ****    * * **      * ***    * *     
 
hDAGLα QEMVLSQAFGRDLGRGTKHYGLIVVGHSLGAGTAAILSFLLRPQY  489 
hDAGLβ NDGILSQAFSIAP-----EYRLVIVGHSLGGGAAALLATMLRAAY  460 
      *****          *    ****** * ** *   **   
 
hDAGLα PTLKCFAYSPPGGLLSEDAMEYSKEFVTAVVLGKDLVPRIGLSQL  534 
hDAGLβ PQVRCYAFSPPRGLWSKALQEYSQSFIVSLVLGKDVIPRLSVTNL  505  




       
hDAGLα EGFRRQLLDVLQRSTKPKWRIIVGATKCIPKSELPEEVEVTT--   576  
hDAGLβ EDLKRRILRVVAHCNKPKYKILLHGLWYELFGGNPNNLPTELDG   549  
  *   *  * *     ***  *             *         
 
hDAGLα -----LASTRL------------WTHPSDLTIALSAST-   597 
hDAGLβ GDQEVLTQPLLGEQSLLTRWSPAYSFSSDSPLDSSPKYP   587 
        *    *                **     *   
 
hDAGLα PLYPPGRIIHVVHNHPAEQCCCCEQEEPTYFAIWGDNKAFNEVII 642 
hDAGLβ PLYPPGRIIHLQEEGASGRFGCCSAAHYSAKWSHEAEFSKILIG- 631 
  **********           **       
 
hDAGLα PAMLHEHLPYVVMEGLNKVLENYNKGKTALLSAAKVMVSPTEVD   687   




DAGLα Tail – 355 aa 
LTPELIFQQQPLPTGPPMPTGLALELPTADHRNSSVRSKSQSEMS  732 
LEGFSEGRLLSPVVAAAARQDPVELLLLSTQERLAAELQARRAPL  777 
ATMESLSDTESLYSFDSRRSSGFRSIRGSPSLHAVLERDEGHLFY  822 
IDPAIPEENPSLSSRTELLAADSLSKHSQDTQPLEAALGSGGVTP  867 
ERPPSAAANDEEEEVGGGGGGPASRGELALHNGRLGDSPSPQVLE  912 
FAEFIDSLFNLDSKSSSFQDLYCMVVPESPTSDYAEGPKSPSQQE  957 
ILLRAQFEPNLVPKPPRLFAGSADPSSGISLSPSFPLSSSGELMD  1002  
LTPTGLSSQECLAADKIRTSTPTGHGASPAKQDELVISAR     1042 
 
 








Figure 1.7 Multiple sequence alignment of human DAGLα and DAGLβ 
Multiple sequence alignment was performed using the alignment program from 
EMBL, ‘CLUSTALW’. Key structural features are segregated, including the 
transmembrane domains (TM 1–4) and their linking helices, the catalytic domain, 
including the cysteine rich insert (highlighted in blue), regulatory loop (orange text), 
catalytic triad (highlighted in green), nucleophile elbow (box) and the highly 
conserved signature motif (orange text, highlighted in purple). Key phospho-sites 
identified are notated in pink bold underlined text to highlight their position within 




The DAGLs contain a Regulatory Lid 
Large insertions are tolerated amongst members of the α/β hydrolase fold family, 
while maintaining conserved catalytic activity (Nardini & Dijkstra, 1999) thereby 
accounting for the array of functional differences between members of this family 
(Suplatov et al., 2012). Most lipases have their active site buried beneath a flap or 
lid-like domain that changes conformational shape to allow substrate access to the 
active site (Holmquist, 2000). Examples of this can be seen in gastric lipase (GL) 
and pancreatic lipase (PL) – when in the ‘closed’ state, this lid acts as a barrier to the 
substrate (van Tilbeurgh et al., 1992; Canaan et al., 1999). Lipases hydrolyze poorly 
soluble substrates (Rubin & Denis, 1997). The lid therefore is responsible for 
‘interfacial activation’, a process consisting of the enzyme forming a complex with a 
protein, thus indirectly opening the lid to act on water-insoluble substrates at water-
lipid interfaces (Winkler et al., 1990; van Tilbeurgh et al., 1992). While the size of 
the lid varies between lipases, it is always well positioned to act as a lid. For 
example, it consists of 24 amino acids in PL (Winkler et al., 1990), 124 amino acids 
in GL (Miled et al., 2003) and as an even larger 150 amino insert in hormone 
sensitive lipase (HSL) (Lampidonis et al., 2011). In GL, the large ‘surface loop’ is 
described as two domains consisting of a ‘cap’ domain and a second ‘lid’ domain 
segment of 58 residues, where both are important for the activity of HSL (as evident 
from mutagenesis studies) (Miled et al., 2003).  
 
The lid-like structure in the DAGLs was first identified as a substantial 50-60 amino 
acid insert of unknown structure between the 7th and 8th β strands (Figure 1.6 B). 
This insert is coded by a single exon and has been referred to as the ‘regulatory loop’ 
(Reisenberg et al., 2012). Homology with fungal DAGL confirms that this 
regulatory loop is well positioned to the catalytic triad to act as a lid shielding the 
catalytic site, as in the case of GL, PL and HSL. The DAGL lid is a considerably 
large, suggesting the potential for substantial conformational changes determining 
whether the lid is open or closed (Reisenberg et al., 2012). The most remarkable 
feature of the regulatory loop is the presence of a highly conserved motif 
(PLYPPGRIIH) (highlighted in dark blue, Figure 1.7). This sequence is conserved in 
both human DAGLα and DAGLβ, as well as across mammalian, vertebrate and also 
found in plants, but less well conserved plant DAGLs (Reisenberg et al., 2012). 
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Although this conservation indicates it as an important binding site, the interaction is 
probably intra-molecular rather than inter-molecular, as the latter would require 
conservation of a binding partner. Therefore this sequence is possibly involved in 
stabilisation of the ‘open’ or ‘closed’ conformation of the regulatory loop and has 
been termed the ‘signature motif’ (Reisenberg et al., 2012).  
 
Understanding how the activity of DAGL is regulated, or what causes the regulatory 
loop to shift from the ‘closed’ to the ‘open’ state, is essential in order to design small 
molecules that specifically target either one of the DAGLs for therapeutic use. The 
potential for this was highlighted in a study on phosphodiesterase 4 (PDE4). 
Inhibitors of this enzyme were shown to either stabilise the ‘capped state’ or occupy 
the uncapped catalytic packet. The discoveries helped to demystify complex 
inhibition kinetics associated with compounds that can inhibit certain enzymes, and 
highlighted the potential to develop inhibitors specific for PDE4 isoforms (Houslay 
& Adams, 2010). The ability to target the ‘dual-gating’ regulatory mechanism of 
PDE4 demonstrates that specific inhibitors could also be developed for the DAGLs, 
following a greater understanding of how they are regulated. Discovering key sites 
important for DAGL regulation would enable effective drug design for therapeutic 
intervention. However, in addition to generating the new hypothesis, there remains a 
requirement to develop new assays to directly measure DAGL activity in cells, and 
also DAGL-dependent eCB signalling in cells.   
 
 
Creation of DAGL KO mice 
Following cloning of the DAGLs, proof of their importance 2-AG synthesis was 
obtained in studies on DAGLα or DAGLβ KO mice which highlighted differential 
functions for the enzymes (Gao et al., 2010; Tanimura et al., 2010). In the brain and 
spinal cord (where DAGLα is enriched) of DAGLα -/- mice, there was an 80% 
reduction in 2-AG levels in these areas, whereas in DAGLβ -/- there was only a 50% 
reduction (Figure 1.8). In an independent study, DAGLα KO mice displayed an 80% 
reduction in 2-AG in the cerebellum, hippocampus and striatum, with little change to 
these brain regions in DAGLβ KO mice (Tanimura et al., 2010). Importantly, this 
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study also showed that stimulus-induced increases in 2-AG are also lost in the brains 
of the DAGLα KO mice, such as depolarisation-suppression of inhibition (DSI) in 
cultured hippocampal neurons (2-AG’s role in DSI is discussed in more detail later).  
 
DAGLα is also expressed in adipose tissue and liver; in the KO animals these tissues 
had a 60% and 50% reduction in 2-AG, respectively (Gao et al., 2010). DAGLβ KO 
had no impact on adipose tissue, but in the liver resulted in a 90% reduction in 2-
AG. These studies show that the DAGLs are responsible for maintaining steady-state 
levels of 2-AG and their individual contribution depends on the tissue in which they 
are expressed. These results are highlighted in Figure 1.8.  
 
Anandamide levels were also affected, with a 40% decrease in the brains of DAGLα 
-/- mice and 20% in DAGLβ -/- brains (Gao et al., 2010). It has been suggested to be 
a result of phospholipid remodelling in KO mice, which affects the fatty acid 
composition of brain precursors for NAPE (Di Marzo, 2011), revealing a degree of 
crosstalk between these lipids. This was demonstrated when either MAGL or FAAH 
were inhibited individually, resulting in compensation activity of one enzyme when 
the other is inhibited (Long et al., 2009b). The crosstalk between anandamide and 2-
AG biosynthesis can make it difficult to dissect one from the other, and data needs to 
be interpreted with this in mind. 
 
2-AG can act as a precursor to AA synthesis by way of MAGL hydrolysis. AA 
levels changed in parallel with 2-AG changes in the brain and spinal cord in DAGLα 
KO mice (~80% reduction) as well as 90% reduction in 2-AG in the liver of DAGLβ 
KO mice (Gao et al., 2010), indicating 2-AG to be the main precursor and points to a 
role for DAGL activity in the regulation of AA synthesis. In combination with 
pharmacological studies, DAGLα and DAGLβ KO animals have unravelled crucial 
roles for these enzymes in development, synaptic plasticity, and adult neurogenesis 














Figure 1.8 Comparison of 2-AG and AA levels in wild-type and DAGL KO mice 
2-AG and AA levels were measured in tissues of mice lacking DAGLα (α -/-) and 
DAGLβ (β -/-) and compared to wild type mice control. Levels of 2-AG were 
markedly decreased in the brain and spinal cord in α-/- mice, resulting in a 80% 
decrease, whereas β-/- mice had no significant difference in the spinal cord and 50% 
reduction in the brain. There was a 50% reduction in 2-AG in the adipose tissue 
while no significant reduction was observed in β -/- mice. In the liver, there was a 
50% reduction in 2-AG in α-/- mice, compared to a 90% reduction in the liver of β -
/- mice. Reduction in AA levels changed in parallel with the reductions in 2-AG in 
the brain, spinal cord and liver, most notably was 80% reduction in AA levels in 
brain and spinal cord of α-/- mice and a 90% reduction in AA in the liver of β -/- 
mice.  
Adapted with permission from Gao et al., 2010.  
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1.5 Functions of DAGL-dependent eCB Signalling 
 
Axonal Growth and Guidance in Development 
The growth cone is a dynamic, actin-supported extension of a developing axon that 
extends fine filopodia to explore the environment. The process of extending the axon 
is regulated in a highly specific manner by growth cone receptors, which can 
promote or inhibit directed growth in response to positive or negative cues, 
respectively (Tessier-Lavigne & Goodman, 1996). Fasciculated growth can be 
driven by cell adhesion molecules (CAMs) and involves axons extending together in 
an ordered manner. It was initially thought that CAMs role in promoting growth was 
to modulate adhesion of the growth cones to their substrates. It is now known that 
they can initiate a second-messenger signalling cascade, for example, activation of 
the fibroblast growth factor (FGF) receptor and that this signalling can drive the 
axonal growth response (Walsh & Doherty, 1997).   
 
The eCB system plays a key role in development of the nervous system and its 
contribution to brain development is increasingly recognised (Bisogno, 2003; Begbie 
et al., 2004; Keimpema et al., 2010; Wu et al., 2010; Keimpema et al., 2013). There 
is considerable evidence to support this hypothesis, including the observation that 
the CB1 receptor is expressed by neurons during development (Buckley et al., 2000; 
Begbie et al., 2004), axonal growth stimulated by CAMs requires DAGL-dependent 
CB1 activation (Williams et al., 2003), eCB signalling is both chemoattractive and 
chemorepulsive to cortical interneurons (Berghuis et al., 2005; Berghuis et al., 2007) 
and finally, eCBs are involved in proliferation of neural progenitor cells, as well as 
their differentiation into their glial and neuronal fates (Jin et al., 2004; Aguado et al., 
2005; Jiang et al., 2005; Aguado et al., 2006). Much of the early work in cultured 
neurons, involving a morpholino-based strategy to knockdown CB1 in the 
developing zebrafish, showed that eCB signalling is essential for fasciculated axonal 
growth in the developing hindbrain (Watson et al., 2008). The phenotype of these 
zebrafish was not dissimilar to that seen in the developing rat retina when DAGL 
activity is inhibited (Brittis et al., 1996), whereby axons exhibited unusual behavior,  
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lacking fasciculated growth with some turning back on themselves. The signalling 
cascade within the growth cone, initiated by activation of the FGF receptor, involves 
stimulation of PLCγ to generate DAG, which in turn is hydrolysed by DAGL to 
generate 2-AG. This then acts on CB1 on the same growth cone to promote motility 
(Williams et al., 2003).  
 
Interestingly, a key role for DAGL activity in growth of the axon in vivo was 
proposed, before it was recognised that 2-AG was a CB1 receptor ligand (Brittis et 
al., 1996; Lom et al., 1998). In these early experiments, neurite outgrowth required a 
DAGL-dependent step in the FGF receptor pathway, downstream from PLCγ 
activation but upstream from calcium influx. Later experiments provided evidence 
that CB1 receptor activation was both required for and sufficient to account for the 
response (Williams et al., 2003). Therefore, DAGL-dependent eCB signalling is 
required for axonal growth and guidance. Its importance was demonstrated in the 
growth promoting activity of FGF2 (FGF receptor agonist) and a number of CAMs 
by making 2-AG available for CB1 activation (Bisogno, 2003). In support of this is 
the fact that MAGL is excluded from the motile neurite tip of the growth cone, being 
confined further back along the axon, thereby allowing 2-AG to be available to 
activate CB1 in a highly restricted manner and this is required for axonal growth 
(Figure 1.9) (Keimpema et al., 2010).  
 
Understanding the role of the eCB system during development is also important in 
the context of human health, as cannabis is one of the most widely used drugs during 
pregnancy (Hall & van Teijlingen, 2006). In conjunction with the key role of the 
eCB system during development, the impact of THC exposure during pregnancy has 
gained considerable attention, given the long-lasting effects of prenatal cannabis use 
on emotional control, social behaviours and cognition in affected offspring (Huizink 










Figure 1.9 DAGL-dependent eCB signalling is required for axon growth and 
guidance 
 
(A) The signalling cascade within the growth cone is initiated by activation of the 
FGF receptor followed by stimulation of PLCγ to generate DAG, which in turn 
is hydrolysed by DAGL to generate 2-AG. In this version of eCB signalling, 2-
AG does not need to leave the cell, whereby it acts on the CB1 receptor on the 
same growth cone to promote motility and fasciculated growth.  
 
(B) Pyramidal cells emit the first axons in cerebral circuits. Their axons exhibit 
moderate CB1 expression (CB1R), being distributed along the axis of the 
elongating axon. The DAGLs are co-expressed in excitatory axons, allowing 
eCB signalling to drive elongation of the growing axon. 2-AG is in much greater 
abundance than anandamide (AEA) and is therefore the more likely eCB to be 
involved. However this does not eliminate the possible, but as yet unidentified, 
role of anandamide. 
Adapted with permission from Harkany et al., 2008. 
 
(C) Schematic of the the axonal growth cone. MAGL (green) expression is restricted 
further down along the axon. This allows 2-AG, synthesised by DAGLα 
(orange), to be available for CB1 (red) activation resulting in stimulatation of 
motility and direction of the growth cone.  

























Synaptic Plasticity – Investigating the role for DAGL in the Adult 
Brain 
In the paper that reported the cloning of the DAGLs, a switch in DAGLα expression 
from the growing axon during development to dendritic fields in the adult was noted. 
It is now clear that DAGLα expression is lost from axons after synapses form, but 
retained at high levels in dendritic spines throughout the CNS (Bisogno, 2003; 
Yoshida et al., 2006). This switch in expression explains the switch in function of 
DAGL-dependent eCB signalling from the role in axonal growth and guidance 
during development, to the role in retrograde synaptic signalling at functional 
synapses in the adult. Coupled with the fact that CB1 is restricted to the presynaptic 
terminal in the adult, the eCB system exhibits a molecular architecture that underpins 
its key role in synaptic plasticity. In this context, the role of the eCB system in 
retrograde synaptic signalling and synaptic plasticity was established in 2001, prior 
to the identification of the DAGLs (Kreitzer & Regehr, 2001; Maejima et al., 2001; 
Ohno-Shosaku et al., 2001; Wilson & Nicoll, 2001). It is now recognised that 
DAGL-dependent eCB signalling plays a role in both short- and long-term synaptic  
plasticity throughout the brain and spinal cord (Kano et al., 2009). 
 
Synaptic plasticity is the ability of both excitatory and inhibitory synapses to 
strengthen or weaken over time in response to increases or decreases in their activity. 
There are several underlying mechanisms that cooperate to achieve synaptic 
plasticity, including changes in the quantity of neurotransmitters (NTs) released into 
a synapse and changes in how effectively cells respond to those NTs. For most of the 
past century, communication between nerve cells was considered to be polarised and 
that it took place at synapses between a sending cell that was presynaptic and a 
receiving cell that was postsynaptic.  
 
Retrograde signalling refers to the process by which a messenger is released by a 
postsynaptic dendrite and travels "backwards" across a chemical synapse to bind to 
the axon terminal of the presynaptic neuron (Regehr et al., 2009). Retrograde 
signalling regulates release of a NT, thereby affecting synaptic strength. In this sense 
retrograde neurotransmission mainly serves to regulate typical, anterograde 
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neurotransmission. In the 1990s, retrograde signalling became an accepted 
phenomenon. During this decade there were many reports on retrograde inhibition of 
neurotransmission. For example, brief activation of Purkinje cells in cerebellar slices 
induced a retrograde inhibition of presynaptic terminals (Llano et al., 1991). Using 
inhibitory post-synaptic currents (IPSCs), suppression of gamma-aminobutyric acid 
(GABA)-ergic signalling was shown in CA1 pyramidal cells of the hippocampus 
following post-synaptic modulations in calcium (Pitler & Alger, 1992). This 
phenomenon, whereby depolarisation of postsynaptic neurons induces a transient 
suppression of inhibitory synaptic transmission, was termed depolarisation 
suppression of inhibition (DSI) (Alger & Pitler, 1995). The fact that DSI is triggered 
by elevation in calcium concentration and is associated with a reduction of NT 
release from postsynaptic terminals (Pitler & Alger, 1992; Vincent & Marty, 1993) 
strongly suggested the involvement of retrograde signalling (Figure 1.10). 
 
One of the first studies to describe inhibition of neurotransmission by CBs was in 
1970, where acetylcholine (Ach) release in the guinea-pig ileum was inhibited by Δ9-
THC (Gill et al., 1970). Following the generation of CB1 antibodies and subsequent 
immunohistochemical studies, together with KO studies, CB1 was identified as a 
predominantly presynaptic receptor throughout the adult brain and spinal cord 
(Katona et al., 2006; Kawamura et al., 2006) at both excitatory and inhibitory 
synapses (Egertova & Elphick, 2000), including at presynaptic terminals of 
glutaminergic synapses in the hippocampus and other areas of the brain (Ferraro et 
al., 2001). The CB1 receptor therefore is well positioned to modulate NT release via 
a retrograde messenger and this has been backed up by extensive pharmacological 
studies - reviewed by Schlicker and Kathmann (Schlicker & Kathmann, 2001). For 
example, Cadogan et al. demonstrated that anandamide and the CB1 agonist CP-
55,940 could inhibit dopamine release in electrically stimulated rat striatal and 
cortical slices, which was reversed by Rimonabant (SR141716), a selective CB1 
antagonist (Cadogan et al., 1997). The CB1 agonist WIN 55,212-2 inhibited release 
of noradrenaline in the hypothalamus and striatum, as well as GABA and ACh 
release from human hippocampal slices, an effect blocked by the CB1 antagonist, 
SR141716 (Gobel et al., 2000; Katona et al., 2000). CB agonists inhibited serotonin 
activity in the cerebral cortex (Nakazi et al., 2000) and ACh release in the medial 
61 
 
prefrontal cortex, hippocampus, and striatum (Carta et al., 1998; Gessa et al., 1998) 
an effect again blocked by SR141716 (Gessa et al., 1998; Tzavara et al., 2003).  CB1 
activation inhibits glutamate release in the cerebellum, hippocampus, prefrontal 
cortex and substantia nigra (Sullivan, 1999; Auclair et al., 2000; Hoffman & Lupica, 
2000; Nakazi et al., 2000). CB1 activation was also shown to modulate synaptic 
transmission itself. This was demonstrated in a study looking at Purkinje cells in rat 
cerebellar slices, where both excitatory postsynaptic currents (EPSCs) and sIPSCs 
were strongly inhibited by WIN 55212-2, an effect again blocked by SR141716 
(Takahashi & Linden, 2000). 
 
In 2001, two groups provided evidence that an eCB was serving as a retrograde 
messenger in DSI using cultured hippocampal neurons (Ohno-Shosaku et al., 2001) 
and hippocampal slices (Wilson & Nicoll, 2001). At the same time, Kreitzer and 
Regehr discovered the counterpart for DSI, depolarisation suppression of excitation 
(DSE) is also mediated by eCBs in cerebellar Purkinje cells (Kreitzer & Regehr, 
2001). (An overview of the role of the eCB system in DSI and DSE is highlighted in 
Figure 1.10)  In the same year, two groups discovered another form of eCB-mediated 
short term depression (STD) in the cerebellum (Maejima et al., 2001) and in the 
hippocampus (Varma et al., 2001). Activation of group 1 metabotropic glutamate 
receptors  (mGluR1s) on postsynaptic neurons induced a transient suppression of 
synaptic transmission at excitatory synapses on cerebellar Purkinje cells (Maejima et 
al., 2001) and inhibitory synapses on CA1 pyramidal cells (Varma et al., 2001), 
which was sensitive to CB1 antagonists and therefore used an eCB as a retrograde 
messenger.  
 
A form of striatal synaptic plasticity, long-term depression (LTD) was also shown to 
be dependent on the eCB system. Striatal LTD induced by high frequency 
stimulation of corticostriatal afferents was prevented by pharmacological or genetic 
depletion of CB1, indicating the involvement of eCBs in a circuit necessary for habit 
formation and motor control (Gerdeman et al., 2002). LTD was demonstrated at 
glutamatergic synapses of the nucleus accumbens, which was eCB-dependent and 
involved mGluRs and elevation in postsynaptic intracellular calcium stores, 
62 
 
revealing a role of the eCB system in the endogenous brain reward system (Robbe et 
al., 2002). 
 
The precise mechanisms of eCB production for retrograde signalling, initiated by 
physiologically relevant synaptic activity was next examined. eCB-mediated 
retrograde suppression can be triggered by membrane depolarisation that elevates 
intracellular calcium concentrations to a micromolar range (Brenowitz & Regehr, 
2003). Activation of Gq-coupled receptors, including mGluR1, coupled with PLCβ 
pathway (leading to the production of DAG) also causes eCB-mediated suppression 
of synaptic transmission (Maejima et al., 2001; Kim et al., 2002; Ohno-Shosaku et 
al., 2003)  Muscarinic Ach receptor activation also stimulates eCB release, resulting 
in DSI in the hippocampus (Kim et al., 2002). Finally, eCB-mediated retrograde 
suppression results from cooperative action of Gq-coupled receptor activation and 
elevated intracellular calcium concentration (Varma et al., 2001; Hashimotodani et 
al., 2005; Maejima et al., 2005). Of these, the third mode appears physiologically 
most relevant as eCB-mediated retrograde suppression is induced by weak activation 
of Gq-coupled receptors and physiological increase in intracellular Ca2+ to a 
submicromolar range, neither of which by itself produces suppression 
(Hashimotodani et al., 2005; Maejima et al., 2005) 
 
As the eCB system’s role in regulating NT release at both excitatory and inhibitory 
synapses became clear, it was important to know which of the eCBs is involved. 2-
AG proved to be the better candidate over anandamide, as it is the most abundant 
eCB in the brain and is strictly recognised as a retrograde messenger (Alger, 2002; 
Kano et al., 2009) being synthesised ‘on-demand’ by DAGL (Stella et al., 1997). 
Studies using inhibitors for 2-AG synthesis showed that 2-AG indeed mediates 
short-and long-term eCB-mediated retrograde suppression (Melis et al., 2004; Safo 
& Regehr, 2005). As mentioned above, DAGLα was found to be located 
postsynaptically in the adult brain, being present in dendrites and absent from axons 
in the brain of the adult mouse (Bisogno, 2003). A number of more detailed studies 
have confirmed and extended this key finding. For example, immune-electron 
microscopy has shown DAGLα to be localised to postsynaptic dendritic spines in 
cerebellar neurons (Yoshida et al., 2006) and concentrated in heads of dendritic 
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spines of glutamatergic synapses throughout the hippocampal formation (Katona et 
al., 2006). DAGLα is therefore in the right place to synthesise 2-AG in response to 
depolarisation signals.  
 
In support of this, 2-AG meets all of the criteria as a retrograde NT, as outlined by 
Regehr and colleagues (Regehr et al., 2009): the appropriate machinery for 
synthesising and releasing the retrograde messenger must be located in the 
postsynaptic neuron (DAGL localised to the postsynaptic neuron), disrupting the 
synthesis and/or release of the messenger from the postsynaptic neuron must prevent 
retrograde signalling (DAGL blockade and KO studies, discussed below), the 
appropriate targets for the retrograde messenger must be located in the presynaptic 
bouton, disruption of which eliminates retrograde signalling (inhibition of the 
presynaptic CB1 receptor disrupts retrograde transmission) and exposing the 
presynaptic bouton to the messenger should mimic retrograde signalling, as seen 
when exogenous CBs suppress NT release (Cadogan et al., 1997; Gobel et al., 2000; 
Katona et al., 2000). Therefore, DAGLα-synthesised 2-AG is the likely NT to signal 
in a retrograde fashion to activate the presynaptic CB1 receptor, thereby contributing 
















Figure 1.10 Depolarisation suppression of inhibition / excitation (DSI/DSE) 
The role of the eCB system in the mechanisms of DSI and DSE. Postsynaptic 
depolarization induces Ca2+ influx through voltage-gated Ca2+ channels. Elevation of 
intracellular Ca2+ concentration triggers biosynthesis of eCBs, which are then 
released from postsynaptic neurons, activate presynaptic CB1 receptors, and 
suppress inhibitory GABA (DSI, left) or excitatory glutamate (DSE, right) release. 
The exact mechanism of how Ca2+ influx into the cell increases activity of DAGL, 
and 2-AG synthesis, has not yet been characterised.  
 
Adapted with permission from Hashimotodani, et al., 2007 
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DAGL-dependent Retrograde Signalling  
The exquisite nature of the relationship between the components of the eCB system 
is exemplified in pyramidal neurons of the basolateral amygdala, where the level of 
CB1 on the presynaptic terminal is matched to the amount of DAGLα at the 
postsynaptic site for three different types of synapse found on the same neuron 
(Yoshida et al., 2011). Pharmacological blockade of DAGL also provided further 
evidence for DAGL’s role in retrograde control of neurotransmission. THL blocked 
DSI and DSE in the cerebellum and hippocampus (Szabo et al., 2006; 
Hashimotodani et al., 2013). Subsequently OMDM-188, a relatively specific 
inhibitor for DAGL (Ortar et al., 2008), effectively blocked DSI in slices from the 
hippocampus, striatum and cerebellum and mGluR-induced retrograde eCB 
signalling in cultured hippocampal neurons (Hashimotodani et al., 2013).  
 
Concrete evidence for the role of 2-AG and DAGL came from KO studies performed 
by two independent groups (Gao et al., 2010; Tanimura et al., 2010). eCB-mediated 
retrograde signalling was lost at synapses of DAGL-KO mice, with DSI being 
entirely absent in the hippocampus, striatum and cerebellum (Figure 1.11). In 
contrast, loss of DAGLβ resulted in only small and insignificant reduction in the DSI 
response (Gao et al., 2010; Tanimura et al., 2010). The general paradigm for 2-AG 
metabolism and signalling at adult synapses is that it results from DAGLα, rather 
than DAGLβ activity, as retrograde suppression is normal in DAGLβ KO mice (Gao 
et al., 2010; Tanimura et al., 2010). A third study also showed a dominant role for 
DAGLα in synaptic plasticity in the prefrontal cortex, where DSI was abolished in 
DAGLα KO mice and was unaffected in DAGLβ KO mice (Yoshino et al., 2011). 
Together these studies pointed to DAGLα, rather than DAGLβ, as the postsynaptic 
2-AG synthesising enzyme for eCB-mediated suppression of NT release.  
 
A more recent study suggested the cooperative production of 2-AG by both the 
DAGLs, as seen using RNAi in autaptic hippocampal neurons (Jain et al., 2013). 
However, these are tissue culture experiments and the authors did not comment on 
the known unreliability of off-targets commonly associated with the use of RNAi - 
the chance of which in some cases can be as high as 80% (Qiu et al., 2005). DAGLβ 
may be capable of playing a role in modulation of neurotransmission, but to what 
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extent has yet to be elucidated. In this context there is as yet no evidence for DAGLβ 
being expressed in post-synaptic spines. 
 
In summary of the findings discussed, the increase in 2-AG production is mediated 
by three different mechanisms; postsynaptic depolarisation-induced calcium influx 
(DSI/DSE), activation of Gq/11 protein-coupled receptors (including mGluR1) with 
less robust calcium signals, or mGluR activation alone in a calcium-independent 
manner (Maejima et al., 2001; Ohno-Shosaku et al., 2001; Hashimotodani et al., 
2005; Maejima et al., 2005; Kano et al., 2009) mGluR1 activation results in the 
formation of DAG via Gq protein and PLCβs (Masu et al., 1991), followed by 
increases in DAGL activity and 2-AG levels.  
 
How these processes influence the action of DAGL, and hence allow an increase in 
2-AG production remains unclear and is the focus of this study. One report 
demonstrated a functional role for the interaction of calcium/camodulin-dependent 
protein kinase IIa (CamKIIa) with DAGLα (Shonesy et al., 2013). DAGLα activity 
was increased by genetic deletion of CamKIIa, resulting in an increase in short-term 
retrograde eCB signalling at striatal glutamatergic synapses. Activated CamKIIa 
interacted with the C-terminal domain of DAGLα, phosphorylated two serine 
residues, resulting in inhibition of DAGLα activity in vitro, suggesting that calcium 
influx into the postsynaptic cell could activate CamKIIa, which in turn could inhibit 
the activity of DAGLα thereby modulating retrograde signalling (Shonesy et al., 
2013). 
 
The precise mechanism of how CB1 itself acts to suppress Ca2+ influx into the cell is 
still controversial. The reduction in calcium entry into boutons following CB1 
activation could be the consequence of either a direct decrease of voltage-gated 
calcium channel function or an indirect effect through the opening of presynaptic 
potassium channels (Daniel & Crepel, 2001). In contrast, the mechanism underlying 
the reduction of inhibitory synaptic transmission upon CB1 activation at single-
bouton level is still unknown. However, recently it was found that in the CA3 region 
of the hippocampus, inhibition of N-type voltage-gated calcium channel function is 
the main mechanism underlying CB1-mediated suppression of synaptic inhibition 
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(Szabo et al., 2014). This was in line with data obtained from an earlier study, where 
CB1 activation reduced the amplitude of voltage-gated calcium currents in a 
neuroblastoma-glioma cell line in a potent and reversible manner (Mackie & Hille, 
1992). More details on how CB1 regulates NT release are yet to be studied in detail, 
but should open up new avenues for a better understanding of how eCBs (and Δ9-











Figure 1.11 Inhibition of neurotransmitter release by retrograde signalling is 
lost in DAGLα KO mice 
DSI in the hippocampus of DAGLα KO (α −/−) and DAGL β KO (β −/−) mice 
compared with wild-type (+/+) mice. The graph above shows a comparison of the 
average time course for eIPSC amplitudes after depolarization between wild-type, 
DAGLα KO and DAGLβ mice. No difference was observed between wild-type and 
DAGLβ mice. However DSI is absent in DAGLα KO mice highlighted a key role for 
DAGLα in retrograde suppression of neurotransmitter release. DSI for each genotype 
was averaged across all cells sampled, four to five DSI protocol repeats per sampled 
cell (+/+, n = 35; α−/−, n = 21; β−/−, n = 21).  
 





Adult neurogenesis was first described in the adult brain by Joseph Altman in 1962 
(Altman, 1962) and again in 1977, where Kaplan suggested the existence of dividing 
neurons in the hippocampus and olfactory bulb (Kaplan & Hinds, 1977). However, 
these remained contentious findings for many years and it was not until the 1990s 
that the study of adult neurogenesis became a mainstream pursuit. The potential of 
adult neurogenesis for the treatment of disease was soon realised when neuronal 
progenitors were isolated from the adult rat hippocampus, cultured in vitro and 
transplanted back into the hippocampus, where they differentiated into neurons. This 
suggested that these cells retained the capacity to generate mature neurons when 
grafted into the adult rat brain (Gage et al., 1995). Adult neurogenesis is now known 
to constitute a form of cellular plasticity in the developed brain that impacts on 
memory, depression and neurodegenerative diseases (Zhao et al., 2008). 
 
Adult neurogenesis occurs in two areas of the mammalian brain; the sub-ventricular 
zone (SVZ) (Alvarez-Buylla & Garcia-Verdugo, 2002) and the hippocampus (van 
Praag et al., 2002). In the SVZ, stem cells generate migratory neuroblasts that 
traverse the rostral migratory stream (RMS) to populate the olfactory bulb. In the 
case of the hippocampus, neurogenesis is localised to the granule cell layer in the 
dentate gyrus, an area associated with the formation of new memories.  
 
The roles of DAGL in axonal growth and guidance during development and in 
retrograde regulation of synaptic plasticity in the adult could have been predicted 
based on the expression patterns of the DAGLs and CB1 receptors. Based on this 
approach, the expression of DAGLα in the lateral walls of the ventricle in the adult 
brain raised the possibility of a function in neurogenesis. In this context, DAGLα is 
present in all the proliferating cells in the SVZ (Goncalves et al., 2008). 
Pharmacological evidence in young adult mice has shown a role for DAGLα/β in 
adult neurogenesis, where use of RHC80267 and THL resulted in a ~ 60% decrease 
in new neurons formed in the olfactory bulb two weeks after drug administration had 
ceased (Goncalves et al., 2008), an effect which could be replicated by blocking CB2 
but not CB1 receptors (Goncalves et al., 2008). This was also seen in DAGLα KO 
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animals, with a 50% reduction in proliferation in the SVZ in DAGLα -/- (but not 
DAGLβ KO mice) and a 50% reduction in the hippocampus in both DAGLα -/- and 
DAGLβ -/- animals (Gao et al., 2010). DAGL-dependent eCB tone is also important 
for the migration of the SVZ-derived neuroblasts to the olfactory bulb, where CB1 
and CB2 antagonists dramatically changed the morphology of the migratory cells in 
the RMS to non-migratory phenotype (Oudin et al., 2011a). Based on both 
pharmacological and KO studies, it has been shown that DAGL activity is required 
for adult neurogenesis in both the SVZ and hippocampus and that this directly 
impacts on the number of proliferating neuronal stem cells in the adult brain.  
 
Adult neurogenesis in the SVZ declines with age in both the mouse (Goncalves et 
al., 2008) and the adult brain (Knoth et al., 2010) and may be due to an overall 
decline in eCB tone that might account for age-related deterioration in neurogenesis. 
The therapeutic implications for targeting the eCB system to treat neurodegeneration 
are vast. A greater understanding of how this process is regulated, as well as 





1.6 Therapeutic implications of targeting the eCB 
system 
 
Neuroprotection following brain injury 
There is growing evidence that the eCBs can have neuroprotective and anti-
inflammatory effects in response to harmful stimuli. Both 2-AG and anandamide 
have been shown to be elevated following brain injury and are believed to exert their 
neuroprotective effects by preventing neuronal damage and protecting against 
excitotoxicity (Hansen et al., 2001; Panikashvili et al., 2001; Marsicano et al., 2003; 
Mechoulam & Lichtman, 2003). For example, 2-AG, anandamide and a non-
hydrolysable analogue of anandamide all increased viability and cell survival in 
primary cultures of cerebral cortical neurons in an in vitro model for ischemia (Sinor 
et al., 2000). 2-AG levels were elevated in the brains of mice following closed head 
injury and when synthetic 2-AG was administered, there were significant and 
concentration-dependent reductions in brain oedema and cell death, indicating a 
protective role of the eCB system in damage and repair (Panikashvili et al., 2001). 
Furthermore, anandamide was shown to be neuroprotective following inflammation-
induced neuronal damage (Eljaschewitsch et al., 2006). The eCB system therefore 
can respond differently to various harmful stimuli. For example, hippocampal levels 
of 2-AG, but not anandamide, were elevated in response to Aβ42 infusion, a model 
of Alzheimer’s disease (AD) (van der Stelt et al., 2006). In contrast, anandamide 
(and not 2-AG) levels were raised following treatment with the excitotoxin, kainic 
acid (Marsicano et al., 2003). These findings demonstrate the ‘on-demand’ synthesis 
of the 2-AG and anandamide in response to harmful stimuli and may play a role in 
brain function homeostasis.  
 
The mechanism for eCB neuroprotection has been linked to an enhanced neuronal 
sensitivity to eCBs by brain-derived neurotrophic factor (BDNF), where BDNF 
increases the expression of CB1 receptor transcripts and decreases expression of 
MAGL transcripts (Maison et al., 2009). Another potential mechanism may be that 
2-AG has the ability to suppress the formation of reactive oxygen species (McCarron 
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et al., 2003), a key player in oxidative stress in a number of neurodegenerative 
diseases, including Parkinson’s disease (PD), Huntington’s disease, AD, Down’s 
syndrome, ataxia, multiple sclerosis, amyotrophic lateral sclerosis, schizophrenia, 
and Tardive Dyskinesia (Kovacic & Somanathan, 2012). However, their 
neuroprotective effects may also be linked to their anti-inflammatory properties.  
 
 
Anti-inflammatory properties of the eCBs 
CBs, both endogenous and exogenous can suppress inflammation (Tanasescu & 
Constantinescu, 2010), while CB receptor expression can be upregulated in immune 
cells by pro-inflammatory cytokines (Jean-Gilles et al., 2015), pointing to a role for 
the eCB system in regulation of neuroinflammation. Both 2-AG and anandamide 
levels have been found to be elevated in the basal ganglia of animal models of PD, a 
disease characterised by a loss of dopaminergic neurons in the basal ganglia. Full 
restoration of locomotion in PD animal models was observed in the presence of CB1 
antagonists (Di Marzo et al., 2000) and anandamide levels in the cerebrospinal fluid 
of PD patients were found to more than double that of controls, pointing to a 
compensatory / protective role of eCBs when dopaminergic neurons have been 
compromised (Pisani et al., 2010). In a rat model of PD, levodopa treatment did not 
affect eCBs in the basal ganglia, while direct activation of CB1 alleviated abnormal 
involuntary movements (Ferrer et al., 2003; Morgese et al., 2007). Interestingly, 
anandamide elevations in these animals as a result of the FAAH inhibitor, URB597 
were only seen when TRPV1 was inhibited (Morgese et al., 2007). Raised eCB 
levels were also found in animal models of Alzheimer’s disease (AD) (van der Stelt 
et al., 2006). The raised eCB levels are likely to be linked with the inflammatory 
response associated with PD and AD, as increased 2-AG levels resulting from 
MAGL inhibition can suppress cytokines and microglial activation in response to a 
pro-inflammatory stimulus (Ramirez et al., 2005; Nomura et al., 2011).  
 
Under normal physiological conditions, microglia, a type of glial cell / macrophage 
in the brain and spinal cord, exhibit a deactivated state associated with anti-
inflammatory and neurotrophic factors (Streit, 2002). Microglia are then activated in 
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response to invading pathogens or tissue damage, resulting in an inflammatory 
response. In a normal state, this is self-limiting and resolves itself once the pathogen 
has been eradicated, or tissue has been repaired. However in some disease states, 
sustained inflammation implies persistence of the inflammatory stimulus, such as a 
protein aggregates seen in AD. Uncontrolled inflammation can result in production 
of neurotoxic factors that amplify underlying disease states. Neuroinflammation, a 
prominent feature in many neurodegenerative diseases, contributes to progressive 
cell damage and neuronal cell loss. Direct evidence for an innate inflammatory 
response in AD was described, with subsequent studies having been documented for 
inflammatory responses in PD and in multiple sclerosis (MS) (Glass et al., 2010). 
MS is an inflammatory, autoimmune, demyelinating disease of the CNS (Compston 
& Coles, 2002) and eCBs are also raised in animal models of the disease (Pertwee, 
2002). Administered CBs have some effect on spasticity and pain in MS, both 
experimentally and in clinical trials in humans (Baker et al., 2000; Baker et al., 
2007; Zajicek et al., 2012), possibly by reducing neuroinflammation. As a result 
Sativex®, has recently become the first botanical cannabis-based medicine to be 
licenced, in some European countries, for the treatment of spasticity (Kmietowicz, 
2010), highlighting the benefit of therapeutically targeting the eCB system and the 
potential benefit for other disease states involving neuroinflammation.  
 
The role of the eCB system in neuroinflammation appears to be two-fold; on the one 
hand eCBs can have anti-inflammatory effects, while on the other hydrolysis of 2-
AG by MAGL results in AA production leading to prostaglandin synthesis. 
Prominent among the known pro-inflammatory stimuli in the nervous system are the 
prostaglandins, which are produced from AA by cyclooxygenase enzymes, COX-1 
and COX-2; both of which are present in neurons and glial cells (Simmons et al., 
2004). Rodents treated with COX inhibitors or lacking COX enzymes show 
protection in models of neurodegenerative diseases that have an inflammatory 
component (Glass et al., 2010). However, gastrointestinal and cardiovascular 
toxicities displayed by COX inhibitors have limited their translational potential for 
neuroinflammatory syndromes (Ng & Chan, 2010). Therefore, the eCB system may 




2-AG serves as the precursor for the primary AA pool of neuroinflammatory 
prostaglandins, by way of MAGL hydrolysis. Genetic or pharmacological blockade 
of MAGL results in elevated brain levels or 2-AG and corresponding reductions in 
AA (Cravatt et al., 2001; Long et al., 2009a; Zhong et al., 2011). One study found 
that inactivation of MAGL also caused significant reductions in several 
prostaglandins and other eicosanoids in the brain and elevations in MAGs, including 
2-AG (Nomura et al., 2011). Mice treated with the pro-inflammatory agent, LPS 
resulted in an increase in brain eicosanoids, an effect inhibited by the specific 
MAGL inhibitor, JZL184 (Nomura et al., 2011). MAGL inactivation robustly 
suppressed production and accumulation of β-amyloid, one of the hallmarks of the 
disease, in a mouse model of AD (Chen et al., 2012). MAGL inactivation also 
prevented neuroinflammation, decreased neurodegeneration, maintained integrity of 
hippocampal synaptic structure and function, improved long-term synaptic plasticity, 
spatial learning and memory in animal models of AD (Chen et al., 2012); this may 
be a result of a combination of reduced AA precursor and increased eCB levels.  
 
It has also been shown that 2-AG can reduce COX-2 expression through signalling at 
the CB1 (but not CB2) receptor. Excessive expression of hippocampal COX-2 is 
reduced by 2-AG in response to proinflammatory and excitotoxic stimuli, thereby 
providing neurons with protection against harmful stimuli (Zhang, 2008). This could 
help explain the eCB system’s role in pain, the activation of which being one 
component in pain alleviation (Pertwee, 2001). Suppression of COX-2 by 2-AG 
could also be of therapeutic benefit in age-associated muscle inflammation. This 
inflammation is a major factor in the degenerative decline in skeletal muscle (Schaap 
et al., 2006), where COX-2 activity is a chief player in initiating and sustaining 
components in tissue inflammation.  
 
Thus, taken together anti-inflammatory and antioxidant properties of eCBs may 
either add or synergise to enhance its activity as a neuroprotective agent 
(Panikashvili et al., 2001), pointing to the role for the elevated eCB levels seen in 
PD, AD and MS. As a result, MAGL is attracting attention as a therapeutic target for 




Other therapeutic implications of targeting the eCB system 
As discussed above, the DAGLs have a clear role in both inflammation and 
neuroprotection, implicating the enzymes in a number of diseases where these 
processes are compromised. The eCB system is now recognised as an important 
physiological modulator of other various CNS processes including pain (Butler et 
al., 2008; Sagar et al., 2009), appetite (Jesudason & Wittert, 2008; Stoving et al., 
2009), motor function (Fernandez-Ruiz et al., 2002; Dowie et al., 2009), neural cell 
fate (Guzman et al., 2002) and as discussed in detail above, synaptic plasticity.  
 
One recent study has linked the eCB system to fragile X syndrome, the most 
commonly known genetic cause of autism (Jung et al., 2012). Fragile X mental 
retardation protein regulates signalling of mGluR5 receptors in the brain, deletion of 
which in mice causes enhancement of mGluR5-mediated LTD in both the 
hippocampus and cerebellum – a process regulated by the eCB system. The term 
‘eCB signalosome’ was used to refer to a multiprotein complex of mGluR5 and 
DAGLα in the presynaptic neuron, which the authors hypothesised provides a 
structural scaffold to allow a 2-AG signalling pool to form, that is distinct from the 
intracellular pool of 2-AG involved in phospholipid remodelling and eicosanoid 
biosynthesis (Piomelli, 2003). This group showed that mGluR5-mediated LTD at 
excitatory synapses of the ventral striatum and prefrontal cortex is absent in fragile X 
KO mice, paired with inadequate 2-AG production and structural disorganisation of 
the eCB signalosome. Importantly, 2-AG enhancement, via JZL184 MAGL 
inhibition, normalised this synaptic defect and corrected the behavioural 
abnormalities in these KO mice (Jung et al., 2012). 
 
CBs, whether as endogenously released eCBs or administered drugs, have been 
shown to reduce symptoms of several disorders. Licensed medicines that exploit 
beneficial effects of direct CB receptor activation have already been developed 
(Pertwee, 2009). Three medicines that activate CB1/CB2 are currently in the clinic: 
Cesamet (nabilone), Marinol (dronabinol; Δ9-THC) and Sativex (Δ9-THC with 
cannabidiol). These medicines can be prescribed for nausea following chemotherapy 
(Cesamet and Marinol), appetite stimulation (Marinol), for pain relief in cancer, and 
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as mentioned above, neuropathic pain and for spasticity in adults with MS (Sativex) 
(Pertwee, 2009). The anti-obesity link with the eCB system led to the development 
of the CB1-specific compound SR141716A, known commercially as Rimonabant, 
which also had potential for treatment of metabolic syndrome and drug addiction 
(Pertwee, 2005; Le Foll et al., 2009). However following the link of this drug with 
anxiety, depression, and suicide, the European Medicines Agency called for its 
withdrawal from the market in 2008 (Le Foll et al., 2009). Since then, major 
pharmaceutical companies have stopped further clinical research on this class of 
drug and seem to have lost interest entirely in all drugs that block CB1 receptors. 
However the potential of targeting the eCB system is still generating a great deal of 
interest for areas such as neuropathic pain (Lau & Vaughan, 2014), liver disease 
(Basu et al., 2014) and for eCB’s anti-proliferative effects in cancer (Mimeault et al., 
2003), with the idea of designing more specific drugs to minimise off-target effects. 
 
These points highlight the potential for therapeutically targeting the eCB system. 
Strategies for improving the efficacy and/or benefit-to-risk ratio of CB agonists in 
the clinic include targeting CB receptors outside the blood-brain barrier or targeting 
CB receptors expressed by a particular tissue. As the DAGLs produces 2-AG ‘on-
demand’ in response to cellular queues, this enzyme could prove to be an attractive 
target, as the enzymes display different levels of activation and could result in an 
overall slower / lower increase in 2-AG across the CNS or elsewhere, thereby 





DAGL as a more attractive target than MAGL 
eCB signalling is terminated by hydrolysis of the eCBs by FAAH or MAGL. 
Specific tools to independently block anandamide and 2-AG metabolism have 
emerged from attempts to uncouple their signalling pathways and associated 
behavioural processes. JZL184 is a potent selective inhibitor of MAGL and was 
identified through activity-based protein profiling (ABPP) (Long et al., 2009a). 
ABPP of serine hydrolases uses reported-tagged fluorophosphonates which serve as 
general activity-based probes for this large and diverse class of enzymes. Use of 
ABPP can evaluate the potency and selectivity of small-molecule enzyme inhibitors 
directly in complex proteomes (Liu et al., 1999; Leung et al., 2003). JZL184 raised 
brain 2-AG by 8-10 fold without altering anandamide and JZL184-treated mice 
exhibited a broad array of CB1-dependent behavioural effects, including analgesia, 
hypothermia, hypomobility and catalepsy (the tetrad test for CB activity) and 
mimicked much of the pharmacological profiles typically seen with CB1 agonists 
(Cravatt et al., 2001; Wiley & Martin, 2003). These effects were mediated through 
the CB1 receptor, as in each case the effects of JZL184 were blocked by pre-
treatment with the CB1 antagonist rimonabant.  
 
Interestingly, FAAH inhibitors caused analgesia but no other CB behavioural 
phenotypes (Long et al., 2009a). While it was thought that the CB phenotypes from 
this study could be pharmacologically uncoupled from more beneficial effects (e.g. 
analgesia) by titrating the magnitude of MAGL inhibition in vivo, 2-AG levels 
increased significantly across the entire dose-range tested, even though lower doses 
resulted in less blockage of MAGL activity; that is to say, even partial inhibition of 
MAGL was sufficient to augment 2-AG-mediated eCB signalling in vivo. In addition 
to this, prolonged MAGL inactivation causes profound alterations in the brain eCB 
system, while JZL184 lost its analgesic activity and produced cross-tolerance to CB1 
agonists, an effect also seen in mice lacking MAGL. Chronic MAGL blockade also 
causes physical dependence, impaired eCB-dependent synaptic plasticity and 
desensitised brain CB1 receptors. In contrast, none of these effects were observed in 
mice with chronically disrupted FAAH, which instead maintained an analgesic 




These findings suggest that therapeutically targeting DAGL, rather than MAGL, may 
have greater potential and benefit for enhancing eCB signalling or reducing the 
availability of AA for prostanoid synthesis.  As discussed previously, establishment 
of the function of the DAGLs as central players in eCB signalling required gene 
knockout studies to complement the pharmacology experiments (Gao et al., 2010; 
Tanimura et al., 2010) and this was essential given the poor selectivity of the 
available drugs.  The situation is perhaps even worse for anandamide given that there 
are no drugs that selectively block its synthesis and no genes that have been 
demonstrated to be essential for this pathway.  At the outset of this thesis it was 
simply not practical to propose a genetic strategy as a timely and cost-effective 
means to dissect out the pathways that regulate eCB signalling in cells.  However, 
this position has been radically transformed with the advent of CRISPR and the 






1.7 Precise Genome modification 
 
Recent advances in the development of genome editing technologies have enabled 
cleavage of DNA in a site-specific manner, thereby substantially improving the 
ability to make precise changes in the genome of eukaryotic cells. This ability to 
engineer biological systems has enormous potential to interrogate genetic 
contribution to disease. There are currently three main technologies used; Zinc-
Finger Nucleases (ZFNs), Transcriptor Activator-like Effector Nucleases (TALENs) 
and RNA-guided Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPR)-Cas nuclease system. ZFNs and TALENs use a strategy of a DNA-
binding domain, to specifically recognise the gene of interest. This is combined with 
a DNA-cleavage (FokI) domain to induce a double-strand break (DSB). FokI 
cleavage domain must dimerise in order to cleave the target DNA, and so a pair of 
DNA-binding domains must be used (to target non-palindromic DNA). Although 
ZFNs and TALENs have proved effective for genetic manipulation, a new ZFN or 
TALEN protein must be generated for each DNA target site, which can have huge 
cost implications. In contrast, Cas9 endonuclease is guided by small RNAs to induce 
a DSB. It achieves this through its two active domains, RuvC (cleaves the 
complementary strand) and HNH (cleaves the non-complementary strand) (Gasiunas 
et al., 2012; Jinek et al., 2012; Nishimasu et al., 2014). CRISPR/Cas9 system can 
facilitate gene editing by simply identifying a 20 nucleotide targeting sequence to 
guide Cas9 to a specific target locus. The CRISPR/Cas9 system is therefore 
markedly easier to design, highly specific, efficient and a much cheaper method for 





What is the CRISPR/Cas System? 
Bacteria and Archaea have evolved adaptive immune defences to cope with various 
environmental stresses, enabling them to defend themselves from invading viruses or 
plasmids. These are called CRISPR and CRISPR-associated (Cas) proteins (Horvath 
& Barrangou, 2010; Bhaya et al., 2011). These defence systems rely on small RNAs 
for sequence-specific detection and silencing of foreign nucleic acids. CRISPR/Cas 
systems are composed of cas genes, organised in operons and CRISPR arrays 
consisting of genome targeting sequences, called spacers, interspersed with identical 




CRISPR/Cas mediated immunity occurs in three broad steps. Firstly, in the adaptive 
phase (Garneau et al., 2010; Marraffini & Sontheimer, 2010), bacteria respond to 
invasion of foreign nucleic acids by integrating short fragments of the foreign 
sequence, or spacers into the host genome. The sequence in the viral genome that 
corresponds to a spacer is known as the protospacer (Deveau et al., 2008). The 
foreign sequences are incorporated at the proximal end of the CRISPR array, and so 
positional information represents a timeline of spacer acquisition events. Each of the 
CRISPR loci encode the acquired spacers and are separated by the repeat sequences 
of CRISPR. Transcription yields a pre-CRISPR RNA (pre-crRNA). This is followed 
by enzymatic cleavage to yield crRNAs, which consist of spacer-repeat fragments 
(Figure 1.12). crRNAs recognise complementary protospacer sequences, which 
directs Cas endonucleases to cleave foreign DNA. This interferes with viral 
replication (or plasmid activity) and imparts immunity to the host (Barrangou et al., 














Figure 1.12 An overview of the endogenous Type II bacterial CRISPR/Cas9 
system 
Within the bacterial genome, a CRISPR array contains spacer sequences with 
homology to foreign DNA (for example from a viral genome) separated by short 
palindromic repeat sequences. The CRISPR array is transcribed to make pre-
CRISPR RNA (pre-crRNA) (A), which is processed into individual crRNAs by 
trans-activating crRNA (tracrRNA), homologous to the short palindromic repeat 
which also enables recruitment of RNAse III and Cas9. Together these enzymes 
separate the individual crRNAs (B). The tracrRNA and Cas9 nuclease form a 
complex with each individual crRNA (C), and each crRNA:tracrRNA:Cas9 complex 
hunts down the target DNA sequence, complimentary to the crRNA. Type II 
CRISPR system requires a PAM (NGG) immediately downstream of the target 
DNA, and this is where the crRNA binds (D). After the complex binds the target 
DNA, Cas9 separates the double strands and cleaves both of them just after the PAM 
sequence (E). The crRNA:tracrRNA:Cas9 complex unbinds after the DSB (F). 
 












Types of CRISPR 
The CRISPR/Cas system can be divided into 3 types, CRISPR I, II and III. These 
classes are based on phylogeny, sequence, locus organization, and content of the 
CRISPRs and associated cas genes (which encode various DNases, RNases, and 
other proteins). Type I and III systems share some overarching features; specialised 
Cas endonucleases that process the pre-crRNAs and once mature, each crRNA 
assembles into a large multi-Cas protein complex. In contrast, type II systems 
process pre-crRNAs by a different mechanism. Trans-activating crRNA (tracrRNA) 
triggers processing by the double-stranded RNA-specific ribonuclease, RNase III in 
the presence of Cas9 protein (Figure 1.12) (Deltcheva et al., 2011; Gottesman, 
2011). Cas9 is thought to be the sole protein responsible for crRNA-guided silencing 
of foreign DNA in this system (Barrangou et al., 2007; Garneau et al., 2010; 
Sapranauskas et al., 2011). Type II CRISPR/Cas9 systems have been engineered to 
mediate robust RNA-guided genome modifications in multiple eukaryotic systems 
(Mali et al., 2013b), substantially improving the ease of genome editing.  
 
 
RNA-Guided Genome engineering via Cas9 
Streptococcus pyogenes CRISPR II system can be heterologously reconstituted in 
mammalian cells, and this has been shown in human cell lines (Cong et al., 2013; 
Mali et al., 2013b). The type II CRISPR-Cas9 system requires crRNA and tracrRNA 
for Cas9 to cleave target DNA. One study has shown that crRNA fused to tracrRNA, 
mature crRNA, is fused to a partial tracrRNA via a synthetic stem loop to mimic the 
natural crRNA:tracrRNA duplex (Figure 1.12). This is sufficient to direct Cas9 to 
the target DNA matching the crRNA (Jinek et al., 2012). Soon after this study, the 
Church lab at Harvard University demonstrated that expression of crRNA-tracrRNA 
fusion transcript, termed ‘guide RNAs’ (gRNAs) from human U6 polymerase III 
promoter, allowed Cas9 to cleave sequences of interest (Mali et al., 2013b). In 
human cells, expression of a human codon-optimised Cas9 protein with an 
appropriate nuclear localisation signal is required, while U6 promoter naturally 
drives the transcription of small RNAs (Makinen et al., 2006). RNase III 
recombinant expression is not required (Cong et al., 2013). This system is 
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constrained only by U6 transcription requiring the gRNA to initiate with ‘G’ and the 
requirement for the sequence ‘NGG’ (where N is any nucleotide), known as the 
protospacer adjacent motif (PAM) (Figure 1.12). The PAM immediately follows the 
20 bp target DNA sequence – GN20GG (Jinek et al., 2012).  
 
 
DNA repair following a double-strand break 
Cas9 contains two active domains, RuvC and HNH domain. Together these cause a 
DSB in genomic DNA at a specific locus (Jinek et al., 2012; Nishimasu et al., 2014). 
The DSB can be repaired by one of two mechanisms; non-homologous end joining 
(NHEJ) or homology-directed repair (HDR). Either pathway can be leveraged 
depending on the desired outcome of gene modification (Figure 1.13). 
 
In the absence of a repair template, DSBs are repaired by the error-prone NHEJ 
pathway. The term ‘NHEJ’ was first coined in 1996 and is referred to as "non-
homologous" as it requires little or no DNA homology to join the ends of DNA. 
NHEJ can therefore result in the loss or gain of nucleotide number (Moore & Haber, 
1996), with the end-joining product possibly having either nucleotide insertion 
mutations or deletions (indels) (Valerie & Povirk, 2003). As a result, NHEJ can be 
harnessed to cause maximum disruption and gene knockout via indel formation, 
leading to frameshift mutations and/or premature stop codons (Perez et al., 2008). It 
is therefore desirable to target an exon closest to the N-terminus to cause maximum 
disruption to the gene of interest.  
 
In contrast to NHEJ, HDR is a high fidelity pathway and requires a repair template. 
In general, HDR is considered to be error-free and most active in the S/G2 stage of 
the cell cycle, where the process of homologous recombination occurs (Valerie & 
Povirk, 2003). Although HDR occurs at lower rates than NHEJ, can be leveraged by 
introducing a repair template, either in the form of homology arms flanking the 
target sequence, or single-stranded DNA oligonucleotides, with the latter providing 




Although CRISPR/Cas9 in its native form (with nuclear localisation signal) has been 
successfully used to disrupt a number of genes in different systems, there have been 
reports of its ineffectiveness. Candida albicans, a pathogenic yeast that causes 
mucosal and systematic infections, is known for being a challenge in terms of 
genome disruption. For example, chromosome number is not rigidly controlled 
resulting in numerous strains containing one (or more) additional copies. It also lacks 
a meiotic phase, meaning loss-of-function mutations can be maintained in a diploid 
(and identified after meiosis). However, one report has modified CRISPR/Cas9 
(such as a codon-optimised Cas9) to successfully disrupt C. albicans genome, which 
could also be used in other fungi (Vyas et al., 2015); this demonstrates how 
CRISPR/Cas9 can also be used in a modified form in more challenging systems. 
 
The CRISPR/Cas9 system has been found to be an effective method for gene 
disruption in most mammalian systems, including U2OS cells (Feng et al., 2015). 
Therefore, this method puts itself forward as effective method to specifically disrupt 
the DAGL genes, aiding us to study their function and ultimately the eCB system. Its 
use in a cell line to disrupt the DAGL genes is explored in detail in Chapter 6 















Figure 1.13 DNA Repair following a double-strand break (DSB) 
The endonuclease Cas9 cleaves both strands of the target DNA, creating a DSB. A 
DSB can be repaired by one of two pathways; non-homologous end joining (NHEJ) 
or homology-directed repair (HDR). NHEJ occurs in the absence of a suitable repair 
template, during which a small number of nucleotides are either inserted or deleted 
(Indel, green) at the site of the DSB at random. Indel formations can cause major 
disruptions within the gene’s open reading frame. This is due to a frameshift as a 
result of the indel. A frameshift can significantly alter the amino acid sequence or 
create a premature stop codon, either at the the site of the DSB or further 
downstream by shifting the reading frame. When a DNA repair template is available, 
the HDR pathway is activated. HDR is less error prone allowing more precise gene 
editing to occur (blue). Introducing a DNA repair template with homology to the 
sequence, both up- and down-stream of the DSB, allows for predictable, single 
nucleotide mutation. 
Adapted with permission from Ran,et al., 2013 
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Off-Target effects of the CRISPR/Cas9 System 
Although Cas9 is directed by a 20 nucleotide gRNA sequence, a certain number of 
mismatches are tolerated by the system, thereby promoting off-target mutagenesis. 
While each base within the 20 nucleotide sequence contribute to overall specificity, 
multiple mismatches between gRNA and its complementary target DNA sequence 
can be tolerated. Cas9 activity at the target DNA sequence is not altered by a one-
base mismatch in vitro both in mammalian and bacterial cells (Jinek et al., 2012; 
Cong et al., 2013; Jiang et al., 2013; Cho et al., 2014). Single and double 
mismatches are tolerated to varying degrees depending on their position along the 
gRNA-DNA interface, the number of mismatches, and distribution. Perfect 
gRNA:DNA alignment is required in the 7-12 bp adjacent to the PAM end of the 
target site (3′ end of the gRNA), with mismatches tolerated at the 5′ end (Jinek et al., 
2012; Cong et al., 2013; Pattanayak et al., 2013).  In fact, off-target mutations have 
been detected in human cells at sites that differed by up to 5 bp, a finding that may 
limit the use of the CRISPR/Cas9 system in research and therapeutic applications 




Cas9 carries out strand-specific cleavage using the conserved HNH and RuvC 
nuclease domains, which can be mutated and exploited for additional function. An 
aspartate-to-alanine (D10A) mutation in the RuvC catalytic domain allows Cas9 
nickase (Cas9n) mutant to nick, rather than cleave DNA yielding single-stranded 
breaks (Sapranauskas et al., 2011; Gasiunas et al., 2012; Jinek et al., 2012). 
Individual nicks are efficiently repaired by the base-excision repair (BER) pathway 
(Dianov & Hubscher, 2013). However, when using paired Cas9 nickases to generate 
two single-stranded breaks / nicks on different DNA strands, high specificity and 
efficiency is retained, while avoiding off-target mutations by 50- to 1500-fold (Ran 




Akin to ZFNs and TALENs, DNA cleavage relies on the synergistic action of two 
independent DNA-binding modules directing Cas9n. Appropriately offset gRNA 
pairs (- 4 to + 20 bp) can guide Cas9n to simultaneously nick both strands of the 
target locus, mediating DSBs and stimulating robust NHEJ. Following the DSB, the 
introduction of a repair template stimulates the HDR repair pathway (Figure 1.13) 














2. Develop assays to directly measure the activity of our DAGL constructs in 
membranes and cells using the surrogate substrates, PNPB and DiFMUO. 
 
 
3. Develop a cellular assay to measure a stimulus driven eCB-dependent CB1 
activation to evaluate the contribution of endogenous DAGLs to the response 
and to use a gain of function approach to determine if the response is limited 
by enzyme level. 
 
 
4. To determine the potential of the CRISPR/Cas9 system as a means of 
















CHAPTER 2. MATERIALS & METHODS 
 







Phosphate Buffered Saline (PBS) 
One PBS tablet (Oxoid, Basingstoke, UK) containing KCl (0.20 g/L), KH2PO4 (0.2 




PBS + 0.1% Tween 20 
 
Tris Buffered Saline (TBS) 
0.5 M Tris, 1.5 M NaCl in ddH20, pH 7.4 
 
TBS-T 
TBS + 0.1% Tween-20 
 
PBS-EDTA 





0.5% Trypsin, from Life Technologies + 0.5 mM EDTA pH 8, in PBS 
 
Cell Culture Dishes, Flasks & Trays; all from Thermo Scientific 
(Loughborough, UK) 
Polystyrene Nunclon™ surface – 4-well dishes, 10 cm dishes, 15 cm dishes 
Nunc Polystyrene T 75 cell culture flask 
Nunc Bio-Assay Dishes (500 cm2) 
 
Transfection / 0% Serum Media 
Opti-MEM® I Reduced Serum Medium, from Life Technologies 
 
Transfection reagents 
Fugene HD transfection reagent, from Promega 





DNA Ligation & Annealing Oligonucleotides 
T4 DNA Ligase & Reaction Buffer (10 X Stock solution), from New England 
Biolabs (Hertfordshire, UK) 








All restriction enzymes purchased from New England Biolabs and used according to 
the manufacturer’s instructions.  
 
Agarose Gel Running Buffer 
TAE (Tris, Acetic Acid and EDTA) Buffer – 40 mM Tris, 20 mM acetic acid, and 1 
mM EDTA, pH 8.4 
 
Agarose 
SeaKem LE Agarose, from Lonza, dissolved in TAE Buffer 
 
DNA Ladder 
1 Kb Plus DNA ladder, from Invitrogen, Life Sciences 
 
DNA Dye 
2,7-Diamino-10-ethyl-9-phenylphenanthridium bromide (ethidium bromide), from 
Applichem 
 
Gel Loading Buffer 
Gel Loading Dye Orange, from New England Biolabs. 
 
Gel Viewer 




Nanodrop 100, from Thermo Scientific 
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Plasmid DNA Purification (All from Qiagen, Manchester, UK) 
Qiagen Spin Miniprep Kit (20 µg plasmid DNA purification from E. coli cells) 
Endofree Plasmid Maxi Kit (500 µg plasmid DNA purification from E. coli cells) 
 
QIAquick Gel Extraction Kit (purification of digested vectors from agarose gels) 
Puregene Core Kit (DNA extraction from recombinant cells) 
 
Transformation - Competent cells  
C3019 NEB 10-beta chemically competent E. coli cells, from New England Biolabs 




TOPO ® TA Cloning ® Kit for Sequencing, from Life Technologies 
 
Agar 
For blasticidin resistance - Fast-Media® Blas Agar, from Invivogen 
For puromycin resistance - Fast-Media® Puro Agar, from Invivogen 
 
Growth Liquid 
For blasticidin resistance - Fast-Media® Blas TB, from Invivogen 
For puromycin resistance-  Fast-Media® Puro TB, from Invivogen 
 
Selection Antibiotics 
Kanomycin Sulphate (diluted in ddH20) 
Blasticidin, from Life Technologies 
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Polymerase Chain Reaction (PCR)  
 
PCR Tubes 
0.2 ml thin wall PCR tubes, from Axygen (distributed by Thermo Scientific) 
 
PCR Plates 
PCR microplates, from Axygen 
 
PCR Polymerases / Master Mixes 
Extensor Long PCR Master Mix, from Thermo Scientific (ab0792) 
Phusion Flash High-Fidelity PCR Master Mix, from Thermo Scientific 
Taq DNA Polymerase and dNTP Mix, from Thermo Scientific 
 
 
Real-time Reverse Transcriptase PCR (RT-PCR) 
 
Homogenisation 
QIAshredder, from Qiagen 
 
RNA Purification 
RNeasy mini kit, from Qiagen 
Genomic DNA Degradation 
RNase free DNA set, from Qiagen - digestion of DNA during RNA purification 





High Capacity cDNA Reverse Transcription Kit, from Applied Biosciences (Thermo 
Scientific) 
 
Real Time RT-PCR (qPCR) Assay 
Taqman Gene Expression Assay for human DAGLα (Hs00391374_m1), human 
DAGLβ (Hs00373700_m1) as well as endogenous control PPIA, from Life 
Technologies 
Taqman Master Mix, from Life Technologies 
RNAase Free Water, from Sigma 
 
RT-PCR Tubes 
MicroAmp® Reaction tube with cap, from Applied Biosystems 
 
 
Cel I Assay 
 
DNA Extraction 
Puregene Core Kit, from Qiagen 
 
Assay Kit 







Large Dishes for Single Clone Selection 
150 x 20 mm Nunclon™ Delta surface dishes, from Thermo Scientific 
 
Cloning Disc 
3 mm Scienceware® cloning discs, from Sigma 
Fluorescent Cell Sorting 
FACs Aria cell sorter, from BD Biosciences (Oxford, UK) 
Incucyte live cell imager, from Essen Biosciences (Hertfordshire, UK) 
 
Resistant Marker Cell Sorting 





DNA Amplification & Sanger Sequencing 
BigDye® Terminator v3.1 Cycle Sequencing Kit, from Life Technologies 
3730 DNa Analyzer, from Applied Biosystems Hitatchi (Thermo Scientific) 
Sanger Sequencing, provided by Source Bioscience (Cambridge, UK) & GATC 




Cell Lysis & Membrane Preparation 
 
Homogeniser 
POLYTRON PT 1200 E handheld homogeniser, from Kinematica (Düsseldorf, 
Germany) 
 
ODG Lysis Buffer 
50 mM Tris pH 8.0, 150 mM NaCl, 10 mM MgCl2, 2 mM CaCl2, 5% glycerol, 1% 
Triton X-100, 1 mM Na3VO4, 10 mM NaFl, 1 mM PMSF, supplemented with Roche 
Complete Protease Inhibitors. 
 
Lysis Buffer for Membrane Preparation 
20 mM HEPES pH 7.0, 2 mM DTT, 0.25 M Sucrose, 10 mM NaF, 1 mM NA3VO4, 
supplemented with Roche Complete Protease Inhibitors. For final re-suspension, use 
buffer containing no sucrose. 
Protein Quantitation Assays 
Protein Assay Dye Reagent, from Bio-Rad 





5 X Protein Loading Buffer 





1 X Running Buffer 
25 mM Tris, 0.2 M Glycine, 0.1% SDS, in ddH20 
 
1 X Transfer Buffer 





Table 2.1 SDS-Polyacrylamide Gel 
 
REAGENT 7.5% Gel 5% Gel 
30% Acrylamide, National  Diagnostics 5 mL 1.67 mL 
1 M Tris, pH 6.8  1.25 mL 
1 M Tris, pH 8.8 7.4 mL  
10% SDS 200 µL 100 µL 
ddH20 7.25 µL 6.86 µL 
TEMED, National  Diagnostics 13.2 µL 20 µL 
0% Ammonium Persulphate (APS) 132 µL 100 µL 
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Table 2.2 Primary Antibodies 
 
ANTIBODY ICC  WB  SPECIES SUPPLIER 
V5 1:500 1:5000 Mouse Life Technologies 
DAGLα  1:1000 Goat AbCam (Cambridge, UK) 
DAGLβ  1:1000 Rabbit Cell Signalling (New 
England Biolabs) 
Actin  1:10,000 Mouse Cell Signalling 




Table 2.3 Secondary Antibodies 
ANTIBODY ICC  WB  SPECIES SUPPLIER 
Alexa Fluor 488 
Anti-mouse  
1:1000  Goat Molecular Probes 
(Thermo Scientific) 
Alexa Fluor 680 
Anti-Rabbit 
 1:1000 Goat Molecular Probes 
Alexa Fluor 700 
Anti-mouse  
 1:5000 Goat Life Technologies 
Alexa Fluor 680 
Anti-Goat 
 1:1000 Rabbit Life Technologies 
Anti-Goat HRP  1:1000 Horse Vector Labs 
(Peterborough, UK) 






4% Paraformaldehyde (PFA) in PBS, pH 7.4 
 
Permeabilising Blocking/Staining Solution for Cell Staining 
0.2% Triton-X, 1% BSA, 0.1% Sodium Azide (NaN3) in PBS 
 
Mounting Solution 
33% glycerine and 17% Mowiol 4-88, from Calbiochem (Nottingham, UK), in PBS 
 
 
DAGL Activity Assays 
 
Enzyme Assay Plates 
96-well clear flat-bottom polypropylene plates, from Costar (Glasgow, UK) 
 
Enzyme Assay Buffers 
50 mM HEPES, made up in ddH20 (for use with PNP-Butyrate / Absorbance) 
50 mM MES, made up in ddH20 (for use with DifMU-Octanoate / Fluorescence) 
 
Readers 
SpectraMax Plus 384 Absorbance Microplate Reader, from Molecular Devices 
(California, USA) 





Parental Tango Cell Line (Tango) 
Tango CNR1-bla U2OS cells, from Life Technologies 
 
V5α11 Cells  
Parental Tango cells stably over expressing DAGLα-V5 
 
V5β4 Cells  
Parental Tango cells stably over expressing DAGLβ-V5 
 
Parental Tango Cell Line Media 
McCoy’s 5A Medium with 10% dialyzed FBS, 0.1 M NEAA, 25 mM HEPES (pH 
7.3), 1 mM Sodium Pyruvate, 100 µg/mL Penicillin / Streptomycin, 200 µg/mL 
Zeocin™ all from Life Technologies 
 
V5α11 / V5β4 Media 
Parental Tango Cell Line Media supplemented with 10 µg/mL Blasticidin, from Life 
Technologies 
 
Standard Plating Medium for Tango Assay 
Freestyle™ F17 from Life Technologies 
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McCoy’s 1% Plating Medium 
McCoy’s 5A Medium supplemented with 1% FBS, 0.1 M NEAA, 25 mM HEPES 
(pH 7.3), 1 mM Sodium Pyruvate, 100 µg/mL Penicillin / Streptomycin, all from 
Life Technologies 
 
For 1% DMEM Plating Medium 
DMEM / F-12, GlutaMAXTM supplemented 1% FBS, 0.1 M NEAA, 25 mM HEPES 
(pH 7.3), 1 mM Sodium Pyruvate, 100 µg/mL Penicillin / Streptomycin, all from 
Life Technologies 
 
Tango Assay Plates 
Costar 96-well black clear bottom polystyrene plates, from VWR International 
(Leicestershire, UK) 
 
Tango Detection Reagent 
LiveBLAzer FRET B / G Loading Kit, from Life Technologies: 
LiveBLAzer FRET B / G Substrate (CCF4-AM), Solution B, Solution C and 













Table 2.4 Compounds 
 











DAGL substrate Life Technologies 
Tetrahydrolipstatin (THL) Serine Lipase Inhibitor Tocris (Bristol, UK) 
OMDM-188 DAGL Inhibitor Gift from Dr. Di Marzo 




CB1 Receptor Agonist Sigma 
AM251 CB1 Receptor Antagonist Sigma 
JZL184 MAGL Inhibitor Sigma 
JZL195 Dual MAGL / 
FAAH Inhibitor 
Sigma 
URB597 FAAH Inhibitor Tocris 




PKC Activator Sigma 








All cell lines were incubated at 37°C in a humidified atmosphere with 5% CO2. Once 
the cells were approximately 80% confluent, cells were plated for subsequent 
analysis (see below) or split for further culture and maintenance. Cells for 
maintenance were plated in 10 cm dishes or T75 flasks and cultured in full growth 
medium. 
 
Passaging of Tango Cells  
Using aseptic technique, growth medium was removed from the cell plate by 
aspiration. Cells were then washed once with an appropriate volume of PBS to 
remove residual serum. The PBS was then aspirated and replaced with an 
appropriate amount of trypsin e.g. 3 mL for a 10 cm dish. The plate was returned to 
the incubator for approximately 3 min. Trypsin was inactivated by addition of an 
equal volume of growth media (containing 10% serum) and centrifuged at 1200 rpm 
for 3 min. The cell pellet was re-suspended in 10 mL Tango media and either used 
for analysis or split as described above. Tango cells were incubated at 37°C, 5% 
CO2. If used for analysis, the concentration of cells in the suspension was first 
determined using a haemocytometer and cells were plated in the appropriate plate 








On the day before transfection, cells were plated either in a 6-well plate or a 10 cm 
dish without antibiotics such that they were 90-95% confluent at the time of 
transfection.  The appropriate amount of Lipofectamine was mixed in Optimem and 
incubated for 5 min before combining with the individual DNA solutions by gentle 
mixing and the solutions were incubated at RT for 20-30 min. During the incubation, 
the media on the cells was replaced with Optimem (as per manufacturer’s 
instructions). The DNA-Lipofectamine complexes were added to the cells and 
incubated for 4-6 h and the medium was replaced.  
 
Fugene HD 
Transfection carried using Fugene HD was according to the manufacturer’s protocol. 
For example, 6 x 105 cells were plated in 8 ml of growth medium in a T25 flask. 8.8 
µg of plasmid DNA was added to a total of 409 µL serum free medium. 31 µL of 
Fugene HD reagent was added mixed by pipetting and incubated at RT for 10 min. 
400 µL of the complex was added to the flask and mixed thoroughly. The medium 
was changed either after 5 h or the following morning to growth medium without 
selection antibiotics. After 24 – 48 h selection antibiotics were introduced to the 








Ligation reactions were performed on ice and in the following order: a solution of 2 
µL T4 DNA ligase reaction buffer, an appropriate amount of digested vector 
backbone DNA and insert DNA were mixed together and made up to 20 µL with 
ddH20. 0.1 µL of T4 DNA ligase was added to the mixture which was then incubated 
in a Thermomixer at 16 ºC for 2-4 h. 
 
Annealing Oligonucleotides 
Annealing was carried out using the quick ligation kit, without ligase. Reactions 
were set up using 10 µL of 2 X reaction buffer solution, equal concentrations of 
oligonucleotides and the volume was made up to 20 µL with ddH20. The mixture 
was heated to 95 ºC in the Thermomixer, which was then switched off and allowed 
to cool slowly for 1-2 h.  
 
Restriction Digest 
Vector DNA was mixed with 1 unit of restriction enzyme per 1 µg DNA, the 
appropriate buffer for that enzyme (Buffer 1-4, New England Biolabs), and made up 
to an appropriate volume with ddH20. The mixture was incubated at 37 ºC (or 
suitable temperature for restriction digest) in a humidified incubator for 1-2 h. 
 
Agarose Gel 
6 µL of gel loading dye was added to 20 µL restriction digest solutions and loaded 
into a well of 0.8% agarose gel. 20 µL of 1 Kb Plus DNA ladder was loaded to the 
farthest left well. The gel was run at 100 V for 30 min. Gels were viewed and 




DNA Gel Extraction 
DNA was separated on an agarose gel as described above. The desired band was cut 
out from the gel using a scalpel blade and placed in an eppendorf tube. QIAquick gel 
extraction kit was used according to the manufacturer’s instructions. DNA 
concentration was then determined using the Nanodrop. 
 
Plasmid DNA Purification 
Following E. coli transformation, a single colony was selected from the agar plate 
and placed in 1 ml of LB-broth with the appropriate antibiotic(s). Plasmid DNA was 
purified using a Qiagen miniprep kit according to the manufacturer’s instructions. 
DNA concentration was determined using the Nanodrop. This may be followed up 
with purifying larger quantities of plasmid DNA. This was done by retaining a 
sample of the cells grown and inoculating them with 100 ml media. DNA was then 
purified using a Qiagen maxiprep kit.  
 
Transformation of Competent Escherichia Coli (E. coli) Cells 
Competent E. coli cells were stored at -80 ºC until ready for use. A vial of the cells 
was removed from the freezer and thawed on ice. 4 µL of the DNA sample was 
placed into a clean eppendorf tube and also placed on ice. Once the cells began to 
thaw, 25 µL were added to the DNA sample and incubated for 30 min on ice. The 
cells were then heat shocked in a water bath at 42 ºC for 40 s – 1 min and then 
placed immediately on ice for a further 5 min. 200 µL of LB-broth was added to the 
mixture, which was then placed in a Thermomixer at 37 ºC for 1 h, shaking at 850 
rpm. The transformed E. coli cells were plated out on agar and incubated at 37 ºC in 




Polymerase Chain Reaction (PCR) 
 
For PCR, each reaction was carried out according to the manufacturer’s instructions 
for the master mix used. In brief, 1 µL DNA was combined with 0.1 µL of primer 
(each at 100 µM), 8.8  µL ddH20 and 10 µL mastermix before the reaction was 
performed in a PCR machine (using the mastermix manufacturer’s recommended 
settings). 
 
RNA Purification and Reverse Transcription to cDNA 
Tango cells for analysis were grown to confluency in a 6-well or 10 cm dish. The 
cells were washed once in PBS and using Qiagen’s RNeasy kit, the cells were lysed 
with RLT buffer. Cells were homogenized by spinning through a QIAshredder 
column, before RNA was purified using RNeasy kit. RNA concentration and purity 
was determined using the Nanodrop. RNA was converted to cDNA using High 
Capacity cDNA Reverse Transcription Kit and a PCR step. In brief, 2 X reverse 
transcription master mix was made up on ice and mixed with the purified RNA in 
PCR tubes. The reaction tubes were loaded into the thermal cycler using the 
following protocol – 25 °C for 10 min, 37 °C for 120 min, 85 °C for 5 min and 
stored at 4 °C until ready for use.                                                                                                                                         
 
Real Time RT-PCR 
For real time RT-PCR, or qPCR, Taqman gene expression assay kits were used 
according to the manufacturer’s instructions. Assays for both DAGLα and DAGLβ, 
as well as the endogenous control assays PPIA. GAPDH and 18S were used. RNA 
was extracted from Tango cells, including α11 and β4 cells for controls, and the 
RNA was reverse transcribed to cDNA, as described above. 1-100 ng of cDNA was 
used in 20 µL reactions in a 96-well PCR plate. The plate was sealed and loaded into 
the Lightcycler RT-PCR instrument using the following protocol – heat to 50 °C for 
2 min, 95 °C for 10 min followed by 45 cycles of 95 °C for 15 s and 60 °C for 1 min. 




Transformation for Sequencing 
Genomic DNA (corresponding to the CRISPR cutting site) was amplified by PCR 
using Taq Polymerase, as described above. The PCR products were purified from 
agarose gels using QIAquick gel extraction kit and cloned into TOPO cloning vector 
by setting up the following 6 µL reaction; 1 µL salt solution (1.2 M NaCl, 0.06 M 
MgCl2), 4 µL PCR product, 1 µL TOPO vector. The reaction was incubated at RT 
for 5-10 min before 4 µL was transformed into chemically competent cells. Positive 






20 µL reactions with BigDye® Terminator enzyme were set up in PCR tubes 
according to the manufacturer’s instructions. The tubes were placed in a PCR 
machine which was heated to 95 ºC for 2 min, before the following protocol was 
used; 95ºC for 10 min, 50 ºC for 20 min, 60 ºC for 4 min. This cycle was repeated 25 
times in order to amplify the DNA and stored at 4 ºC until ready for use. Following 
PCR of one of the strands of DNA, it was then precipitated with ethanol/EDTA. 5 
µL of 125 mM EDTA was added to each sample, followed by 60 µL of 99.5% 
ethanol and incubated at RT in the dark. The samples were then centrifuged for 15 
min at 4000 g at 4 ºC and the supernatant was gently removed. 60 µL of 70% ethanol 
was added to each sample, which were centrifuged again at maximum speed (in a 
bench top centrifuge) for 5 min. The supernatant was removed, and while keeping 
the PCR tubes inverted, they were placed into a plate centrifuge and spun at lowest 
speed for 30 s to remove residual ethanol. Each DNA sample was then re-suspended 
in 10 µL ddH20 and placed in a v-shaped 96-well plate. The sequence for each 
sample was determined by 3730 DNA Analyzer from Applied Biosciences and 
comparing the results by ‘blasting’ it against the DAGL sequences. Sequencing was 
also analysed by Source BioScience, Cambridge. 
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Cel I Assay 
 
Summarised in Figure 2.1 
Genomic DNA from Tango cells was extracted using Puregene Core Kit (Qiagen) 
approximately 72 h after transfection as described above. The genomic regions 
flanking the gRNA site (for CRISPR/Cas9 genome editing) were PCR amplified 
using the technique above. The PCR products were purified using QiaQuick Spin 
Column (Qiagen) and subjected to re-annealing to generate heteroduplexes: 95°C for 
10 min; 85°C for 1 min; 75°C for 1 s; 65°C for 1 s and ramping to 25°C at -0.3°C/s; 
and 25°C hold for 1 min and finally hold at 4°C. After re-annealing, 10 µL of PCR 
products were treated with 1 µL of Cel I Surveyor nuclease and 1 µL of enhancer 
(supplied with the kit). Cel I Surveyor nuclease cleaves mismatched DNA at the 3’ 
side for each strand at the site of the mismatch. The samples were incubated at 40 ºC 
for 40 min and were then run on a 10% Acrylamide gel for 24 min at 240 V. The gel 
was washed twice in water and incubated on a roller with ethidium brominde 
solution for 1 h. The gel was visualized using UV light (Molecular imager from 
BioRad). Any smaller bands separate from the larger bands indicates cleavage by 
















Figure 2.1 Schematic of the SURVEYOR Cel I assay for detection of double 
strand break-induced insertions and deletions (Indels) 
(A) Genomic PCR is used to amplify the Cas9 target region from a heterogeneous 
population of modified and unmodified cells. Highlighted in red is an indel 
formation resulting from Cas9 endonuclease double-strand break. (B) The PCR 
products are boiled and then reannealed slowly to generate heteroduplexes. (C) The 
reannealed heteroduplexes are cleaved by SURVEYOR Cel I nuclease, which 
recognizes mismatched DNA, whereas homoduplexes are left intact. The 
SURVEYOR Cel I assay was used to determine Cas9-mediated cleavage efficiency 





Fluorescent Cell Sorting with FACS 
Cells were allowed to recover for 1-2 days following transfection. Cells were washed 
once, trypsinised and re-suspended in ice cold PBS containing 2% FCS. Cells were 
then sorted for GFP expression using the FACS aria. 100 - 200 cells were then plated 
into a large dish for colony selection. When single colonies were visible, they were 
removed using a cloning disc. The disc was carefully removed and placed into a well 
of a 24-well cell culture plate.  
 
Resistance Marker Cell Sorting 
Cells were co-transfected with CRISPR/Cas9 nickase construct for DAGLα and with 
a DNA repair homology arm containing a blasticidin resistance gene. Cells were 
allowed to recover for ~24 h post-transfection. 100 - 200 cells were then placed into 
a large dish for colony selection and again allowed to recover for 1-2 days, before 
being introduction of 4 µg / mL blasticidin to the medium. Clonal cells were selected 





Cell Lysate Preparation 
Cells were cultured in 6-well plates or in 10 cm dishes until reaching 70 – 80% 
confluence, washed in ice-cold PBS and lysed in 50-500 µL ODG lysis buffer. The 
lysate was collected in 1.5 mL eppendorf tubes and left to rotate for 30 min at 4°C to 
separate out cell debris. The lysate was centrifuged at 3,000 rpm for 5 min at 4°C. 
Protein concentration was determined using Protein Assay (Bradford) Dye Reagent, 





Growth media on confluent Tango cells from either a dish or a tray was aspirated, 
the cell plate placed on ice and washed in ice-cold PBS three times. Cells were lysed 
by addition of lysis buffer (for membrane preparation) to the cell plate for 1-2 min, 
removed using a cell scraper and collected into a 1.5 mL eppendorf. Protein was 
homogenised on ice by Polytron homogeniser (3 cycles of 7 seconds, set to 
maximum speed). Following homogenisation, membrane protein was centrifuged 
using ultracentrifugation (Beckman Coulter Optima TLX-120 Ultracentrifuge; 
54,000 rpm, 30 min at 4°C). The pellet was re-suspended in sucrose-free lysis buffer 
(2 ml / dish) using the Polytrone homogeniser, frozen into small aliquots and stored 
at -80⁰C. Protein concentration was determined using Coomassie (Bradford) Protein 






SDS-Polyacrylamide gels were pre-made and used on the same day or kept damp 
overnight at 4°C. When ready for use, the comb was removed to expose the wells, 
and the gel was immersed in 1 X running buffer. Equal amounts of protein lysate 
were made up in 5 X protein loading buffer, made up to a total volume of 50 µL and 
boiled for 5 min at 100°C. (These were either stored at -20°C or used immediately.) 
The samples were then separated on SDS-Polyacrylamide gels by running them at 
100 V for 2 h and were then transferred to nitrocellulose hybond membranes 





The membrane was then blocked in 5% Milk at RT for 1 h and the primary antibody 
was applied overnight at 4⁰C, or for 1 h at RT. Next the membrane was washed 3 
times in PBS-T for 10 min and then incubated with the secondary antibody solution 
at RT for 1 h. The secondary antibody was chosen according to development method 
(ECL or Odyssey) and suitable for the primary antibody used. This step was 
followed by another wash step - 3 times in PBS-T for 10 min. 
 
For analysis using Li-Cor Odyssey, Alexa Fluor 700/800 fluorescently-labelled 
secondary antibody in 2% milk / PBS-T were used and incubated with the blot for 1 
h at RT. The blots were analysed using the Li-Cor Odyssey infrared imaging and 
software. 
 
Alternatively, blots were analysed using Amersham’s enhance chemiluminescent 
(ECL) western blotting substrate i.e. chemiluminescent substrate for the detection of 
horseradish peroxidase (HRP) on immunoblots. Thus HRP-tagged secondary 
antibodies were used for this procedure and incubated with the blot for 1 h at RT in 
2% Milk in the appropriate buffer. ECL substrate was made up according to the 
manufacturer’s instructions. The solution was added directly to the blot and 
incubated for 1 min. The blot was then placed into a cassette and developed in a dark 
room.  
 
If required, blots from either method were stripped using Re-Blot Plus (Chemicon 
International) according to the manufacturer’s protocol and probed for Actin as a 





ECL/ECL plus visualised western blots were scanned in at 2400 dpi using a 
perfection V700 scanner (Epson) and quantified using Image J analysis software. 
Where possible, samples were loaded with an equal concentration of protein and 
were also normalised to the actin control. Western blots which were visualised by 





13 mm glass coverslips were individually coated in poly-lysine in a 4-well dish for 
30 min. The poly-lysine was removed before addition of 5,000 - 20,000 cells/well in 
full growth medium and left to adhere overnight at 37°C 5% CO2. The following day 
cells were fixed to the slide with 500 µL 4% PFA for 30 min followed by 3 x 5 min 
washes in PBS. Cells were blocked with 500 µL 0.2% Triton-X, 1% BSA, 0.1% 
sodium azide for 1 h, then incubated with the primary antibody overnight at 4°C. 
The primary antibody was removed, cells were washed 3 times in PBS for 5 min. 
Secondary antibody and the nuclear dye Hoecsht were added in the same solution 
and incubated for 1 at RT. The coverslips were then mounted with Miowol. Images 








A Surrogate Substrate DAGL Activity Assay 
All DAGL activity assays were carried out at room temperature (RT) unless 
otherwise stated in accordance with the method previously described; DAGL activity 
assays were adapted from a protocol previously described (Pedicord et al., 2011). 
 
Membrane-based DAGL Activity Assay  
200 µL reactions were set up in clear enzyme assay plates. For reactions with 
membrane protein (from membrane preparations, described above) and substrate 
only, 100 µL of 2 X final assay concentration (FAC) of membrane protein and 
100µL of 2 X FAC of substrate were used. For reactions with inhibitors, 100 µL of 2 
X FAC of membrane protein, 50 µL of 4 X FAC of inhibitor, and 100 µL of 2 X 
FAC of substrate were used.  
 
For the colourimetric absorbent assay, 4-nitrophenol butyrate (PNP-Butyrate) was 
added directly from DMSO stocks to buffer containing 50 mM HEPES, pH 7.5 only 
i.e. 1:20 dilution. The final concentration typically used was 250 µM (5% DMSO). 
Reactions were monitored kinetically every 12 s, for a total of 30 min, by a 
Spectramax Plus (Molecular Devices) set at an OD of 400 nm. A linear regression of 
the first 10 min was used for calculation of the reaction rate. 
 
For the fluorescent assay, DiFMU Octanoate was added directly from a DMSO stock 
to buffer containing 50 mM MES pH 6.0 only i.e. 1:20 dilution. The final 
concentration typically used was 10 µM. Reactions were monitored kinetically every 
30 s by the Flexstation (Molecular Devices), set at an excitation wavelength of 360 
nm and an emission wavelength of 450 nm. A linear regression of the first 10 min 
was used for calculation of the reaction rate. 
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Tango™ CNR1-bla U2OS Cell-Based Assay  
Parental Tango cells (CNR1-bla U2OS Cells) were plated (20,000 cells/well) in 
Tango assay plates in 100 µL of plating medium and incubated at 37°C, 5% CO2. 
Compounds were prepared in the same plating medium used and 50 µL total 
compound was added to each well i.e. for agonist assay, 50 µL of 3 X FAC of 
agonist compound;  for antagonist assay, 25 µL 6 X FAC of antagonist followed by 
25 µL of 6 X FAC of agonist (DMSO < 1%). After the incubation time with the 
compound, Tango substrate was made up according to the manufacturer’s 
instructions (Life Technologies) and 30 µL of this substrate was added per well. 
Plates were incubated in the dark for 2 h at RT and read on the Flexstation, with the 
following filter selections: 
 
 
 Scan 1 Scan 2 
Excitation 
Filter 
409 nm 409 nm 
Emission Filter 460 nm 530 nm 
Purpose Measurement in the blue 
channel 







Data was analysed using Microsoft Excel or SigmaPlot. Student’s 2-sided t-test was 





CHAPTER 3. RESULTS I – Phosphorylation of the 




Biochemical characterisation of the DAGLs was first attempted approximately 30 
years ago (Farooqui et al., 1984; 1986), yet still very little is known about their 
regulatory mechanisms. Due to increasing interest in the therapeutic implications 
associated with the DAGLs and the eCB system, there is a growing need to 
understand how these enzymes are regulated. As discussed in the general 
introduction, we first identified the structural components of these enzymes to 
understand their regulatory mechanisms. In addition to identifying the regulatory 
loop, structural studies of the DAGLs identified a number of phospho-sites that may 
regulate activity.  
 
Phosphorylation is the reversible PTM involving the addition of a phosphate group 
from ATP to the hydroxyl groups of serine, threonine and/or tyrosine residues. It is 
an ubiquitous regulatory mechanism in both eukaryotes and prokaryotes (Johnson & 
Lewis, 2001). Intracellular phosphorylation by protein kinases, triggered in response 
to extracellular signals, provides a mechanism for the cell to switch on or switch off 
many diverse processes. This includes enzyme activity, achieved mainly by 
introducing conformational changes to the protein. Several lipases are regulated by 
phosphorylation at specific sites; for example PLCγ (Gresset et al., 2010), TGL4 
(Kurat et al., 2009) and hormone sensitive lipase (HSL) (Lampidonis et al., 2011). 
HSL is the most studied in terms of phosphorylation controlling its activity. It is 
regulated by reversible phosphorylation on five critical residues. The closing and 
opening of the lid regulates access of the substrate to the catalytic site of the enzyme, 
and this is under control of phosphorylation (Holm, 2003). Phosphorylation alone is 
not enough to activate HSL and conformational alterations, resulting in a 
translocation from the cytoplasm to lipid droplets, may also be involved 
(Lampidonis et al., 2011). However, phosphorylation stands as a likely mechanism 
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for regulating DAGL activity. For example, DAGL from brain microsomes was 
shown to be phosphorylated by PKA (Rosenberger et al., 2007) and phosphorylation 
of bovine rod membranes by PKA resulted in a ~70% increase in DAGL activity 
(Perez Roque et al., 1998). Similarly, PKA and PKC activation stimulated 2-AG 
synthesis (Vellani et al., 2008).  
 
As a result we have built a working model for each DAGL enzyme, allowing us to 
identify key phospho-sites based on the number of reports and location within their 
structure (Reisenberg et al., 2012). Given that the publically available databases used 
to identify these sites are updated on a regular basis, the latest analysis on potential 











The DAGL Phospho-map 
Using phospho-peptide databases, candidate regulatory phospho-sites within the 
DAGL sequence can be identified. This provides evidence that the DAGLs can be 
phosphorylated, indicating its role in regulation of activity. We first used the 
phosphorylation prediction tool, NetPhosK 1.0. This tool uses sequence and 
structural data of reported phosphorylation events to predict phospho-sites (~70% 
accuracy against known sites (Blom et al., 1999; Iakoucheva et al., 2004). We then 
cross examined identified sites with those identified experimentally, such as through 
mass spectrometry, on Cell Signalling Technology (CST) database 
(phosphosite.org). The software on this website identifies potential phospho-sites 
based on proteomic databases. I have compiled the results into a table, Table 3.1 for 
DAGLα, Table 3.2 for DAGLβ. A number of the CST studies have not yet been 
published; therefore we were mindful of the number of times a particular site has 
been identified. There were 30 sites identified from both CST and NetPhosK 1.0 for 
DAGLα, and 13 for DAGLβ (Tables 3.1 & 3.2). If one is to place a minimal 
requirement of 3 independent published studies to consider a phospho-site as 
genuine (as well as being identified by NetPhos K 1.0), then the total number 
identified for DAGLα is 10 and for DAGLβ is 1. These sites are highlighted in the 
‘phospho-map’ in Figure 3.1 (4 other potential sites for DAGLβ that were not picked 
up by NetPhosK 1.0 have also been included because of the higher number of 
reports.) This a linearized diagram of each DAGL sequence, colour-coded to 
highlight the structural features. From this we can see where each of these phospho-
sites is located on each DAGL. All 5 of the sites highlighted for DAGLβ are located 
within the regulatory loop (S570, S574, S576, S577, and S579). However, only one 
has been identified in this region for DAGLα (T560) with rest being located in the 
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Figure 3.1 Phospho-map of human DAGLα and DAGLβ 
Phospho-map highlighting predicated phosphorylation sites on DAGLα (top) and 
DAGLβ (bottom) in both A and B. The phosphorylation sites on the map were 
identified by mass-spectrometry analysis of various cells and tissues. Structural 
features are highlighted; TM domain in blue, catalytic domain in dark red, with 
regulatory loop in green and signature motif in red. The first report showing the 
potential of phosphorylation as a regulatory mechanism highlighted all sites reported 
for the DAGLs (A). We have updated this phospho-map to include only phospho-
sites that have been reported 3 times or more, thereby gaining confidence that these 
sites are important for function. The number of times a potential phospho-site has 
been reported is indicated in brackets next to the site’s name (B). The carboxyl-
terminal tail region of DAGLα has been found to be especially heavily 
phosphorylated and may have a role in intra-molecular interactions with the catalytic 
domain (Shonesy et al., 2013). 
 
 







    
 




























Identification of potential phosphorylation sites for regulation 
of DAGL function 
When considering the importance of phospho-site(s) for regulation, location and 
orientation at the membrane are key aspects. DAG, the substrate for the DAGLs, is 
generally found integrated into the cell membrane (Goni & Alonso, 1999). The 
DAGLs are therefore likely to be sub-localised at the membrane, via their TM 
domains and palmitoylation of the cysteine rich insert. This would position the 
enzymes close to the substrate, and may also orientate the catalytic domain to 
facilitate segregation of the substrate from the membrane. The membrane proximal 
surface of the DAGLs was identified based on the orientation of the catalytic triad, 
which would need to be in this position to hydrolyse DAG. Consequently, the 
regulatory loop is likely to be membrane (and substrate) proximal, positioning it to 
facilitate interfacial activation. As a result, phospho-sites involved in regulation of 
substrate access are more likely to also be membrane proximal. The phospho-sites 
(mentioned above) that were identified within the regulatory loop of DAGLα and 
DAGLβ are membrane proximal, posing themselves as potential regulatory 
candidates, and are likely to determine whether the regulatory loop is in the ‘open’ or 
‘closed’ conformation. 
 
The DAGLα tail appears to be heavily phosphorylated, but this is dispensable in 
terms of activity, indicating the sites in the tail do not play a direct role in regulation 
of the enzymatic function (Pedicord et al., 2011). However, a more recent study 
showed that the DAGLα tail is phosphorylated by CamKIIa, resulting in inhibition of 
DAGLα activity by ~40% (Shonesy et al., 2013). Although the mechanism 
underlying this inhibition is unknown, it may be due to intra-molecular interactions 





3.3 Summary & Conclusions 
 
The aim of this chapter was to provide an update on the role of phosphorylation in 
the regulation of DAGL activity. In order to determine the role of phosphorylation 
(or indeed any other type of PTM), we took a bioinformatics approach to assess the 
wealth of information freely available and regularly updated online. We gathered this 
information together to determine if there is sufficient evidence for a regulatory role 
of phosphorylation in DAGL activity.  
 
The structure of the catalytic domain is a member of the α/β hydrolase fold family of 
enzymes. Common structural features of this enzyme family can tolerate 
considerably sized inserts at certain locations (Nardini & Dijkstra, 1999). In the case 
of the DAGLs, two inserts were identified, a cysteine rich insert and a lid-like 
structure termed the ‘regulatory loop’. The DAGLs have previously been shown to 
be palmitoylated (Kang et al., 2008; Martin & Cravatt, 2009). Palmitoylation of the 
cysteine-rich insert may serve to localise the DAGLS to the membrane. The 
regulatory loop, on the other hand, is a 50-60 amino acid insert which has an 
important role in substrate access to the catalytic site. This lid is responsible for 
interfacial activation, a process whereby activity of lipases is enhanced upon contact 
with a lipid–water interface, which is believed to trigger the opening of the lid 
(Nardini & Dijkstra, 1999; Holmquist, 2000). The regulatory loop is in the right 
position to shield DAG access to the catalytic site and also contains a highly 
conserved ‘signature motif’ whose function has yet to be elucidated (Reisenberg et 
al., 2012).  
 
The activity of several lipases is controlled by phosphorylation (Kurat et al., 2009; 
Gresset et al., 2010; Lampidonis et al., 2011). HSL, another member of the α/β 
hydrolase fold family, is probably the most studied in terms of phosphorylation. HSL 
is regulated by reversible phosphorylation on 5 critical residues by PKA, resulting in 
~2fold increase in activity by displacing the regulatory lid that shields the catalytic 
activity (Holm et al., 1994; Lampidonis et al., 2011). Phosphorylation of HSL in 
vitro not only displaces the lid, it also increases the hydrophobic surface area of the 
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protein, probably to enhance substrate access (Krintel et al., 2009; Lampidonis et al., 
2011). The evidence for the role of phosphorylation in regulating the activity of HSL 
gives us a working model for studying possible regulatory mechanisms of the 
DAGLs, based on its key structural features. 
 
Through cross-examination of the DAGLs’ sequences between online databases, we 
have identified key phospho-sites that may be important for regulation of function. 
These sites are explored in Tables 3.1 and 3.2 and are highlighted in the phospho-
map (Figure 3.1). A total of 43 DAGLα/β phospho-sites have been reported, 
identified through mass spectrometry analysis of complex samples (cells/tissues), 
which can often result in false positives and/or negatives (Alcolea et al., 2009). 
Therefore, phospho-sites identified 3 times or more and through the prediction tool 
NetPhosK 1.0 have been included on the phospho-map, as NetPhosK 1.0 has a 70-
80% success rate in predicting experimentally-verified phospho-sites (Blom et al., 
1999; Iakoucheva et al., 2004). The DAGLs are therefore potentially phosphorylated 
at a number of sites, and this may be important for regulation.  
 
Glycosylation of the TM domains, and/or palmitoylation of the cysteine-rich insert, 
may serve to localise the DAGLs to the membrane (and thus close to their substrate 
DAG). However phosphorylation of the regulatory loop has positioned itself as a key 
potential regulatory mechanism of DAGL’s activity by way of opening or closing the 
loop that shields the active site. 
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CHAPTER 4. RESULTS II – Establishing Tango cell 




The main regulation point of the eCB system is the synthesis and degradation of the 
two eCBs, 2-AG and anandamide. These lipophillic agents are synthesised ‘on-
demand’ from membrane components. As previously discussed, there are many 
reports supporting the role of 2-AG as the retrograde signalling molecule. Alongside 
this, the DAGLs have been implicated in a number of disease areas such as 
Alzheimer’s disease, Parkinson’s disease, obesity and pain. As a result, this project 
is aimed at studying the enzymes that synthesizes 2-AG, the DAGLs α and β. As 
discussed in the previous chapter, we believe phosphorylation to have a key 
regulatory function in DAGL activity, akin to HSL, whose regulatory lid is displaced 
upon phosphorylation (Holm, 2003) 
 
In order to study the activation state of the DAGLs, an assay is required that can 
measure activity and report on functional activators and inhibitors of the enzymes. 
Previous reports on analytical methodologies for measuring DAGLs’ activity include 
radio-thin layer chromatography (radio-TLC) (Majerus & Prescott, 1982; Bisogno, 
2003; Bisogno et al., 2006) and LC/MS (Hoover et al., 2008; Pedicord et al., 2011). 
However, detecting 2-AG production through these means has proven to be 
challenging and has limited screening efforts (to identify inhibitors) to small 
compound collections, mainly due to low throughput. This limited throughput has 
also led to expensive mechanism-based inhibitors (Bisogno et al., 2006) that have 
been largely unattractive as potential candidates to put through an expensive drug 
discovery process. To date, only non-specific compounds have been shown to inhibit 
DAGL formation of 2-AG, such as RHC-80267 and the lipase inhibitor 
tetrahydrolipstatin (THL), also known as Orlistat®. These compounds inhibit DAGL 
at concentrations lower than those required to inhibit other lipases, thereby showing 




More recently, assays that can report on DAGL function more easily have been 
described, largely driven by the need of drug discovery programs for a more 
convenient and cost effective method to measure activity. Johnston et al. (2012) 
developed fluorescence resonance energy transfer (FRET) reporter substrates, which 
rely on DAGL activity to relieve internal quenching in the reporters, resulting in an 
increase in fluorescence (Johnston et al., 2012). A commercially available 
fluorogenic lipase substrate, EnzChek is based on the same principle (Basu et al., 
2011). The study described by Pedicord et al. (2011) was aimed at further 
characterising DAGLα and to provide tools to initiate a pharmaceutical discovery 
effort for activators or inhibitors of the enzyme (Pedicord et al., 2011). This resulted 
in the identification of two commercially available, non-specific substrates, that 
DAGLα is capable of hydrolysing in vitro. Using a stable HEK293F cell line 
expressing full length human DAGLα, the authors showed they could report on 
specific activity of DAGLα, compared to HEK293F wild-type control cell line, 
which reported little or no activity. Since the completion of this study, a natural 
substrate assay has been described that also allows easier detection of DAGLα 
activity. This assay detects production of 2-AG from 1-stearoyl-2-arachidonoyl-sn-
glycerol (SAG) hydrolysis by DAGLα overexpressing membrane preparations from 
transiently transfected HEK293T cells. The 2-AG production is coupled to the 
oxidation of a commercially available peroxidase substrate, Amplifu Red, via a 
multi-enzyme cascade, resulting in a fluorescent signal from the dye resorufin (van 
der Wel et al., 2015). 
 
The two surrogate substrates described by Pedicord et al. (2011) were the 
chromogenic substrate 4-nitrophenyl butyrate (PNPB) and the fluorescent substrate 
6, 8-difluoro-4-methylumbelliferyl octanoate (DiFMUO) (Pedicord et al., 2011). The 
structures of these two substrates, as well as their products released through DAGL 
hydrolysis, are compared to the native substrate DAG in Figure 4.5. While these 
substrates are potentially useful tools for designing inhibitors of the enzymes, their 
limitations have meant they are unsuitable for studying DAGL regulation. For 
example, they are much smaller molecules than DAG, the molecular weights of 
PNPB and DifMUO being 209 Da and 338 Da respectively, compared to 645Da for 
DAG (Figure 4.5), meaning they are likely to access the catalytic site regardless of 
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the position of the regulatory loop; treatments aimed at increasing DAGL activity, 
such as kinase activation, do not result in an increase in substrate hydrolysis (work 
completed with Praveen Singh, unpublished data). They are also not specific 
substrates to the DAGLs, and so may be hydrolysed by other lipases. Furthermore, 
we wanted a more ‘physiological’ type assay that could measure an eCB-dependent 
CB1 response.  
 
In this chapter, I will report on the successful adaptation of a recombinant cell line to 
allow measurement of DAGLα/β activity. The Tango cells are an osteosarcoma cell 
line (U2OS) overexpressing the human CB1 receptor. These cells can report on 
direct CB1 activation through β-lactamase reporter gene synthesis (van der Lee et 
al., 2009) (discussed in more detail in chapter 4). Adaptation of the Tango cells will 
allow us to utilise the same cell line for measurement of DAGLα/β activity via CB1 
receptor activation. We overexpressed the DAGLs in these cells to generate a ‘gain 
of function’ assay, whereby any difference between parental Tango cells and the 
overexpressing cells could directly be attributed to DAGLα/β activity.  
 
Here, transgenic DAGLα/β localisation will be shown at the membrane, vital to 
access their native substrate, DAG, which is generally found associated to the cell 
membrane (Goni & Alonso, 1999). I will compare both endogenous and transgenic 
expression of DAGLα to DAGLβ; their relative expression will be an important 
factor when studying and comparing their activity in the Tango assay. We used both 
PNPB and DiFMUO substrates to show that DAGLα is active in membrane 
preparations. We also used the known DAGL inhibitors, THL, OMDM and 
RHC80267 to show that this activity can be inhibited. However, these substrates are 
not suitable for studying DAGLβ activity. Nevertheless, the fact the DAGLs can 
hydrolyse these substrates at different rates shows potential for specific therapeutic 





Establishing Tango cell lines stably expressing DAGLα and 
DAGLβ at the membrane 
The Tango cells (U2OS) harbour a recombinant assay system designed to 
specifically measure CB1 activation, known as the Tango assay. We adapted these 
cells to overexpress DAGLα and DAGLβ. The adapted cells could be used to study 
the effects of kinase activation/inhibition, based on their ability to modulate eCB-
dependent CB1 signalling in the Tango assay (see chapter 5, Results II for further 
results and discussion). 
 
Human DAGLα and DAGLβ constructs were cloned into the vector pcDNA6.2/V5-
DEST. These vectors enabled expression of the DAGL transgenes with a C-terminus 
V5 tag and contained an antibiotic selection gene for blasticidin resistance; a suitable 
selection marker for use with the Tango cells. The constructs containing either 
human DAGLα or human DAGLβ (full length) were transfected into the Tango 
cells. Their expression was determined by immunocytochemistry using fixed cells 
and western blotting analysis with cell lysates, both with a V5 antibody (Dr. Fiona 
Howell and Dr. Praveen Singh). 
 
Having confirmed successful expression of both constructs using transient 
transfection, we next used the blasticidin selection marker in these constructs to 
generate stable Tango cell lines expressing DAGLα (named V5α11) or DAGLβ 
(named V5β4). In order to confirm stable expression of the transgenes and whether 
our cell lines were clonal, we performed immunocytochemistry after more than 10 
passages, with a V5 antibody (Figure 4.1). No V5 staining was seen in control Tango 
cells, showing little, if any background staining using this antibody. As expected, V5 
staining can be seen throughout the membrane in V5α11 cells.  
 
Unexpectedly, V5 staining in V5β4 cells appeared punctated and perinuclear. 
However, this was in line with a previous report by Piomelli’s group in 
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overexpressing mouse neuroblastoma cells, where they observed DAGLβ to be 
associated with intracellular structures rather than with the plasma membrane (Jung 
et al., 2007). After further examination, DAGLβ was found to be largely associated 
with the Golgi (thesis of Dr. Praveen Singh).  
 
No difference was observed in proliferation or confluency between parental Tango 
cells and our overexpressing cell lines. Although DAGL has been implicated in 
axonal pathfinding and migration (Oudin et al., 2011a; Oudin et al., 2011b), the 
overexpressing cell lines are grown in the presence of blasticidin; the added 
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Figure 4.1 The cell lines V5α11 and V5β4 stably express human DAGLα-V5 and 
human DAGLβ-V5 respectively 
Tango cells were transfected with either hDAGLα-V5 or hDAGLβ-V5 plasmids 
using lipofectamine 2000 and then grown in the presence of the selection marker 
blasticidin. Clones were selected and explanded and screened for stable expression 
of the DAGL genes by immunocytochemistry. Two clones were selected, V5α11 
and V5β4 which were found to stably express hDAGLα-V5 and hDAGLβ-V5, 
respectively. After approximately 10 passages, cells from V5α11 and V5β4 were 
grown on poly-L-lysine coated coverslips and left to adhere overnight. The cells 
were fixed, permeabilised and stained with a V5 antibody for immunocytochemical 
analysis. This confirmed that the cell lines were clonal and stably expressing the 
transgenes. Parental Tango cells were used as control. (A: blue = hoechst; green = 







It was important to establish that there was both DAGLα and DAGLβ expression at 
the membrane to enable our future studies with the Tango assay. To confirm 
expression of the transgenes at the membrane, we used membrane preparations 
rather than whole cell lysates. Tango, V5α11 and V5β4 cells were grown to 
confluency, washed and lysed (via sucrose in the buffer). The lysed cells were 
removed from the culture dish with a cell scraper and homogenised (total particulate 
matter), followed by ultra-centrifugation to concentrate membrane protein. The 
supernatant was removed and the pellet / membrane fraction was re-suspended in 
membrane preparation buffer. The membrane protein from all cell lines was diluted 
to equal concentrations and loaded into wells of a western blot. Expression of the 
transgenes was confirmed at the membrane by probing the western with a V5 
antibody. The blots were also stripped and re-probed for β-actin to control for 
loading (Figure 4.2 A).  
 
The predicted molecular weights for DAGLα and DAGLβ are ~120kDa and ~75 
kDa, respectively (Bisogno, 2003). Expression of the DAGL transgenes was detected 
at slightly larger sizes than expected when probing with a V5 antibody; but this is to 
be expected when considering the transgenic DAGLs have a V5 tag at their C-
terminus. Therefore, we also wanted to determine their expression using a specific 
antibody for each DAGL and how this compared to the endogenous levels in 
parental Tango cells.   
 
To do this, membranes were prepared from each of our cell lines, as described 
above, and analysed in a western blot using an antibody specific for each DAGL. 
The blots were also controlled for loading by probing for β-actin. The results for 
DAGLα are shown in Figure 4.2 B. There is a large band seen in V5α11 membranes 
with a higher molecular weight than that predicted for DAGLα, corresponding to the 
larger V5-tagged version of the enzyme. The band corresponding to the endogenous 
DAGLα is less obvious. There is a band present from all 3 cell lines at a molecular 
weight smaller than that predicted for DAGLα. However, this band is not enriched in 
membrane preparations (thesis of Praveen Singh) and is not altered following genetic 
disruption (discussed in more detail in chapter 6, results IV). Therefore, it is unlikely 




When using the DAGLβ antibody, a band at the predicted molecular weight was 
seen for all three cell lines. We saw much greater expression in V5β4 cell 
membranes, thereby confirming overexpression of DAGLβ at the membrane (Figure 
4.2 C). The band corresponding to DAGLβ-V5, however, was not a distinct band 
from the endogenous DAGLβ band suggesting that the epitope tag does not 
obviously affect the mobility of the enzyme. In summary, we confirmed stable 
expression of the transgenes in our cell lines at their predicted molecular weights and 
confirmed their expression at the membrane. 
 
It was prudent at this stage to confirm whether or not our Tango cells endogenously 
express DAGLα, as we were unsure the DAGLα antibody was sensitive enough to 
pick up endogenous protein expression. Therefore, we subsequently analysed 
DAGLα expression at the transcript level in the Tango cells. This allowed us to 
compare transcripts levels of the two DAGLs, enabling us to interpret future 












Figure 4.2 V5α11 and V5β4 cells stably express DAGLα and DAGLβ, 
respectively, at greater amounts than endogenous levels 
Tango, V5α11 and V5β4 cells were lysed following ~ 10 passages and 20 µg protein 
(membrane preparation) was analysed in a western blot using a V5 antibody (A), 
DAGLα antibody (B), and a DAGLβ antibody (C). The blots were stripped and re-
probed for β-actin as a loading control (blot displayed under each). V5-tagged 
version of the DAGLs is expressed at a slightly larger molecular weight (MW), as 
expceted (A). The apparent endogenous DAGLα is a distinct band from the much 
larger DAGLα-V5, being expressed at a slightly smaller size than their predicted 
molecular weight of ~120 kDa, or could be running at the same MW, as indicated 
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Taqman analysis DAGL expression in Tango cells 
At this stage we had confirmed overexpression of the DAGLs in our two cell lines, 
V5α11 and V5β4, as well as their localisation at the membrane from the western 
blot. The western also indicated that the Tango cells endogenously express the 
DAGLβ. Using the overexpressing cells, we used real time RT-PCR to determine the 
relative level of endogenous DAGLβ expression and to confirm whether or not the 
parental Tango cells express endogenous DAGLα.  
 
To do this, RNA from Tango, V5α11 and V5β4 cells was extracted and reverse 
transcribed to cDNA. The cDNA was used to perform real time RT-PCR using 
Taqman assays for either DAGLα or DAGLβ, where detected fluorescence is 
directly proportional to the amount of PCR product. Taqman assays for PPIA, 
GAPDH and 18S were also used as control housekeeping genes. Relative 
quantification relates the PCR signal of the target transcript in a group of unknown 
expression (Tango cells) to that of another sample which absolutely expresses the 
transcripts; in this case the V5α11 and V5β4 cells. The data was analysed using the 
2-ΔΔCt method, where endogenous expression is calculated as a fraction of 1; 1 being 
equivalent to the overexpression in V5α11 / V5β4 cells (Livak & Schmittgen, 2001).  
 
The results confirmed endogenous expression of both DAGLα and DAGLβ 
transcripts in Tango cells, as seen in Figure 4.3. We also confirmed the relative level 
of overexpression of each enzyme, with DAGLα being expressed ~14 times more 
than endogenous expression in V5α11 cells, and ~7 times greater DAGLβ expression 
in V5β4 cells.  
 
As this is a relative assay, we wanted to try to obtain some comparison between the 
transcript levels of the endogenous DAGLα to DAGLβ. To do this, we performed 
Taqman assay on our three cell lines, as described above, for DAGLα and DAGLβ, 
and the three housekeeping genes, PPIA, GAPDH and 18S. To gain an insight into 
the relative expression of DAGLα to DAGLβ (in all three cells lines) the data was 
normalised to two of the housekeeping genes and expression compared to the third 
housekeeping gene (using the 2-ΔΔCt method). Data was first compared to PPIA 
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(Figure 4.4 A), then GAPDH (Figure 4.4 B) and finally 18S (Figure 4.4C), the 
values of which were all set to 1 (results excluded from graph) and DAGLα/β 
expression is displayed as the relative fraction.  
 
In comparison to each of the housekeeping genes, DAGLβ transcripts appear to be 
expressed ~2.5 times greater than DAGLα transcripts in parental Tango cells. This is 
also true for the overexpressing cells lines, where DAGLβ transcripts (endogenous + 
overexpressed) are expressed 1-2 times greater in V5β4 cells, compared to DAGLα 
transcripts in V5α11 cells. Therefore, endogenous DAGLβ protein expression may 
be greater compared to DAGLα expression in Tango cells, and also when comparing 
their relative expression between V5α11 and V5β4 cells – these results are 




Table 4.1 Summary of results from expression analysis using Taqman assays 
DAGLβ relative expression in our overexpressing cell line (V5β4) was set to 100 
(results from Fig. 4.4). The mean of the results from the other Taqman assays was set 
as a fraction of DAGLβ expression (100) to give an indication of the relative 
DAGLα and DAGLβ expression between the three cell lines, parental Tango, V5α11 
and V5β4. (There are no units as this is a relative ratio compared to housekeeping 
gene expression.) 
 
  Endogenous Overexpressed 
Taqman Assay DAGLα 4 76 







































Figure 4.3 Taqman analysis reveals the relative endogenous expression of the 
DAGLs in Tango cells 
RNA from Tango, V5α11 and V5β4 cells was extracted and reverse transcribed to 
cDNA. The cDNA was used to perform real time PCR with a Taqman probe. The 
primers in each of the Taqman assays are located in exons that span predicted splice 
variants of that gene. During the PCR process, bound probe is degraded by the PCR 
enzyme due its 5’ exonuclease activity, releasing the fluorescent marker from the 
quencher. Detected fluorescence is directly proportional to the amount of PCR 
product, and therefore the amount of RNA in the original sample. The quantity 
detected is a relative expression, therefore endogenous expression of either DAGLα 
or DAGLβ is related to expression in V5α11 and V5β4 cells, respectively. Three 
housekeeping genes were also used; PPIA, 18S and GAPDH. Data was normalised 
to these genes and analysed using the 2-ΔΔCt method ± SEM (Livak & Schmittgen, 














Figure 4.4 DAGLα expression relative to DAGLβ in parental Tango cells and 
between V5α11 and V5β4 cells 
RNA from Tango, V5α11 and V5β4 cells was extracted and reverse transcribed to 
cDNA. The cDNA from each cell type was used to perform real time PCR with a 
Taqman probe for either DAGLα or DAGLβ, as described previously. Three 
housekeeping genes were also analysed; PPIA, GAPDH and 18S. To determine 
relative DAGLα expression to DAGLβ, the Ct values were first normalised to two of 
the housekeeping genes and then compared to the third, either PPIA (A), GAPDH 
(B) or 18S (C). The relative expression of the DAGLs was first compared in parental 
Tango cells (endogenous). DAGLα overexpression in V5α11 cells was then 
compared to DAGLβ overexpression in V5β4 cells (overexpression). Data was 
analysed using the 2-ΔΔCt method ± SEM (Livak & Schmittgen, 2001). Data shown 



































































































































Determining DAGLα and DAGLβ activity using surrogate 
substrates 
We had established DAGL expression in three cell lines – parental Tango cells, 
V5α11 and V5β4 cells. We next used the chromogenic substrate PNPB and 
fluorogenic substrate DiFMUO, as previously described (Pedicord et al., 2011) to 
determine if the DAGLs were active in these cells. The structure of these substrates 
and their products were compared to the native substrate DAG in Figure 4.5.  
 
 
DAGLα activity in Tango and V5α11 membranes using the 
chromogenic substrate PNPB 
The ability of membranes from parental cells and V5α11 cells to hydrolyse a 
surrogate substrate was first assessed using PNPB in clear 96-well polypropylene 
plates. PNPB is a chromogenic substrate and hydrolysis to 4-nitrophenyl can be 
measured at OD400 on the SpectraMax (Figure 4.6). Membranes were prepared from 
Tango and V5α11 cells that had been in grown in McCoy's media supplemented with 
10% FCS (full growth media). Membranes were prepared by mechanically lysing the 
cells using a homogenizer and separating the membrane enriched fraction (pellet) 
from the soluble cytoplasmic proteins (supernatant) by ultra-centrifugation at 
100,000 g for 30 minutes, as described above. The membrane enriched fraction was 
then re-suspended in membrane buffer (20 mM HEPES, pH 7.2) using a 
homogeniser. The protein concentration of the membranes was determined and they 
were frozen in aliquots at a concentration of 1-2 mg/ml.  
 
To test for hydrolytic activity, the membranes were thawed and plated at 12.5 µg/mL 
with 250 µM PNPB. The reaction was monitored every 12 seconds for a total of 30 
minutes and a time course is shown in Figure 4.6 A. The reaction rate for V5α11 
membranes is considerably higher than membranes from parental Tango cells. 
Moreover, this enhanced activity was suppressed by THL. Use of THL reveals the 
background activity, perhaps driven by other lipases and / or other enzymes. When 
the signal was normalised to the THL response (considered the background, non 
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DAGL-dependent response), the enhanced activity in the V5α11 membranes was 
more prominent when compared to the parental Tango membranes, suggesting that it 














Figure 4.5 Native and surrogate DAGL substrates 
The native (DAG) and surrogate (PNPB and DiFMUO) substrates (molecular 
weights in brackets) of DAGL and the products generated following their hydrolysis 
by DAGL are presented above. PNPB is a chromogenic substrate, whereas DiFMUO 
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Figure 4.6 Measuring DAGLα activity using the chromogenic substrate PNPB 
in membranes from Tango and V5α11 cells 
Tango and V5α11 membranes were prepared from lysed cells and used at a final 
concentration of 12.5 µg/ml, and PNPB was used at a concentration of 250 µM. The 
OD was read at 400 nM for 30 min every 12 s. The graph shown is the mean of three 
wells ± SEM from a single representative experiment (A). The absorbance reading 
measured in the presence of THL was considered as background for both membrane 
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147 
 
The effects of varying membrane and substrate concentration in the PNPB assay 
were next established, and results are presented in Figure 4.7. Tango and V5α11 
membranes were used at a concentration range between 0 and 15 µg/mL final assay 
concentration (FAC), with 250 µM PNPB. Activity was determined by measuring 
the rate of product formation (OD400 / minute) over 10 minutes using SoftMaxPro 
software. Increasing activity was dependent on increasing concentrations of V5α11 
membranes, with little increase in hydrolysis by Tango membranes by comparison. 
The V5α11 membranes therefore showed more activity than the parental Tango 
membranes (> 6-fold) at all concentrations tested (Figure 4.7 A).  
 
Varying concentrations of PNPB (0-8 mM FAC) showed the reaction rate was also 
initially linearly related to substrate concentration using V5α11 membranes. In 
comparison there was a much smaller increase in activity from Tango membranes 
(Figure 4.7 B). The response from V5α11 appears to plateau above 250 µM PNPB, 
perhaps reflecting the poor solubility of the substrate at higher concentrations. Even 
though the Tango cells clearly express endogenous DAGLβ, and possibly express 
endogenous DAGLα, the endogenous activity levels are relatively small in this 
assay. Therefore the proportion of the reaction rate seen in V5α11 membranes is 
most likely due to the transgenic DAGLα activity.  
 
We tested three DAGL inhibitors, OMDM-188, THL and RHC-80267 for their 
ability to inhibit the hydrolytic activity associated with the V5α11 membranes. 
V5α11 membranes, prepared and plated as described above. 12.5 µg/ml membrane 
protein was pre-incubated with a concentration-response curve from each of the 
three inhibitor compounds for 5 minutes. For OMDM-188 and THL, 200 nM top 
concentration was used, diluted 1:2 (8 point curve); for RHC-80267 the top 
concentration used was 200 µM (1:2, 8 point curve). After 5 minutes, the reaction 
was initiated with 250 µM PNPB. The OD400 was again measured over 30 minutes 
and the reaction rates were calculated from the first 10 minutes.  
 
All three compounds inhibited PNPB hydrolysis in the assay in a concentration-
dependent manner (Figure 4.8 A-C). Although each inhibitor had different efficacies, 
the order of potency was in line with previous reports (Hoover et al., 2008; Ortar et 
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al., 2008). OMDM-188 is the most potent inhibitor of the DAGLs to date (Ortar et 
al., 2008) and it was found to be the most potent inhibitor in this assay. The 
approximate IC50 values were ~ 3 nM for OMDM-188, ~ 12.5 nM for THL and ~100 
µM for RHC-80267. The fact that PNPB hydrolysis by V5α11 membranes can be 
fully inhibited by the three DAGL inhibitors is further evidence that this assay is 
measuring the activity of the transfected DAGLα.  
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Figure 4.7 The effect of varying membrane and PNPB substrate concentration 
on DAGLα activity 
Membranes from Tango and V5α11 cell lines were extracted and plated at varying 
concentrations (1.5 - 50 µg/ml FAC). PNPB was added to the plate at 250 µM FAC, 
before being read immediately on the SpectraMax at 400 nM. The plate was read 
every 12 s for a total of 30 min (A). Varying concentrations of the PNPB (0 - 8 mM 
FAC) were added to wells of a clear 96-well plate. The reaction was initiated with 
addition of 12.5 µg/ml Tango or V5α11 membranes and the plate was read 
immediately at OD400, as described above (B). The mean of three wells ± SEM from 















Figure 4.8 DAGLα activity is inhibited by the three DAGL inhibitors in the 
PNPB Assay 
Reactions were set up with inhibitors and substrate in a 96-well plate before being 
initiated with addition of membrane protein. Concentration response curves of 
OMDM-188 (200 nM top FAC), THL (200 nM top FAC) and RHC-80267 (200 µM 
top FAC); 1:2 dilution, 8 point curve. The inhibitor concentration responses were 
added to half of the wells. 250 µM PNPB was added to all wells and the reactions 
were initiated with 12.5 µg/ml final concentration of V5α11 membranes. 
Approximate IC50 values were ~ 3 nM for OMDM-188 (A), ~12.5 nM for THL (B) 
and 100 µM for RHC-80267 (C). Results show mean of three wells ± SEM from a 




































































DAGLα activity in membrane preparations using the 
fluorogenic substrate DiFMUO 
We next tested the second substrate, DiFMUO which can be hydrolysed by DAGLα 
to the fluorescent product 6,8-Difluoro-7-Hydroxy-4-Methylcoumarin (DiFMU) 
(Figure 4.5) (Pedicord et al., 2011). DAGLα activity can therefore be detected by 
measuring DiFMU at an excitation wavelength of 360 nm and an emission 
wavelength of 450 nm. We first set up this assay in the same manner as for the 
PNPB assay – 12.5 µg/ml of membranes were plated into a clear 96-well 
polypropylene plate. Half of the membranes were treated with 1 µM THL for 5 
minutes before the reaction was initiated with 10 µM DiFMUO. The relative 
fluorescent units (RFU) were measured every 30 seconds for a total of 30 minutes 
(Figure 4.9 A). There was a considerable hydrolytic activity associated with the 
parental Tango membranes, but the response from V5α11 membranes was much 
greater; revealed by obtaining the THL-sensitive response (Figure 4.9 B). However, 
it was noted that the response from Tango membranes was much greater than that 
seen in the PNPB assay. This response was partially inhibited by THL, indicating 
this portion of the response may be due to endogenous DAGLα/β activity. 
 
We next tested the effects of varying membrane and substrate concentrations. The 
reaction in each was monitored every 30 seconds and the rate was calculated over 10 
minutes (RFU / second). Hydrolysis of DiFMUO increases with increasing 
membrane concentration (Figure 4.10 A). The response also plateaus above 10 µM 
DiFMUO, as seen in Figure 4.10 B. Again a substantial response is seen from Tango 
cell membranes. To determine whether this response is due to the endogenous 
DAGLs being active, we tested the three DAGL inhibitors, OMDM-188 (100 nM), 
THL (1 µM) and RHC-80267 (100 µM) (Figure 4.11). The response from Tango 
membranes is inhibited by both THL and OMDM-188, but not RHC-80267. RHC-
80267 is known to bind to off-targets, thereby reducing potency; this may indicate 
that the endogenous DAGLs are active. However, DiFMUO may also be hydrolysed 
by other lipases at the membrane (Pedicord et al., 2011). The much greater response 
seen from V5α11 cells is inhibited by THL and OMDM-188, which can be attributed 
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Figure 4.9 Measuring DAGLα activity in Tango and V5α11membranes using 
the fluorescent substrate DiFMUO 
Tango and V5α11 membranes were plated at 12.5 µg/ml in the presence and absence 
of 1µM THL. The surrogate substrate DiFMUO was then added to the membranes at 
a FAC of 10 µM. Fluorescence was measured immediately after substrate addition 
for 30 min every 30 sec at an excitatory wavelength of 360 nM and an emission 
wavelength of 450 nM (A). The fluorescent reading measured from membranes in 
the presence of THL was considered as background and was subtracted from the 
fluorescence from the untreated membranes (B). Each time point represents the mean 
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Figure 4.10 DAGLα activity is dependent on membrane and substrate 
concentration in the DiFMUO assay 
Membrane protein was prepared from Tango and V5α11 cell lines. The membrane 
protein was plated at a top concentration of 25 µg/ml followed by a 1:2 serial 
dilution, 5 point curve in assay buffer (50 mM MES, pH 6.5). The reaction was 
initiated with 10 µM FAC DiFMUO. The plate was read immediately on the 
Flexstation at an excitation of 360 nM and emission of 450 nM (A). 12.5 µg/ml 
membrane protein were plated with varying concentrations of DiFMUO (15, 10 5 
and 1 µM). The reaction was monitored as described above (B). Data shown 











































Figure 4.11 DiFMUO hydrolysis is inhibited by the DAGL inhibitors THL, 
RHC-80267 and OMDM-188 in both Tango and V5α11 membranes 
Tango or V5α11 membranes were plated at 12.5 µg/ml into wells of a 96-well plate. 
Half the wells were treated for 5 minutes with the DAGL inhibitors THL (1 µM), 
RHC-80267 (100 µM) or OMDM-188 (100 nM). The reaction was initiated with 10 
µM DiFMUO and the reaction was monitored, as described previously. Vmax 
represents the rate of substrate hydrolysis, calculated within the first 10 min of the 




As none of the inhibitors are selective for the DAGLs, we tested a full range of 
concentration for each compound to determine the order of potency (Figure 4.12). 
The approximate IC50 values were ~ 3 nM for OMDM-188, ~ 12 nM for THL and ~ 
10 µM for RHC-80267 (see Table 4.2 below) which is in line with the PNPB assay, 
as well as with values reported in the literature (Hoover et al., 2008; Ortar et al., 
2008). This clearly indicated that the response was from the transgenic DAGLα-V5, 





Table 4.2 Summary of IC50 values obtained from the DAGL inhibitors and 
surrogate substrates 
 OMDM-188 THL RHC-80267 
PNPB 3 nM 12.5 nM 100 µM 















Figure 4.12 DAGLα-V5 activity in the membrane DiFMUO assay in inhibited 
by three different DAGL inhibitors 
Concentration response curves of RHC-80267 (100 µM top concentration), OMDM 
(100nM top concentration) and THL (10 µM top concentration); 1:3 dilution, 11 
point curve. Each inhibitor concentration-response curve was added to half the wells 
of a clear 96-well plate, before addition of 10 µM DiFMUO to all wells. The reaction 
was initiated by addition of 12.5 µg/ml V5α11 membranes and the plate was read 
immediately, as previously described. Approximate IC50 values were ~ 3 nM for 
OMDM-188 (A), ~12 nM for THL (B) and ~ 10 µM for RHC-80267 (C). Results 








































































DAGLβ activity in V5β4 membrane preparations 
We determined if we could measure DAGLβ activity in V5β4 cells. Membrane 
preparations were isolated from Tango and V5β4, as described above, with the 
membrane fraction being concentrated through ultra-centrifugation. We first tested 
activity against the chromogenic substrate, PNPB. Tango and V5β4 membrane 
protein was plated at 12.5 µg/ml in clear polypropylene 96-well plates. The 
membranes were incubated with 1 µM THL, before addition of 250 µM PNPB and 
the plate was read immediately on the SpectraMax. The reaction was monitored 
every 12 seconds and the reaction rate was calculated from the first 10 minutes. 
Surprisingly, V5β4 membranes did not hydrolyse PNPB at a greater rate than that 
seen with parental Tango membranes (Figure 4.13 A). We next tested the 
fluorogenic substrate, DiFMUO. 12.5 µg/ml of Tango and V5β4 membranes were 
plated as described above, before being treated for 5 minutes with 1 µM THL. The 
reaction was initiated with 10 µM FAC DiFMUO and was monitored on the 
Flexstation. As with results with PNPB, we did not see a significant level of 
substrate hydrolysis above Tango membrane control (Figure 4.13 B). 
 
The level of DAGLβ expression is greater in V5β4 cells than DAGLα expression 
V5α11 cells. Yet it may be that the level of DAGLβ expression at the membrane 
may still be insufficient to hydrolyse these substrates above the level of that seen in 




































Figure 4.13 PNPB and DiFMUO are not suitable substrates to measure DAGLβ 
activity 
The activity of membranes isolated from the V5β4 cells was measured using 
surrogate substrates. Membranes (12.5μg/ml) prepared from V5β4 and Tango cells 
were incubated in the presence or absence of THL (1μM) for 5 min. Activity was 
measured using PNPB (250μM) and the reaction rate was calculated over the first 10 
minutes (A). Activity of the membranes was also measured using DiFMUO (10µM) 
as the substrate, as described above (B). The data represents the THL-sensitive 
activity detected and the mean of 3 wells ± SEM from a single experiment. 







4.3 Summary & Conclusions 
 
In this chapter, I describe a cell line we have developed for each DAGL using the 
Tango (U2OS) cells. The Tango cells harbour a recombinant assay system to 
measure CB1 activation. Using the Tango cells allows us to develop an assay to 
measure eCB-dependent CB1 activation, whereby DAGLα/β hydrolysis of DAG 
would produce 2-AG, thereby activating the CB1 receptor. The overexpressed 
DAGLα/β would allow a ‘gain of function’ assay, whereby any increase in response 
over parental Tango cells could be directly attributed to the transfected DAGL, 
allowing us to study its function.  
 
We successfully generated a clonal cell line for DAGLα (V5α11) and a cell line for 
DAGLβ (V5β4). In the last chapter, we identified structural features that are likely to 
orientate the DAGLs at the membrane for substrate access. As expected, DAGLα 
staining revealed expression throughout the cell surface, although DAGLβ 
expression appeared punctated and perinuclear (Figure 4.1). A portion of DAGLβ 
expression in our V5β4 cells is localised to the Golgi (thesis of Dr. Praveen Singh), 
which may be a result of an artefact of overexpressing the enzyme.  
 
To confirm DAGLα and DAGLβ expression at the membrane we probed all three 
cell lines (Tango, V5α11 and V5β4) in a western blot (Figure 4.2). The resulting 
bands using a V5 antibody were larger than those predicted for the DAGLs (~120 
kDa for DAGLα, ~75 kDa for DAGLβ) and correspond to the larger, V5-tagged 
version of each enzyme (Bisogno, 2003). The DAGLα was less reliable, resulting in 
a band at a much smaller (~110 kDa) than that predicted for DAGLα (Figure 4.2 B). 
On the other hand, using a DAGLβ antibody we confirmed endogenous expression 
of DAGLβ in the Tango cells. The Taqman assay revealed the Tango cells to have 
transcripts for both the DAGLs. By comparing expression to three housekeeping 
genes, we have shown DAGLβ expression is likely to be much greater than DAGLα 
expression, both endogenously in the Tango cells and between V5α11 and V5β4 
cells – a point to be considered when comparing results between the 3 cell lines in 




We confirmed DAGLα to be active in V5α11 cells, as hydrolysis of both PNPB and 
DifMUO was much greater in membranes from these cells compared to parental 
Tango membranes and this response could be inhibited by THL (Figure 4.6 – 4.11). 
However, we could not detect a greater response in V5β4 membranes over parental 
Tango cell membranes using these surrogate substrates (Figure 4.13), which is 
surprising considering the greater level of DAGLβ transcripts in these cells. This 
could be due to different kinetics of the DAGLs when hydrolysing these substrates. 
Although future studies may include DAGLβ, or indeed measuring 2-AG production 
by these cells lines, our initial focus is on regulation of DAGLα in the context of the 
CNS. 
 
In conclusion, we have successfully developed two recombinant cell lines that 
overexpress DAGLα and DAGLβ, and have concluded that the transgenic DAGLα in 
V5α11 cells is active. There is substantial evidence that phosphorylation can change 
the activity of the DAGLs and that this results in increased 2-AG production. The 
limitations of using the surrogate substrates means we were unlikely to detect any 
changes in the membrane assays. However, by establishing overexpression in the 
Tango cells, we could develop an eCB-dependent CB1 assay using these cell lines. 
This assay could report on production of the endogenous ligand for CB1, 2-AG to 
allow us to study regulatory mechanisms of the DAGLs. The potential for this assay 
is explored in the next chapter.  
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CHAPTER 5. RESULTS III – Development of an 




DAG is hydrolysed by DAGL to form the eCB 2-AG (Farooqui et al., 1984; Stella et 
al., 1997; Bisogno, 2003) and that is one of the main regulation points of the eCB 
system. Our focus was to measure DAGLα and/or β activity and how this can 
directly impact ‘on demand’ synthesis of 2-AG. At present, studying activity of the 
DAGLs relies heavily on quantifying 2-AG following cellular stimulation, or 
addition of synthetic DAG (Bisogno, 2003; Jung et al., 2007); quantification of 
which relies on mass spectrometry techniques, which itself requires an expensive 
laboratory set up (Balgoma et al., 2013). Our aim was to develop an assay to more 
easily study activity of the DAGLs. In this chapter, I will explain how we adapted 
the well-established CB1-Tango assay that measures direct activation of the CB1 
receptor by pharmacological agents, in order to detect eCB-dependent CB1 
activation.  
 
The CB1-Tango assay is a recombinant assay system that reports directly on GPCR 
activation (summarised in Figure 5.1). A chimeric CB1 receptor is overexpressed in 
U2OS cells, where it is extended at the C-terminus with a non-native transcription 
factor, separated from the receptor by a linker containing a protease cleavage site. In 
addition, a chimeric version of β-Arrestin 2 is fused to a non-native protease and is 
also expressed. Upon CB1 activation, the recruitment of β-Arrestin 2 brings the 
protease into close proximity to the receptor where it acts on the cleavage site. The 
released transcription factor moves to the nucleus, activating a third transgene, 
namely a mammalian-optimised β-lactamase (bla) reporter gene. At the end of the 
treatment period, cells are loaded with a fluorescent substrate containing two 
fluorophores, coumarin and fluorescein. In the absence of bla expression, the 
substrate remains intact. In this state, excitation of coumarin results in FRET to the 
fluorescein moiety and emission of green fluorescent light. However, when bla is 
expressed the substrate is cleaved by β-lactamase. This separates the fluorophores, 
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disrupting energy transfer and results in a blue fluorescence signal. The resulting 
coumarin:fluorescein (green:blue) ratio provides a readout for activation of the CB1 
receptor. 
 
We reasoned that the CB1-Tango assay might be adaptable to report on eCB 
signalling via the CB1 receptor, provided that the cells have the ability to synthesise 
eCBs and appropriate stimulants could be identified. Unlike other neurotransmitters, 
lipid signalling molecules are thought to be biosynthesised by neurons at the moment 
of their intended action and degraded ‘on-demand’, rather than being stored in 
vesicles prior to signalling (Leung et al., 2006). We hypothesised that we could 
stimulate 2-AG biosynthesis by activating the DAGLs, through treatments aimed at 
kinase activation. Consequently, CB1 activation in this instance would be indirectly 
reporting on DAGLα/β activity. Nonetheless, at the outset it was clear that the assay 
might also report on the activity of other eCBs. 
 
Long before 2-AG was identified as an eCB, 2-AG release was examined following 
cell stimulation. For example, arachidonylglycerol was shown to be released from 
Swiss mouse 3T3 cells following stimulation by platelet-derived growth factor 
(Hasegawa-Sasaki, 1985). 2-AG was more recently shown to be released by other 
stimuli, such as the calcium ionophore ionomycin. Neuroblastoma (N18TH2) cells 
released 2-AG into the medium in a calcium-dependent fashion and in a 
concentration analogous to that released from 3T3 cells (Bisogno et al., 1997b). 
Agonists for GPCRs known to be located at the postsynaptic terminal can also result 
in 2-AG mobilisation for retrograde activation of CB1, for example the agonist for 
the mGlu receptor type 1 (DHPG) in rat brain slices (Jung et al., 2007). These 
studies have looked at stimulating cells on a broader scale for measuring 2-AG 
production and not on the cellular machinery that regulate its manufacture.   
 
In Chapter 3 (Results I), I have described consensus phosphorylation sites on the 
regulatory loop of the DAGLs that are potentially important for regulating substrate 
access to the catalytic domain. Based on this, we hypothesise that the DAGLs are 
activated by phosphorylation by kinases such as PKA and PKC. This mechanism 
could explain the increase in 2-AG production from cells treated with ionomycin; 
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calcium influx into the cell activates various kinases, which in turn might 
phosphorylate the regulatory loop on the DAGLs. We sought to test this hypothesis 
by initially investigating the effects of activating PKA and PKC directly and how 
this compared to ionomycin treatment of our CB1-Tango cells.  
 
However, as suggested above it must be noted that kinase activation might also 
results in anandamide being produced, which might also trigger signalling in this 
model. In this context, multiple synthetic pathways for anandamide synthesis have 
been suggested. For example, NAPE-PLD generation of anandamide (Di Marzo et 
al., 1994; Cadas et al., 1997), GDE1 hydrolysis of a glycerophospho-NAE 
intermediate (Simon & Cravatt, 2006; 2008) or indeed a combination of both (Simon 
& Cravatt, 2010b). Anandamide synthesis has also been detected in LPS-stimulated 
macrophages by an as yet unidentified PLC (Liu et al., 2006).  This is complicated 
further by the fact that anandamide synthesis can be stimulated by calcium (Di 
Marzo et al., 1994; Cadas et al., 1997; Schmid, 2000; Leung et al., 2006). 
Furthermore, a number of other potential eCBs have been identified, the synthesis of 
which could potentially be stimulated by calcium, such as virodhamine (Porter et al., 
2002), NADA (Huang et al., 2002), noladin ether (Hanus et al., 2001; Fezza et al., 
2002), and the ethanolamide derivatives DHEA and EPEA (De Petrocellis et al., 
2000; Brown et al., 2010; Yang et al., 2011), although evidence for stimulation of 
their biosynthesis has yet to be documented. As discussed in Chapter 4 (Results II), 
the CB1-Tango cells endogenously express the DAGLs. We also engineered the 
CB1-Tango cells to overexpress either DAGLα (V5α11) or DAGLβ (V5β4). This 
would enable us to directly relate the difference between parental CB1-Tango cells 
and our overexpressing cell lines to the DAGLα/β generation of 2-AG (and not 
another eCB). Furthermore, overexpression of DAGLα has previously been shown to 
increase 2-AG levels in a recombinant system (Jung et al., 2007). This 2-AG should 
activate the CB1 receptor, creating a DAGLα/β-dependent CB1 activation assay. 
Nonetheless, at the outset it was self-evident that the first objective was to identify 
conditions that stimulate eCB signalling in the CB1-Tango cells, with secondary 




The activity of eCBs can be limited by the activity of the enzymes that degrade 
anandamide and/or 2-AG; these are primarily FAAH (Cravatt et al., 2001; Deutsch 
et al., 2002) and MAGL (Beltramo & Piomelli, 2000; Piomelli et al., 2000; Dinh et 
al., 2002; Muccioli et al., 2007; Long et al., 2009a; Schlosburg et al., 2010). 
However, 2-AG can also be hydrolyzed by FAAH or by αβ-hydrolase domain-
containing protein 6 (ABHD6) (Blankman et al., 2007; Long et al., 2009b). To test 
the importance of these enzymes in limiting and/or gating eCB-CB1 activation and 
to determine the role of these enzymes in the CB1-Tango cells, we used a selective 
MAGL inhibitor, JZL184 (Long et al., 2009a) and a dual MAGL/FAAH inhibitor, 
JZL195, that also inhibits ABHD6, albeit at a lower potency (Long et al., 2009b).  
 
In this chapter, we demonstrate the successful adaption of the CB1-Tango assay to 
monitor eCB activation of the CB1 receptor. At the outset of this study, there were 
no specific inhibitors to differentiate between DAGLα and DAGLβ, and no 
inhibitors of anandamide synthesis. Therefore, we recognized that a genetic 
intervention to delete candidate enzymes responsible for eCB synthesis would 
ultimately be required in order to identify pathways regulating eCB signalling in the 
CB1-Tango cells. However, it was important to first establish whether or not we 
could detect eCB-dependent CB1 activation in the CB1-Tango assay and if we could 











Figure 5.1 Schematic overview of the CB1-Tango Assay system 
In the CB1-Tango assay, the CB1 receptor is extended at the C-terminus with a non-
native transcription factor followed by a linker that contains a protease cleavage site. 
β-Arrestin 2 is fused to a protease. Upon CB1 activation by 2-AG, β-arrestin is 
recruited to the receptor. Close proximity of the protease and the cleavage site allows 
the transcription factor to be released, which activates β-lactamase (bla) reporter 
gene in the nucleus. During the assay, cells are loaded with a fluorescent substrate 
containing two fluorophores, coumarin and fluorescein. In the absence of bla 
expression, the substrate remains intact and excitation of coumarin results in FRET 
and emission of green fluorescent light. When bla is expressed, the substrate is 
cleaved by β-lactamase. This separates the fluorophores, disrupting energy transfer 
and results in a blue fluorescence signal. The resulting coumarin:fluorescein 
(green:blue) ratio at an excitation of 409 nM provides a normalized CB1 response. 
The figure highlights the role of DAGLα, but eCB signalling might also be 





CB1 activation is maintained in cells overexpressing  DAGLα  
Having developed a cell line to overexpress DAGLα, the V5α11 cells (described in 
Chapter 4, Results II), our first step was to determine whether the CB1-Tango assay 
was still functional in these cells. To this end, we tested the standard agonist for the 
CB1 receptor, arachidonyl-2'-chloroethylamide (ACEA) and the standard antagonist, 
AM251 (as recommended by the manufacturer). To do this, we performed the CB1-
Tango assay using the standard manufacturer’s protocol (and as described in the 
methods section). 20,000 CB1-Tango and V5α11-CB1-Tango cells (hereafter just 
called V5α11 cells) were seeded into black, clear-bottom 96-well plates and 
maintained overnight in the recommended medium, Freestyle. This medium is serum 
free to starve the cells in order to reduce background noise in the assay. The 
following day, compounds were made up in the same medium. Varying 
concentrations of AM251 were added to half the cells (10 µM top concentration, 
diluted 1:2, 6 point curve), and incubated for 30 minutes. A concentration-response 
curve of ACEA was then made using 10 µM top concentration (diluted 1:2, 6 point 
curve), and was added to the second half of the plate. 2 µM ACEA was also added to 
the AM251 concentrations and the plate was incubated for 4 h to allow accumulation 
of β-lactamase expression in the cells. Expression was detected using a FRET-enable 
substrate (“LiveBLAzer”), which was added to the plate for 2 h. Fluorescence ratio 
between the green and the blue channel was detected on the Flexstation; emission 





Table 5.1 Excitation and emission wavelengths for the CB1-Tango assay 
 Scan 1 Scan 2 
Purpose 
Measure fluorescence in the 
Blue channel 
Measure FRET signal in the 
Green channel 
Excitation filter 409/20 nm 409/20 nm 




The results from each concentration curve are presented in Figure 5.2. Differences in 
maximal responses can be seen between the two cell lines. This might reflect the 
added pressure on V5α11 cells caused by the additional antibiotic for DAGLα 
expression in the media, or perhaps just clonal variation. The EC50 values for CB1-
Tango and V5α11 cells were ~ 50 nM and ~ 160 nM, respectively. However, 
AM251 IC50 values of ~ 126 nM were robust and comparable between the two cell 
lines. Based on this, we deemed that a concentration of 1µM ACEA and 10 µM 
AM251 would be maximally active in both cell lines, and these concentrations were 
used for subsequent experiments (unless otherise stated). 
 
Other key points to note include the observation that the addition of AM251 to 
control cultures does not reduce the signal below the control value in both the 
parental and DAGL overexpressing cell lines (background value for CB1-Tango 
cells was 1.4 and for V5α11 cells was 1.6). Thus under these conditions we can 
conclude that there is no basal eCB tone in the cultures, and on this basis conclude 
the simple over expression of the DAGL is not sufficient to generate a basal eCB 


















































Figure 5.2 CB1-Tango activity is unaffected by the transfected DAGLα  
20,000 Tango and V5α11 cells were seeded in Freestyle medium into black 96-well 
plates. The cells were treated with varying concentrations of the CB1 selective 
agonist, ACEA (10 µM top conc, 1:2, 5 pt curve) (A) and the  standard antagonist 
AM251 in the presence of 1µM ACEA (10 µM top conc, 1:2 5 pt curve) (B). 
Compounds were incubated for 4 h. Fluorescent detection of β-lactamase reporter 
gene transcription was measured using a FRET-enabled substrate, as per 
manufacturer’s protocol. Graphs show the mean of 4 wells ± SEM (n=1). ACEA 






Detection of an eCB tone using the specific MAGL inhibitor, 
JZL184 
Next we wanted to determine if we could induce an eCB tone in the CB1-Tango 
cells by treating the cells with the MAGL inhibitor, JZL184 (Long et al., 2009a). We 
reasoned that JZL184 might allow any 2-AG being produced by the DAGLs to 
accumulate and then signal through the CB1 receptor (Schlosburg et al., 2010). An 
eCB tone should manifest itself as a reduction in basal response by AM251, in the 
presence of JZL184.  
 
Using the standard manufacturer’s protocol, CB1-Tango cells were starved in 
Freestyle medium for 24 h. On the day of the assay, compounds were diluted in the 
same medium in the presence of 100 nM JZL184, which is sufficient for maximum 
inhibition of MAGL (Long et al., 2009a). Half the cells were treated with 10 µM 
AM251 for 30 minutes before addition of either Freestyle medium alone (+ JZL184) 
or ACEA as a positive control. The cells were treated for 4 h to allow accumulation 
of Bla expression. The FRET-enabled substrate, LiveBLAzer was used to detect 
fluorescence and the plate was read on the Flexstation, as described above. The 
results are presented in Figure 5.3.  
 
JZL184 treatment did not stimulate an eCB tone in the assay, as AM251 did not 
inhibit the control response in the presence of the drug. The CB1-Tango assay is 
functional in the presence of JZL184, as there is a robust response seen from 1 µM 
ACEA. This was fully inhibited by AM251, showing the response to be through the 
CB1 receptor. The lack of tone in the presence of JZL184 alone is a possible 
indicator that the endogenous DAGLs are not active, or perhaps other enzymes can 
hydrolyse the basal production of 2-AG.  
 
It has been reported that activation of PKA can lead to the synthesis of 2-AG 
(Vellani et al., 2008). Based on this, we determined whether cAMP-dependent PKA 
activation, by treating the cells with forskolin, would stimulate eCB signalling. 
Forskolin activates adenylyl cyclase, increasing intracellular levels of cAMP which 
in turn activates PKA (Seamon & Daly, 1986). 
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Parental CB1-Tango cells were plated and starved in Freestyle medium, as described 
above. On the day of the assay, all compounds were made up in the same medium 
containing 100 nM JZL184 (in an attempt to maximise any response), and half the 
cells were treated with 10 µM AM251 for 30 minutes. A range of forksolin 
concentrations were then tested (0.08 – 10 µM FAC) in the presence and absence of 
AM251, and the cells were treated for 4 h. Addition of media containing JZL184 
alone was used as control. Fluorescent ratio was again determined by treating the 
cells with the FRET-enabled substrate for 2 h, before reading the plate on the 
Flexstation. Results were normalised to the control, which is represented as a 100% 
in Figure 5.4.  
 
Forskolin appeared to stimulate a significant CB1-Tango response over that seen 
from the control. This response is inhibited by AM251, and is therefore CB1-
dependent. However, the forskolin response did not reach significance, as 
established using the one-way analysis of variance (ANOVA) (Figure 5.4).  
 
In conclusion, a basal eCB tone is not present in parental Tango cells, nor is one 
revealed when MAGL is inhibited by JZL184. The forskolin response was also not 
significant; this could possibly be due a limiting factor, such as lack of substrate, 
lack of enzyme, or enzyme not being active. To determine if the lack of enzyme is a 





































Figure 5.3 The use of the MAGL inhibitor JZL184 reveals no eCB tone in the 
Tango assay 
20,000 parental Tango cells were plated into black, clear-bottom 96-well plates in 
Freestyle medium. The cells were left to adhere overnight at 37⁰C before assay. 
Compounds were made up in Freestyle medium containing 100 nM of the MAGL 
inhibitor, JZL184. Half of the cells were treated with 10 µM AM251 for 30 min, 
before addition of either Freestyle medium (‘control’ cells) or 1 µM ACEA. After 4 
h, fluorescent detection of β-lactamase reporter gene transcription was measured 
using a FRET-enabled substrate, as per manufacturer’s protocol. The graph shown is 


































Figure 5.4 The forskolin stimulated response is not dependent on concentration 
20,000 parental Tango cells were plated in black, clear-bottom 96-well plates and 
left to adhere overnight in Freestyle medium. The following day, compounds were 
diluted in Freestyle medium containing 100 nM JZL184. Half the cells were treated 
with 10 µM AM251 for 30 min, before addition of varying concentrations of 
forskolin (FSK; 0.08 – 10 µM) for 4 h to all wells. β-lactamase expression was 
detected by addition of a FRET-enabled substrate, as per manufacturer’s protocol. 
The resulting data was normalised to the control background response, fixed at 
100%. Data presented is pooled from 3 independent experiments, with each of these 





Detection of an eCB tone in V5α11 cells in the presence of 
JZL184 
To determine whether an increased level of DAGLα expression could induce an eCB 
tone (in the presence of JZL184), we used our DAGLα overexpressing cell line, 
V5α11, which were starved in Freestyle medium for 24 h. Compounds were diluted 
in the same medium containing 100 nM JZL184. We first treated V5α11 cells with 
10 µM AM251 for 30 minutes, followed by 1 µM ACEA, or medium as control. 
Using AM251 alone tells us whether the CB1 receptor is being activated when 
JZL184 prevents 2-AG breakdown. We compared this to the ACEA response being 
inhibited by AM251, and results from a single representative experiment are shown 
in Figure 5.5.  
 
No basal eCB tone was detected in V5α11 cells, as evident from treatment with 
AM251 alone, which did not reduce the background signal in the presence of 
JZL184. There is a robust ACEA response from these cells, which is inhibited by 
AM251. Again, the response from V5α11 cells is smaller than that seen from 
parental CB1-Tango cells, possibly reflecting the added antibiotic pressure on the 
cells in culture and/or simple clonal variation.  
 
The lack of eCB tone observed in these cells might reflect a lack of substrate or 
perhaps substrate is available but unable to access the active site of the enzyme due 
to steric hindrance by the regulatory loop. Therefore, we tested responsiveness to 
PKA activation. To do this, V5α11 cells were plated in Freestyle media for 24 h, 
before addition of compounds also made up in Freestyle with 100 nM JZL184 (to 
again try to maximise any response). 10 µM AM251 was added to half of the cells 
for 30 minutes, before addition of varying concentrations of forskolin (0.08 – 10 µM 
FAC) for 4 h. Fluorescence was detected as described previously and read on the 
Flexstation. The results were normalised to the control response, which was set to 
100% and results are presented in Figure 5.6. 
 
In the presence of 10 µM forskolin, a minor yet significant response is induced that 
is CB1-dependent, as it is inhibited by AM251. However, as seen with parental CB1-
Tango cells, the response is not concentration-dependent (over the tested range). The 
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response is also not significantly different from that seen from parental CB1-Tango 
cells, suggesting the level of enzyme expression is not rate-limiting under these 
conditions; lack of eCB tone might therefore be due to insufficient substrate and/or 
an inability of the substrate to access the active site of the enzyme.  
 
In conclusion, after 4 h in the presence of JZL184 there was no basal eCB tone seen 
from either parental CB1-Tango or V5α11 CB1-Tango cells. Similarly, forskolin 
treatment did not induce a concentration-dependent response in the 4 h assay. A 
previous report has shown that increasing the compound incubation time can 
highlight subtle increases or decreases in CB1 activation, by allowing β-lactamase 
expression to accumulate (van der Lee et al., 2009). It follows that increasing the 
length of the assay might increase sensitivity and thereby reveal tone and/or 
responsiveness to forskolin and as such we increased the compound incubation time 





































Figure 5.5 JZL184 does not reveal a basal eCB response in V5α11 cells 
V5α11 cells were plated and maintained in black, clear-bottom 96-well plates in 
Freestyle medium at 20,000 cells per well, as previously described for the parental 
CB1-Tango cells.  Compounds were made up in Freestyle medium containing 100 
nM JZL184, and half of the cells were treated with 10 µM AM251. The cells were 
then treated with the same medium as control (with JZL184) or with 10 µM ACEA, 
for 4 h. β-lactamase expression was detected by addition of a FRET-enabled 
substrate, as per manufacturer’s protocol. Data presented is a single representative 





































Figure 5.6 The forskolin-stimulated response in not revealed by increased 
DAGLα expression 
V5α11 cells were plated and maintained in Freestyle medium, as described 
previously. The following day, compounds were made up in Freestyle medium 
containing 100 nM JZL184 and half of the cells were treated with 10 µM AM251 for 
30 min. Varying concentrations of forksolin were added to the plate (0.08 – 10 µM) 
for 4 h and β-lactamase expression was detected using a FRET-enable substrate, as 
per manufacturer’s protocol. The results were normalised to the control response, 
fixed at 100%. The data shown is from 3 independent experiments representing the 
mean of 8 wells ± SEM. Statistics were performed using one-way ANOVA, as 
indicated below. 
* p< 0.05; one-way ANOVA 
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The effect of increasing compound incubation time on the 
response from CB1-Tango cells 
We first wanted to determine the effects of increasing compound incubation time 
from 4 h to 18 h (overnight assay) on basal and maximal ACEA responses. The 
assay was run in a similar manner as before, where parental CB1-Tango cells were 
starved for 24 h in Freestyle medium prior to the assay (as recommended by the 
supplier). Compounds were made up in the same medium containing 100 nM 
JZL184 to maximise any response. 10 µM AM251 was added to half the cells for 30 
minutes, before addition of media alone or 1 µM ACEA as a positive control. The 
cells were treated overnight for a total of 18 h. Bla expression was detected using the 
FRET-enabled substrate for 2 h and the plate was read on the Flexstation.  No eCB 
tone was observed in this new assay format, as the basal signal was not reduced in 
the presence of AM251 (Figure 5.7). A much greater ACEA response was seen in 
the 18 h assay compared to the 4 h assay, indicating that increasing the compound 
incubation (and therefore time in starvation medium) did not have a detrimental 
effect on the assay and does in fact increase the response (Figure 5.7). The ACEA 
response was also fully inhibited by AM251.  Our next step was to see whether the 
increased assay length could reveal a more robust forskolin-induced response in a 
concentration-dependent manner.  
 
To do this, CB1-Tango cells were plated and maintained in Freestyle medium as 
described above. All compounds were diluted in the presence of 100 nM JZL184 and 
half the cells were treated with 10 µM AM251 for 30mins, before addition of 
varying concentrations of forskolin (0.08 – 10 µM), or medium as control. 
Compounds were incubated overnight, for a total of 18 h and the fluorescent ratio 
was calculated, as before. The results were normalised to the control response, set to 
100%. Statistics were performed using one-way ANOVA and the results are shown 
in Figure 5.8. The response seen from 10 µM forskolin reached significance in the 
18 h assay, resulting in a much greater response above control from forskolin (~ 
30%) compared to that seen in the 4 h assay (~ 8%). However, and very importantly, 
this response was not inhibited by AM251 suggesting that it is not related to specific 



































Figure 5.7 The ACEA response increases in the overnight Tango assay 
Tango cells were plated and maintained in black, clear-bottom 96-well plates in 
freestyle medium, as previously described. Half of the cells were treated with 10 µM 
AM251, before addition of 10 µM ACEA or medium as control for an increased 
length of 18 h (overnight assay). β-lactamase expression was detected by addition of 
a FRET-enabled substrate, as per manufacturer’s protocol. Results are pooled from 3 
independent experiments, with 8 replicates used to generate the results in the 




































Figure 5.8 Increasing compound incubation time does not stimulate an eCB 
response in Tango cells 
20, 000 Tango cells were plated into a black, clear-bottom 96-well plate and 
maintained overnight in Freestyle medium. The following day, compounds were 
diluted in the same medium containing 100 nM JZL184. Half the cells were treated 
with 10 µM AM251 for 30 min, before addition of varying concentrations of 
forskolin (FSK; 0.08 – 10 µM) or media as control. Bla expression was detected 
using a FRET-enabled substrate, as per manufacturer’s instructions. The data was 
normalised to the control (fixed at 100%) and the data presented is the mean of 8 
wells ± SEM pooled from 2 independent experiments. Significance was established 
using one-way ANOVA, as indicated below. No significant effect was found in the 
presence of AM251. 
**p<0.01; one-way ANOVA 
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Evaluating a more physiological medium for the CB1-Tango 
assay 
The failure to detect a substantial basal eCB signalling in cells that overexpress 
DAGLα in media containing JZL184 in the presence and absence forskolin was 
surprising given the report that PKA activation leads to 2-AG synthesis (Vellani et 
al., 2008).  The CB1-Tango assay requires the cells to be serum starved for 24 h in 
Freestyle medium to reduce background interference, and the manufacturers will 
also not reveal the composition of the Freestyle media, apart from confirming to us 
that it is a calcium free media. The cells are therefore cultured for a long period 
without serum and calcium, in media that might lack other factors required for the 
synthesis of 2-AG and perhaps other eCBs. Based on this it was decided to change 
track and determine if a CB1-Tango assay could be developed in a better defined 
tissue culture media.  
 
For this reason, we decided to test McCoy’s as it is the recommended growth 
medium for U2OS cells and it also contains 1 mM calcium. Additionally, we 
introduced a low concentration of FBS (1%) to ensure cell viability, while keeping it 
low enough as to not interfere with the assay. Low levels of serum might also 
increase substrate availability by stimulating various receptors in the cells. We 
compared these results to another media type, DMEM as a comparison and to ensure 
the phenol red in McCoy’s medium does not interfere with the fluorescent assay. To 
do this, we plated parental CB1-Tango cells in DMEM 1% FBS, McCoy’s 1% FBS, 
or Freestyle 1% FBS and tested the effects of ACEA (1µM in the same media) in a 4 
h or 18 h assay. The cells were initially ‘starved’ for 24 h in these media. Reporter 
enzyme activity was determined using the standard assay protocol, as described 
previously, and the results are shown in Figure 5.9. In a single experiment, results 
for all 3 media were very similar in both 4 h and 18 h assays. The major difference 
observed was the background signal. The background response seen in the 4 h assay 
was not inhibited by AM251 giving similar values to the background response, and 
is therefore not CB1-dependent (data not shown). All 3 media obtained similar 
results from ACEA, with a much more substantial response seen in the 18 h assay, 
largely due to the background being greatly reduced. As McCoy’s 1% FBS is a 
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defined medium (full contents are known), contains calcium and is the recommended 
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Figure 5.9 McCoy’s 1% FBS is optimal as an assay medium for the CB1-Tango 
assay 
Tango cells plated in 96-well plates at 20,000 cells/well were maintained for 24 h in 
different media types containing 1% FBS, as indicated. Compounds were made up in 
the individual media types. Half of the cells were treated with 10 µM AM251 for 30 
min, followed by addition of 1 µM ACEA to all wells, for 4 h and 18 h, as indicated. 
(Control wells had media only.) Fluorescent detection of β-lactamase reporter gene 
transcription was measured using a FRET-enabled substrate, as per manufacturer’s 
protocol. Results shown is from a single experiment and is the mean + SEM of 8 
replicate wells. Significance between control and ACEA responses in each was 
established using the two-sided Student’s t-test and is indicated as stated below. 
 
*** p<0.001 Student’s t-test 
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The effects of JZL195 on the eCB response following a 24 h 
‘starvation’ period in McCoy’s 1% FBS 
When establishing whether we could detect an eCB tone in cells using McCoy’s 1% 
FBS as the assay medium, we also included the inhibitor JZL195 in the assay. 
JZL195 is a dual inhibitor of the eCB-degrading enzymes MAGL and FAAH, and 
will also inhibit ABHD6. We decided it would be prudent to block all of these 
enzymes, as previous reports have shown some of these pathways are capable of 
crosstalk, where anandamide and 2-AG pathways can interact to regulate specific 
behavioural processes in vivo (Long et al., 2009b); therefore blocking only one of 
these enzymes could lead to compensation by the other. For example, including 
JZL195 rather than JZL184 would eliminate FAAH compensating for the lack of 
MAGL activity.  
 
We first established the effects of JZL195 on basal eCB tone in the 4 h and 18 h 
assays. To this end, parental CB1-Tango cells were plated in McCoy’s 1% FBS 
medium. Following a 24 h ‘starvation’ period, compounds were made up in the same 
medium in the presence and absence of 100 nM JZL195. Half the cells were treated 
with 10 µM AM251 for 30 minutes, before addition of McCoy’s 1% FBS media to 
all cells for either 4 h or 18 h. Bla expression was determined using the LiveBLAzer 
substrate for 2 h and the plate was read on the Flexstation, as described previously. 
The results are highlighted in Figure 5.10, which have been normalised to the control 
response in the absence of JZL195 (represented as 100%). 
 
In both the 4h and 18 h assays, AM251 failed to significantly reduce the response 
below 100% in the absence of JZL195, indicating no basal eCB tone in this assay. 
However, there is a significant response seen over control in the presence of 100 nM 
JZL195. Therefore, the lack of eCB tone when JZL195 is absent might reflect 
MAGL/FAAH/ABHD6 acting as ‘gate-keeping’ enzymes, that hydrolyse 2-AG (or 
other eCBs) thereby preventing it from stimulating the CB1 receptor. Once these 
enzymes are inhibited by JZL195, β-lactamase activity increases after both 4 h and 
18 h by ~15% and ~30%, respectively. This response was fully inhibited by AM251, 
providing evidence it is dependent on CB1 activation. Our lab has previously 
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established that 100 nM was a maximally active concentration of JZL195 and this 
has also been reported in the literature (Long et al., 2009b). 
 
Due to the eCB tone in the presence of JZL195, we determined whether the ACEA 
response is also potentiated when JZL195 is present. Cells were treated with ACEA 
+/- AM251 in control media and media supplemented with 100 nM JZL195, as 
described above. The results were normalised and presented as a percentage of the 
control response (100%) in Figure 5.11. A robust ACEA response was seen in both 
assays. As expected, the 18 h assay resulted in a much greater ACEA response 
(Figure 5.11 B). The ACEA responses were not significantly different from each 
other in both assays; therefore JZL195 neither potentiates nor does it add to the 
ACEA response. This is consistent with them operating via the same pathway (CB1 


















































Figure 5.10 The dual MAGL/FAAH inhibitor JZL195 stimulates an eCB 
response following a 24-hour starvation period 
20,0000  Tango cells were plated into black 96-well plates and maintained for 24 h 
in McCoy’s 1% FBS. Compounds were made up in the same medium either in the 
absence (-) or presence (+) of 100 nM JZL195. Half of the cells were treated for 30 
min with 10 µM AM251, before addition of control media. Compounds were 
incubated for either 4 h (A) or 18 h (B). Fluorescent detection of β-lactamase 
reporter gene transcription was measured using a FRET-enabled substrate, as per 
manufacturer’s protocol. Data is represented as a percentage of the control response 
(set to 100%) and is the mean of 8 wells ± SEM from 3 pooled, independent 
experiments. Statistics were performed using one-way ANOVA, as indicated below.   

















































Figure 5.11 JZL195 does not have an additive effect on the ACEA response 
Tango cells were plated in black 96-well plates at 20,000 cells/well and maintained 
for 24 h in McCoy’s 1%. Compounds were made up in the same medium either in 
the absence (-) or presence (+) of 100 nM JZL195. Half the cells were treated for 30 
min with 10 µM AM251, before addition of 1 µM ACEA for either 4 h (A) or 18 h 
(B). Fluorescent detection of β-lactamase reporter gene transcription was measured 
using a FRET-enabled substrate, as per manufacturer’s protocol. The results are 
presented as a % of the control response, set to 100% and is the mean of 8 wells + 
SEM from 3 pooled, independent experiments. Statistics were performed using one-
way ANOVA, as indicated below.   
 





The effects of PKA activation in the presence of JZL195 
Having established a small basal eCB with JZL195, we then determined whether we 
could now stimulate an eCB response from PKA activation. To this end, we treated 
the cells with forksolin using our new assay format. CB1-Tango cells were plated 
and maintained in McCoy’s 1% FBS, as described above. After 24 h, compounds 
were made up in the same medium with and without 100 nM JZL195 and half the 
cells were treated with 10 µM AM251. We then treated the cells with 10 µM 
forskolin for 4 h and 18 h, and fluorescence ratio was calculated as before. The 
results were normalised to the control response (100%) and significance over the 
control was established.   
 
As seen in Figure 5.12, forskolin alone stimulates an eCB tone to a similar extent as 
JZL195 alone, in both 4 h and 18 h assays (Figures 5.10 & 5.12). The response to 
these agents together is greater (and reached significance) compared to that seen with 
either one of them on their own (Table 5.2). The response to these agents acting 
together was fully inhibited by AM251 and is therefore CB1-dependent. This 
indicated that the forskolin-stimulated response was much greater when MAGL and 
FAAH, and perhaps ABHD6 are inhibited.  
 
Overall, the above results clearly indicate that following a 24 h ‘starvation’ protocol, 
eCB tone can be generated in parental CB1-Tango cells by treating them with 
JZL195 or with forskolin, with a significant response seen only when both are 
present together. The response seen after 18 h is much greater, being ~ 2 times 
greater than the control response. 
 
Our aim was to optimise this response by reducing the background signal in the 
presence of JZL195 alone. A response seen when MAGL and FAAH are inhibited 
indicates that one or both of the endogenous DAGLs could be active. Subsequently, 
our aim at this stage was to increase the starvation period in order to reduce this 





Table 5.2 CB1-Tango cell response (%) above control in the presence of JZL195 
The Table below shows the percentage (%) response above control (background 
response) in the presence of JZL195 alone, in the presence of forskolin alone, or in 





24 hour Starve 
      4 h                  18 h 
48 hour starve 
      4 h                18 h 
JZL195 (%)     12     34  16 31 
Forskolin (%)     10     37  8 42 

















































Figure 5.12 Forskolin stimulates an eCB response in Tango cells 
20,000 Tango cells were plated into black 96-well plates and maintained for 24 h in 
McCoy’s 1% FBS. Compounds were made up in the same medium either in the 
absence (-) or presence (+) of 100 nM JZL195. Half of the cells were treated for 30 
min with 10 µM AM251, before addition of 10 µM forskolin (FSK) for either 4 h 
(A) or 18 h (B). Fluorescent detection of β-lactamase reporter gene transcription was 
measured using a FRET-enabled substrate, as per manufacturer’s protocol. The 
results are presented as a percentage of the control response (set to 100%), pooled 
from 3 independent experiments, representing the mean of 8 wells + SEM. Statistics 
were performed using one-way ANOVA, as indicated below. 





eCB tone and PKA activation following a 48 h starvation period 
 The aim of this part of the study was to reduce background signal seen in the 
presence of JZL195 alone, as this may have been due to basal activity of an eCB-
synthesising pathway. To do this, we increased the ‘starvation’ period in McCoy’s 
1% FBS from 24 h to 48 h. Our first step therefore, was to determine if we could 
detect basal eCB tone following the increased starvation period.  
 
Parental CB1-Tango cells were seeded in McCoy’s 1% FBS in black, clear-bottom 
96-well plates, as described previously. The cells were maintained for a starvation 
time of 48 h following which, compounds were made in the same medium in the 
presence or absence of 100 nM JZL195, as previously described. The cells were first 
treated for 30 minutes with 10 µM AM251, before addition of media containing 
JZL195. Compounds were then incubated for either 4 h (Figure 5.13 A) or 18 h 
(Figure 5.13 B). Results were normalised to the response seen from the control alone 
(set to 100%). 
 
No eCB tone was seen from either 4 h or 18 h assays, which would manifest itself as 
inhibition below 100% in the presence of AM251 alone. There was a clear and 
significant response seen from JZL195 alone in the 4 h assay that was inhibited by 
AM251 (Figure 5.13 A). However, although significant, a much smaller CB1-
dependent significant response was seen above control in the 18 h assay (Figure 5.13 
B). This is could be due to the extended starvation period associated with 18 h assay 
and could reflect lower or absent synthesis of eCBs over this longer time period of 
18 h, following a 48 h starvation period. However, it may also have been due to lack 
of CB1 receptor activity; therefore we next tested the response to ACEA.  
 
To this end, CB1-Tango cells were plated and maintained in McCoy’s 1% FBS for 
48 h, as described above. Compounds were also made in up in a similar manner, in 
the presence of absence of 100 nM JZL195. The cells were treated with AM251 
before addition of 1 µM ACEA for either 4 h or 18 h and fluorescence ratio was 
calculated, as before. The values obtained were normalised to the control response 
(set to 100%) and the results are presented in Figure 5.14. A robust ACEA response 
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was seen in both 4 h and 18 h assays, indicating the CB1-Tango assay is still 
functional following a 48 h starve. As seen following a 24 h starvation, JZL195 has 
no effect on the magnitude of the ACEA response, most probably because this 
represents maximal activation of the CB1 receptor pool (Figure 5.14). Therefore, 
increasing the starvation period to 48 h reduces the basal eCB tone in the presence of 
100 nM JZL195 after 18 h, while having no effect on the ACEA response.  
 
We next tested responsiveness to forskolin using the new assay format. CB1-Tango 
cells were plated, maintained and the compounds were diluted in the same way as 
described above. The cells were treated with 10 µM AM251, followed by 10 µM 
forskolin and the cells were incubated for either 4 h (Figure 5.15 A) or 18 h (Figure 
5.15 B). The responses obtained were normalised to the control response in the 
absence of JZL195 (100%). In contrast to the results seen following a 24-hour starve, 
no response was seen in the presence of forskolin alone in both 4 h and 18 h assays 
(Figure 5.15). There is a clear and significant response seen from forskolin in the 
presence of JZL195, indicating that forskolin does indeed stimulate an eCB response 
in the CB1-Tango assay (Figure 5.15). However, this response is only revealed when 
the hydrolytic ‘gate-keeping’ action of MAGL and FAAH, and perhaps ABHD6, are 
inhibited. We next tested this assay format using our overexpressing cell lines to 
determine if we could see an increase in response from forskolin treatment when 


















































Figure 5.13 JZL195 stimulates an eCB response Tango cells 
20,000 Tango cells were plated into black 96-well plates and maintained for 48 h in 
McCoy’s 1% FBS. Compounds were made up in the same medium either in the 
absence (-) or presence (+) of 100 nM JZL195. Half of the cells were treated for 30 
min with 10 µM AM251, before addition of control media for either 4 h (A) or 18 h 
(B). Fluorescent detection of β-lactamase reporter gene transcription was measured 
using a FRET-enabled substrate, as per manufacturer’s protocol. The results are 
presented as a percentage of the control response (set to 100%) and are the mean of 8 
wells + SEM, pooled from 3 independent experiments. Statistics was performed 
using one-way ANOVA, as indicated below.   


















































Figure 5.14 JZL195 does not potentiate the ACEA response following a 48-hour 
starvation period 
20,000 Tango cells were plated into black 96-well plates and maintained for 48 h in 
McCoy’s 1% FBS. Compounds were made up in the same medium either in the 
absence (-) or presence (+) of 100 nM JZL195. Half of the cells were treated for 30 
min with 10 µM AM251, before addition of 1 µM ACEA for either 4 h (A) or 18 h 
(B). Fluorescent detection of β-lactamase reporter gene transcription was measured 
using a FRET-enabled substrate, as per manufacturer’s protocol. The results are 
presented as a percentage of the control response (set to 100%) and are the mean of 8 
wells + SEM, pooled from 3 independent experiments. Significance was established 
using one-way ANOVA, as indicated below.   




















































Figure 5.15 Forskolin stimulates an eCB response in the presence of JZL195 
following a 48-hour starvation period 
Tango cells were plated into black 96-well plates at 20,000 cells/well and maintained 
for 48 h in McCoy’s 1% FBS. Compounds were made up in the same medium either 
in the absence (-) or presence (+) of 100 nM JZL195. Half of the cells were treated 
for 30 min with 10 µM AM251, before addition of 10 µM forskolin (FSK) for either 
4 h (A) or 18 h (B). Fluorescent detection of β-lactamase reporter gene transcription 
was measured using a FRET-enabled substrate, as per manufacturer’s protocol. The 
results are presented as a percentage of the control response (set to 100%) and are 
the mean of 8 wells + SEM, pooled from 3 independent experiments. Significance 
was established using one-way ANOVA, as indicated below.   





eCB tone and effects of PKA activation in V5α11 and V5β4 cells 
We evaluated the response from V5α11 and V5β4 cell to forskolin, with a view to 
determining if we could stimulate a ‘gain of function’ assay with these cells. We first 
established whether JZL195 alone could potentiate a response in the overexpressing 
cell lines. V5α11 and V5β4 cells were plated and maintained in McCoy’s 1% FBS. 
After 48 h, 10 µM AM251 was added to half the cells, before addition of media in 
the absence or presence of 100 nM JZL195. Compounds were incubated for either 4 
h or 18 h and bla expression was detected, as before. The results for V5α11 are 
presented in Figure 5.16 and for V5β4 in Figure 5.17, and were normalised to the 
control in each (set to 100%) 
 
There was no eCB tone detected in V5α11 cells, as AM251 did not inhibit basal 
response in either the 4 h or 18 h assays. JZL195 alone stimulated a significant but 
small response above control in the 18 h assay (< 10 %); this potentiated response 
was not inhibited by AM251 and so is not CB1-dependent (Figure 5.16 B). These 
results suggest that the level of enzyme is not rate limiting, with the lack of eCB 
signalling in both absence and presence of JZL195 reflecting either a shortage of 
substrate and/or available substrate not accessing the active site in the catalytic 
domain.  
 
A similar result was seen in V5β4 cells, whereby no eCB tone was detected and 
JZL195 appeared to simulate a small but significant, non CB1-dependent response 
after 18 h (Figure 5.17 B). So, again enzyme level is clearly not rate-limiting. 
 
We also compared ACEA responses in all 3 of our cell lines following a 48 h 
starvation period. To do this, parental Tango, V5α11 and V5β4 cells were plated and 
maintained in McCoy’s 1% FBS medium for 48 h. Compounds were made up the 
same medium and half of the cells were treated for 30 minutes with 10 µM AM251, 
before addition of either 1 µM ACEA or media as control. The cells were treated for 
4 h or 18 h, before fluorescent ratio was determined, as described previously. The 




A robust ACEA response was seen from all 3 cell lines and as expected, this 
response was much greater after 18 h; in each case the response was fully inhibited 
by AM251. As a result, we could conclude that the lack of eCB tone seen in the 
DAGL overexpressing cell lines in both control and JZL195 containing media 













































Figure 5.16 JZL195 response is not inhibited by AM251 in V5α11 cells 
20,000 V5α11cells were plated into black 96-well plates and maintained for 48 h in 
McCoy’s 1% FBS. Compounds were made up in the same medium either in the 
absence (-) or presence (+) of 100 nM JZL195. Half of the cells were treated for 30 
min with 10 µM AM251, before addition of control media for either 4 h (A) or 18 h 
(B). Fluorescent detection of β-lactamase reporter gene transcription was measured 
using a FRET-enabled substrate, as per manufacturer’s protocol. The results are 
presented as a percentage of the control response (set to 100%) and is the mean of 8 
wells + SEM from a single representative experiment. Significance above the control 
response was established using the two-sided Student’s t-test, as indicated below.  
However there was no significant inhibition of the response by AM251. 














































Figure 5.17 The JZL195-stimulated response in V5β4 cells is not inhibited by 
AM251 
20,000 V5β4 were plated into black 96-well plates and maintained for 48 h in 
McCoy’s 1% FBS. Compounds were made up in the same medium either in the 
absence (-) or presence (+) of 100 nM JZL195. Half of the cells were treated for 30 
min with 10 µM AM251, before addition of control media for either 4 h (A) or 18 h 
(B). Fluorescent detection of β-lactamase reporter gene transcription was measured 
using a FRET-enabled substrate, as per manufacturer’s protocol. The results are 
presented as a percentage of the control response (set to 100%) and are the mean of 8 
wells + SEM of a single representative experiment. Significance above the control 
response was established using the two-sided Student’s t-test, as indicated below.  
However, there was no significant inhibition of the response with AM251. 























































Figure 5.18 The ACEA response from all 3 cell lines is inhibited by AM251 
20,000 Tango, V5α11 and V5β4 were plated into black 96-well plates and 
maintained for 48 h in McCoy’s 1% FBS. Compounds were made up in the same 
medium either in the absence (-) or presence (+) of 100 nM JZL195. Half of the cells 
were treated for 30 min with 10 µM AM251, before addition of 1 µM ACEA (or 
media as control) for either 4 h (A) or 18 h (B). Fluorescent detection of β-lactamase 
reporter gene transcription was measured using a FRET-enabled substrate, as per 
manufacturer’s protocol. The results are presented as a percentage of the control 
response (set to 100%) and are the mean of 8 wells ± SEM from a single 
representative experiment. Statistics were performed using one-way ANOVA, as 
indicated below. 
 





We then determined if forskolin was able to stimulate eCB signalling in cells that 
have been starved for 48 h.  To this end, V5α11 and V5β4 cells were plated and 
maintained in McCoy’s 1% FBS medium for 48 h. Compounds were made up in 
McCoy’s 1% FBS medium either in the absence or presence of 100 nM JZL195. The 
cells were first treated with AM251, before addition of 10 µM forskolin (or media as 
control) and incubated for 4 h and 18 h. Fluorescence was detected using the 
standard protocol and results were normalised to the response from media alone.  
The results for V5α11 are presented in Figure 5.19 and for V5β4 in Figure 5.20.  
 
Similar to the results from parental CB1-Tango cells, no response from V5α11 cells 
was seen from forskolin in the 4 h assay (Figure 5.19 A). However, a significant 
response above control was seen from forskolin alone after 18 h, which was inhibited 
by AM251, and this response is much more substantial when JZL195 is present 
(Figure 5.19 B). The response from V5α11 cells is also similar to CB1-Tango cell 
response in the 18 h assay (Figure 5.15 B), indicating that the activity of the 
transfected DAGLα is not obviously increased following PKA activation, or that 
amount of enzyme is not limiting. With the DAGLβ overexpressing cell line, 
forskolin did not stimulate response at 4 h in control media, but interestingly, there 
was a significant CB1-dependent response at 4 h when JZL195 was present.  
However, this was a relatively small response (~20% increase over the control) 
(Figure 5.20 A). The response to forskolin was much more substantial in the 18 h 
assay, and was again clearly potentiated by JZL195 (Figure 5.20 B). For reasons that 
are not clear, both responses were substantially, but not fully inhibited by AM251.  
 
The greater response seen in V5β4 cells might reflect the greater level of DAGLβ 
expression in these cells (compared to DAGLα expression in V5α11 cells), 
indicating we may have a gain-of-function assay for DAGLβ. However, the 
possibility remains that we are simply seeing a phenomenon related to clonal 
variability.  No increase in response was seen from V5α11 cells which may reflect 
the lower level of transfected DAGLα compared to transfected DAGLβ; yet DAGLα 
is expressed ~ 17 times more than endogenous levels in these cells. Therefore, the 
reason why the response was not greater in these cells is not clear, although it may 














































Figure 5.19 The forskolin-stimulated response in V5α11, revealed after 18 h, is 
much more substantial in the presence of JZL195 
V5α11cells were plated into black 96-well plates at 20,000 cells/well and maintained 
for 48 h in McCoy’s 1% FBS. Compounds were made up in the same medium either 
in the absence (-) or presence (+) of 100 nM JZL195. Half of the cells were treated 
for 30 min with 10 µM AM251, before addition of 10 µM forskolin (FSK) or media 
as control, for either 4 h (A) or 18 h (B). Fluorescent detection of β-lactamase 
reporter gene transcription was measured using a FRET-enabled substrate, as per 
manufacturer’s protocol. The results are presented as a percentage of the control 
response (set to 100%) and are the mean of 8 wells + SEM of a single representative 



















































Figure 5.20 Forskolin stimulates a response in both 4 h and 18 h assay in V5β4 
cells 
V5β4 cells were plated into black 96-well plates at 20,000 cells/well and maintained 
for 48 h in McCoy’s 1% FBS. Compounds were made up in the same medium either 
in the absence (-) or presence (+) of 100 nM JZL195. Half of the cells were treated 
for 30 min with 10 µM AM251, before addition of 10 µM forskolin (FSK) or media 
as control, for either 4 h (A) or 18 h (B). Fluorescent detection of β-lactamase 
reporter gene transcription was measured using a FRET-enabled substrate, as per 
manufacturer’s protocol. The results are presented as a % of the control response (set 
to 100%) and are the mean of 8 wells + SEM from a single representative 






Evaluating eCB tone following a 48 hour starvation period and 
PKA activation  
The phorbol ester, phorbol 12-myristate 13-acetate (PMA) is an activator of protein 
kinase C (Castagna et al., 1982). The effects of PMA on PKC result from its 
structural similarity to DAG, one of the natural activators of classic PKC isoforms. 
PKC is activated by increases in concentration of DAG or calcium ions (Ca2+), and 
phosphorylates the hydroxyl groups of serine and threonine amino acid residues 
(both present on the DAGLs). We hypothesised that PMA, like forskolin, would 
induce a response in parental CB1-Tango cells, in the presence of 100nM JZL195. 
To test whether PMA can also induce an eCB tone, the CB1-Tango cells were plated 
as before in McCoy’s  1% FBS medium for 48 h. The cells were treated with 10 µM 
AM251before addition of 25 nM PMA (or medium as control) for 4 h and 18 h.  The 
results were normalised to the control resposne (100%), and are summarised in 
Figure 5.21 with significance over the control reponse idicated (one-way ANOVA). 
 
In the 4 h assay, PMA has little effect on eCB signalling; note that the extremely 
small response of ~10% was not inhibited by AM251 and so cannot be taken as an 
eCB response.  However, when JZL195 was present in the media, PMA stimulated a 
significant response (~ 45% above the control) and this was fully inhibited by 
AM251 (Figure 5.21 A).  In the overnight assay, the results in the absence of JZL195 
are not conclusive due to the relatively large variation that we observed with this set 
of independent experiments. However, in the presence of JZL195, there was a much 
greater response that reached significance and was substantially inhibited by 
AM251. Thus it is clear that, like activation of PKA with forskolin, stimulation of 
PKC with PMA can stimulate eCB signalling, but this is again only convincingly 
















































Figure 5.21 PMA can stimulate eCB signalling, but only in the presence of 
JZL195 
CB1-Tango cells were plated in black 96-well plates at 20,000 cells/well and 
maintained for 48 h in McCoy’s 1% FBS. Compounds were made up in the same 
medium either in the absence (-) or presence (+) of 100 nM JZL195. Half of the cells 
were treated for 30 min with 10 µM AM251, before addition of 25 nM 25 nM 
phorbol-12-myristate-13-acetate (PMA) for either 4 h (A) or 18 h (B). Fluorescent 
detection of β-lactamase reporter gene transcription was measured using a FRET-
enabled substrate, as per manufacturer’s protocol. The results are presented as a % of 
the control response (set to 100%) and represent the mean of 8 replicate wells pooled 
from 3 independent experiments ± SEM. Statistics were performed using one-way 
ANOVA, as indicated below.   





eCB tone in CB1-Tango cells following ionomycin treatment 
It has previously been shown that 2-AG biosynthesis in neurons requires calcium 
(Bisogno et al., 1997a). Furthermore, transfected DAGLα/β led to much greater 
levels of 2-AG production by COS cells, which was prevented by DAGL inhibitors 
(Bisogno, 2003). As this assay was now developed using McCoy’s 1% FBS, the 
assay medium now contained calcium. If this calcium was allowed to enter the cells, 
then we may be able to stimulate endogenous activation of protein kinases required 
for DAGL phosphorylation. Our next step therefore was to treat the CB1-Tango cells 
with ionomycin. Ionomycin is a Ca2+ ionophore and was added to the cells to induce 
an elevation of intracellular Ca2+
 
concentration. Furthermore, ionomycin-induced 
elevation of calcium within the cell could result in a more ‘endogenous-like’ 
activation of potential kinases essential for DAGL phosphorylation and activation.  
 
The ionomycin treatment experiments were carried out by additional members of the 
lab using the same protocol as described above, and also using 30,000 cells/well in 
McCoy’s supplemented with 0.5% FBS. The results using the two different protocols 
were not significantly different from each other, and so the results were collated and 
pooled where possible. 
 
To test whether ionomycin could induce a response in a concentration –dependent 
manner, we plated 30,000 CB1-Tango cells in McCoy’s 0.5% FBS medium for 48 h. 
Half the cells were treated for 30 minutes with 10 µM AM251, before addition of 
varying concentrations of ionomycin (0-4 µM), made up in the same medium. The 
cells were maintained for 4 h and Bla expression was detected by addition of the 
FRET-enabled substrate for 2 h, and the plate was read on the Flexstation. The 
results were normalized to the control response, set to 100% and the results are 
presented in Figure 5.22.  
 
There was a clear and highly significant response seen from all concentrations at and 
above 1 µM ionomycin over the control response. Importantly, the response was 
inhibited by AM251, showing the response to be signalling through the CB1 
receptor. The response to 4 µM ionomycin was substantially (~75%) but not fully 
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inhibited by AM251, which may be reflecting interference in the assay at this higher 
concentration. Nonetheless, there was a clear concentration-dependent response from 
ionomycin that is largely CB1 dependent. Therefore, our next step was to elucidate 









































Figure 5.22 The ionomycin response is inhibited by AM251 
30,000 CB1-Tango cells were plated in McCoy’s medium supplemented with 0.5% 
FBS and maintained for 48 h. 10 µM AM251 was made up in the same medium and 
half the cells were treated for 30 min. Varying concentrations of ionomycin were 
also diluted in the same medium (4 µM top concentration, diluted 1:2, 5 point curve). 
The cells were treated overnight for a total of 4 h. Bla expression was detected using 
the FRET enabled substrate, as described previously. The data presented has been 
normalised to the control response (set at 100%) and represents the mean of 8 wells 
from n independent experiments ± SEM (for 4 µM and 0.5 µM n=5; for 2 µM n=17; 
for 1 µM n= 8). Significant difference was established using the two-sided Student’s 
t-test, as indicated below. 
* p< 0.05; ***p<0.001, Student’s t-test 
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The DAGL component of the ionomycin response in CB1-Tango 
cells 
Ionomycin has been shown to induce 2-AG production, as well as anandamide (Di 
Marzo et al., 1994; Bisogno et al., 1997b; Cadas et al., 1997; Schmid, 2000; Leung 
et al., 2006). We wanted to determine to what extent DAGL was responsible for the 
ionomycin response in CB1-Tango cells.  
 
To this end, we plated 30,000 CB1-Tango cells in McCoy’s 0.5% medium for 48 h. 
Varying concentrations of THL were diluted in the same medium (0-20 µM), which 
was then added to the cells for 30 minutes, before addition of 2 µM ionomycin for a 
further 4 h. Fluorescent ratio was determined by adding the FRET-enabled substrate 
for 2 h and reading the plate on the Flexstation. The results were normalized to the 
ionomycin response (‘0 µM’, set to 100%) and the results are presented in Figure 
5.23.  
 
The ionomycin response was not significantly reduced by THL at any concentration. 
The response in the presence of 5 µM THL or greater was only inhibited by ~ 15-
20%, indicating that ~80% of the ionomycin response may not be due to DAGL 
activity. It was noted that THL on its own did not reduce basal tone in these cells 
(data not shown). As these experiments were carried out in the absence of JZL195, it 
may be that the ‘gate keeping’ activity of MAGL and FAAH was reducing the 
detectable DAGL activity from ionomycin treatment. Therefore, it was important to 
test whether we could to determine the relative contribution of the hydrolytic activity 




































Figure 5.23 The ionomycin response can be inhibited by THL 
30,000 CB1-Tango cells were plated and maintained in McCoy’s medium containing 
0.5% FBS for 48 h. Half the cells were treated with varying concentrations of THL 
(0-20 µM) for 30 min, before addition of 2 µM ionomycin for a further 4 h. Bla 
expression was detected using a FRET-enabled substrate, as described previously. 
The data was normalised to the response from ionomycin alone (set to 100%). The 
graph represents the mean of 8 wells pooled from n independent experiments (for 0 
µM n=5; for 20 µM n=6; for 10 & 5 µM n= 3; for 2.5 µM n=2). Statistics were 
performed using one-way ANOVA. 
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The effects of inhibiting MAGL and/or FAAH on the ionomycin 
response in CB1-Tango cells 
Our previous results have shown that by inhibiting MAGL and FAAH, a much 
greater response is revealed from kinase activation (Figures 5.15, 5.19, 5.20 and 
5.21). To determine whether the ionomycin response could be potentiated, we used 
the dual MAGL/FAAH inhibitor, JZL195. To understand the relative contribution of 
MAGL and FAAH, we also tested JZL184 (MAGL inhibitor) and the specific FAAH 
inhibitor, URB597 (Mor et al., 2004; Alexander & Cravatt, 2005). To do this, we 
plated 30,000 CB1-Tango cells in McCoy’s 5% medium for 48 h. The cells were 
then treated for 30 minutes with either 100 nM JZL195 (Figure 5.24 A), 1 µM 
JZL184 (Figure 5.24 B) or with 100 nM URB597 (Figure 5.24 C) The cells were 
then treated with the same medium as control, or with either 1 µM or 2 µM 
ionomycin for a further 4 h. Bla expression was detected, as described previously 
and the data was normalized to the control response in the absence of drug, set to 
100%. JZL195 induces a basal eCB tone, as seen when treated alone. Similarly, the 
ionomycin response from both 1 and 2 µM is much greater in the presence of 
JZL195 (Figure 5.24 A). In contrast, neither JZL184 nor URB597 increased basal 
eCB tone or potentiated the ionomycin response (Figure 5.24 B & C), indicating that 
inhibiting either MAGL or FAAH alone is not sufficient to potentiate the eCB 
response in CB1-Tango cells; the response is greater only when the hydrolytic 
activity of both of these enzymes is inhibited, thereby allowing eCBs being produced 
to signal through the CB1 receptor.  
 
Next, we compared the concentration response from ionomycin in the absence and 
presence of JZL195. It was also important to assess whether this response could be 
inhibited by AM251, to determine if the response was CB1-dependent. To this end, 
CB1-Tango cells were plated and maintained as described above. Half of the cells 
were first treated with 10 µM AM251 for 30 minutes, before addition of varying 
concentrations of ionomycin (0.5-4 µM) +/- 100 nM JZL195 for a further 4 h. Bla 
expression was detected as described previously and the results were normalized to 
the control response in the absence of JZL195, set to 100%. There was a clear and 
concentration-dependent response from ionomycin alone in the absence of JZL195 
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(Fig 25A), which was consistent with our previous results (Figure 5.22). However in 
the presence of 100 nM JZL195, this response is much greater and is highly 
significant compared to response in the absence of JZL195 at all concentrations of 
ionomycin below 4 µM. The responses from 4 µM are similar, which may indicate 
the level of eCB production is sufficient to signal through the CB1 receptor, 
regardless of MAGL/FAAH activity. Importantly, these responses were fully 
inhibited by AM251 at all concentrations and were therefore signalling through the 














Figure 5.24 Basal eCB tone and ionomycin response from CB1-Tango cells is 
potentiated by JZL195, but not by JZL184 or URB597 
30,000 CB1-Tango cells were plated and maintained in McCoy’s medium containing 
0.5% FBS for 48 h. Half the cells were treated with either 100 nM JZL195 (A), 1 
µM JZL184 (B), or 100 nM URB597 (C) for 30 min, before addition of either media 
alone (control) or varying concentrations of ionomycin, as indicated (either 1 µM or 
2 µM) for 4 h. Bla expression was detected using a FRET-enabled substrate, as per 
manufacturer’s protocol. The data was normalised to the control response (in the 
absence of drug, set to 100%). Graphs represent the mean of 8 replicate wells pooled 
from 4 independent experiments (7 for JZL195) ± SEM. Significance was 
established using the two-sided Student’s t-test, as indicated below. 




































































































































Drug + AM251 
 
Figure 5.25 The ionomycin response is potentiated in the presence of the dual 
MAGL/FAAH inhibitor, JZL195 
CB1-Tango (20,000 or 30,000) cells were plated and maintained in McCoy’s media, 
containing either 0.5% or 1% FBS, for 48 h. Half the cells were treated with 10 µM 
AM251 for 30 min. Varying concentrations of ionomycin were diluted in the same 
medium +/-100 nM JZL195, which were added to all wells for 4 h. Bla expression 
was detected, as described previously. Data was normalised to the control response 
in the absence of JZL195 (set to 100%). Ionomycin concentration-response curve is 
presented in A, and in the presence of AM251 in B. Each graph represents the mean 
of 8 replicates pooled from 5-20 independent experiments, performed by all 
members of the lab (using different cell number / FBS concentrations, as stated 
above); the data was not significantly different using the two protocols and data was 
pooled. Significance was established using the two-sided Student’s t-test, as 
indicated below. 





The effects of the DAGL inhibitors, THL and OMDM-188 on the 
ionomycin response in CB1-Tango cells 
As we had seen in the above results, ionomycin could significantly induce a response 
in CB1-Tango cells, and this is much greater in the presence of JZL195 (Figure 
5.25). To determine what extent this enhanced response was due to DAGL activity, 
we tested whether the DAGL inhibitors, THL and OMDM-188 could inhibit this 
response. While neither of these compounds is a specific inhibitor for the DAGLs, 
these enzymes are the only targets these compounds have in common (Hoover et al., 
2008; Ortar et al., 2008). Therefore, using these inhibitors in combination provides 
evidence as to which portion of the ionomycin response is DAGL-dependent. We 
also used these compounds to determine if the eCB tone seen in the presence of 
JZL195 alone can be attributed to DAGL activity. To do this, CB1-Tango cells were 
plated and maintained in McCoy’s 1% for 48 h. All compounds were made up in the 
same medium in the presence of 100 nM JZL195. The cells were then treated with 
either 2 µM OMDM-188 or 20 µM THL for 30 minutes, followed by media (+ 
JZL195, ‘control’) or 2 µM ionomycin, for a further 4 h. Bla expression was detected 
using the FRET-enabled substrate for 2 h, as described previously. The results were 
normalized to the control response in the absence of drug, set to 100%.  
 
Both OMDM-188 and THL significantly reduced the basal response in these cells by 
~20%, which may indicate basal DAGL activity revealed by the presence of JZL195 
(Figure 5.26 A). As seen before, 2 µM ionomycin significantly induces a response 
above control (~140%) in the presence of JZL195. The ionomycin response in the 
presence of either OMDM-188 or THL is increased from a reduced baseline of 
~70% to a response of ~150% and so these compounds inhibit the ionomycin 
response by ~ 50%. Therefore, in the presence of JZL195, ~50% of the ionomycin 















































Figure 5.26 The DAGL inhibitors OMDM-188 and THL reduce basal eCB tone 
and inhibit the ionomycin response, in the presence of JZL195 
20,000 CB1-Tango and V5α11 cells were plated and maintained in McCoy’s 
medium containing 1% FBS for 48 h. Compounds were made up in the same 
medium, containing 100 nM JZL195. The cells were treated with either 2 µM 
OMDM or 20 µM THL for 30 min, before addition of control media (‘control’, A) or 
2 µM ionomycin (B). Bla expression was detected using the standard manufacturer’s 
protocol, as described previously. The data was normalised to the control response 
(set to 100%) and the graphs represent the mean of 8 replicates ± SEM pooled from 
5 independent experiments. Significant difference was established from the control 
response or from the ionomycin response for OMDM and THL in B, using the one-
way ANOVA, as indicated below.  





The ionomycin response in CB1-Tango, V5α11 and V5β4 cells 
In examining whether we had a ‘gain of function’ assay, we treated our V5α11 cells 
with ionomycin, in the presence of JZL195. Two in-house protocols were used; one 
using 20,000 cells plated in McCoy’s 1% and the other using 30,000 cells plated in 
McCoy’s 0.5%. As results from either protocol were not statistically different from 
each other (data not shown), the data was collated and pooled. In summary, CB1-
Tango and V5α11 cells were ‘starved’ for 48 h. Half the cells were treated with 10 
µM AM251 for 30 minutes, before addition of varying concentration of ionomycin 
(0.25 - 2 µM) for a further 4 h. Fluorescent ratio was determined as described 
previosuly, and the data was normalised to the control in the absence of drug, set to 
100%. The data presented in Figure 5.27 shows that there was no significant 
difference in the ionomycin response seen between CB1-Tango and V5α11 cells, 
indicating that the level of enzyme expression is not limiting. Most of the responses 
seen were fully inhibited by AM251. The response in the presence of 2 µM 
ionomycin seen from V5α11 cells was significantly above the control response, but 
was still inhibited by > 95% (Figure 5.27 B). 
 
Finally, we wanted to compare the ionomycin response from CB1-Tango and V5α11 
cells to ionomycin treatment of V5β4 cells in the presence of JZL195. To this end, 
20,000 parental Tango, V5α11 and V5β4 cells were plated as described before, in 
McCoy’s 1% for 48 h. The cells were treated with 0.1 µM and 1 µM ionomycin (or 
medium as control) in the presence of 100nM JZL195. The cells were incubated 
overnight for a total of 4 h, and fluorescence was detected as described previously, 
and the results were normalised to the control response (100%).  
 
The results in Figure 5.28 show a significant response from both concentrations of 
ionomycin, and this is true for all 3 cell lines. Furthermore, the ionomycin response 
was greater in all cell lines than either forkolin or PMA treatments (Table 5.3), 
possibly indicating different activity levels of the DAGLs. However, the response 
obtained from the overexpressing cell lines was not obviously greater than that seen 
in parental CB1-Tango cells. In fact, from 3 independent experiements the resposne 
from CB1-Tango cells was greater than the overexpressing cell lines (Table 5.3). 
This may be because the level of DAGLα/β is not rate-limiting and may be due to 
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insufficient substrate; or it may be because the DAGLs are not active, with the 
ionomycin response being a result of another eCB being produced in response to the 






Table 5.3 Comparison of % response to FSK, PMA and ionomycin (48 h starve, 
+ JZL195) 
The table below show the % response above control (background) response in all 
three cell lines in response to forskolin, PMA and ionomycin treatment, in both 4 h 




   Forskolin 
  4h       18h 
  PMA 
       4h       18h 
Ionomycin 
      4h         
Tango (%)    4    26 46 162 146 
V5α11 (%)    8    30 56   - 86 

























































Figure 5.27 The ionomycin response is not increased when DAGLα is 
overexpressed in CB1-Tango cells 
CB1-Tango and V5α11 (20,000 or 30,000) cells were plated and maintained in 
McCoy’s media, containing either 0.5% or 1% FBS, for 48 h. Half the cells were 
treated with 10 µM AM251 for 30 min. Varying concentrations of ionomycin were 
diluted in the same medium containing 100 nM JZL195, which was added to all 
wells for 4 h. Bla expression was detected, as described previously. Data was 
normalised to the control response in the absence of JZL195 (set to 100%). 
Ionomycin concentration-response curve is presented in A, and in the presence of 
AM251 in B. Each graph represents the mean of 8 replicate wells pooled from 2-16 
independent experiments, performed by all members of the lab (using different cell 
number / FBS concentrations, as stated above); the data was not significantly 
different using the two protocols and the data was pooled. Significance was 
established using the two-sided Student’s t-test, as indicated below. 







































Figure 5.28 Ionomycin stimulates an eCB response in the 4 h Tango assay 
20,000 Tango, V5α11 and V5β4 cells were plated and maintained in 96-well plates 
in McCoy’s 1% medium, as described previously. After 48 h, compounds were 
diluted in the same medium containing 100 nM JZL195. The cells were treated with 
two concentrations of ionomycin (0.1 µM and 1 µM), or media as control for 4 h. 
Bla expression was detected using a FRET-enabled substrate, as per manufacturer’s 
protocol. The results were normalised to the control response (set at 100%). Data 
presented represents the mean of 8 wells ± SEM pooled from n independent 
experiments (0.1 µM n=2; 1 µM n=3). Significance above the control response was 
established using one-way ANOVA, as indicated below. 
**p<0.01; ***p<0.001, one-way ANOVA 
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5.3 Summary & Conclusions 
 
The aim of this study was determine if we could establish a simple model to easily 
stimulate eCB signalling by adapting a CB1-Tango cell assay, with a view to 
determining the contribution that either one of the DAGLs make to the response.  In 
this context, we have developed the CB1-Tango assay in McCoy’s 1% medium to 
maintain viability and so the full contents of the medium are known, including the 
presence of 1 mM calcium. We have shown that PKA and PKC activation can 
stimulate eCB signalling, but robust responses are only seen when JZL195 is 
included in the media. Ionomycin treatment also stimulated a robust response, with 
more subtle differences highlighted in the presence of JZL195. Responses are only 
revealed by dual blockade of MAGL and FAAH (and possibly ABHD6 activity) and 
not when either one of these agents are inhibited alone; this was in line with previous 
reports (Long et al., 2009b). 
 
By using our overexpressing cell lines, we have tested whether the level of these 
enzymes are “rate-limiting” for a number of stimuli, whereby an increase in response 
could be directly related to the transfected DAGL. However, no obvious increase in 
response was seen using V5α11 or V5β4 cells (Figures 5.26 & 5.27). As mentioned 
earlier, this may be because the level of enzyme expression is not limiting, and may 
be due to insufficient substrate. It may also be it is not likely due to a lack of enzyme 
activity, as the DAGLs do appear to be active in response to forskolin, PMA and 
ionomycin treatment. Since the completion of this part of the study, others in our lab 
have shown that the PKA and PKC responses to be largely inhibited by the DAGL 
inhibitors (Emma Williams, unpublished data). Furthermore, almost 50% of the 
ionomycin response is inhibited by OMDM-188 and THL, which may reflect a large 
portion of these responses to be a result of DAGL activity. However, production of 
other eCBs following these treatments is possible and is most likely contributing to 
the residual clear response that is seen in the presence of OMDM and THL.  
 
Given that there were no specific inhibitors for DAGLα or DAGLβ at the time of 
this study, and the fact there are no inhibitors for anandamide production, we 
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recognised that a genetic intervention in the production of these eCBs was required 
to further elucidate the pathways governing the responses to forskolin, PMA and the 
calcium ionophore. A cell line lacking eCB-producing activity would allow us to 
think about gain-of-function and structure/function experiments with wild-type and 
mutated versions of the DAGLs. We initially focussed on a “feasibility” study to 
determine if the recently described CRISPR/Cas9 can readily be applied to knockout 
the DAGLs and/or to introduce mutations that would disrupt the catalytic activity of 
the enzymes.  This work would serve as a prelude to future gain of function studies 




CHAPTER 6. RESULTS IV – Generating a DAGL-





As we saw in chapter 3 (Results I), the human DAGLs have similar structural 
features and their catalytic domain is a member of the α/β hydrolase fold family. The 
activity of another member of this family, hormone sensitive lipase (HSL) is 
protected by a regulatory lid, which shields the catalytic domain from substrate 
access. Upon phosphorylation, this lid is displaced and the substrate can access the 
catalytic site for hydrolysis (Holm, 2003). Through homology modelling with fungal 
and drosophila DAGL, our group identified a similar insert in human DAGL, termed 
the ‘regulatory loop’. We have identified phosphorylation as a potential regulatory 
mechanism for the DAGLs which we believe displaces the regulatory loop to allow 
access of DAG to the catalytic domain, akin to HSL. To study which 
phosphorylation sites are key to DAGL function, we require a simple assay that is 
amenable to structure/function studies.  
 
To this end, we have developed the CB1-Tango assay to measure an eCB response. 
In chapter 4 (Results II), we showed the Tango cells to endogenously express 
transcripts for both the DAGLs, with DAGLβ protein also readily detectable (the 
case for DAGLα is still uncertain). The eCB tone in the CB1-Tango assay can be 
stimulated when PKA or PKC are activated or following treatment with ionomycin, 
presumably as a consequence of calcium influx into the cell (Chapter 5, Results III). 
These stimuli will all activate kinases and our data is consistent with, but does not 
prove, a role for DAGL phosphorylation in eCB generation. Data presented on the 
ionomycin response shows that it is in part dependent on DAGL activity, but it is 
unclear as to whether this reflects DAGLα or DAGLβ activity, as at the outset of 
this study there were no specific inhibitors for either of the DAGLs. Our results with 
cells that overexpress DAGL constructs, that we have shown to be enzymatically 
active against surrogate substrates in the case of DAGLα, have failed to show a 
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“gain-of-function” phenotype in response to any stimuli, suggesting that the level of 
enzyme is not rate limiting. Furthermore, the eCB response was only seen in the 
presence of the dual MAGL/FAAH inhibitor, JZL195 and not when MAGL was 
inhibited alone; possibly due to compensation by FAAH, as shown in previous 
reports (Long et al., 2009b).  
 
Based on the above we have decided that a radically different strategy is required in 
order to fully exploit the potential of the CB1-Tango cells as a vehicle for dissecting 
out the structure/function activity of the individual DAGLs. In brief, this strategy 
involves genetic manipulation to strip back the ability of the parental cells to respond 
to the three stimuli mentioned above, by the systematic elimination of enzymes 
likely to be responsible for the generation of the eCBs. Our initial aim was to 
eliminate DAGLα and DAGLβ activity, with a view to then taking on the perhaps 
more challenging task of “eliminating” the DAGL-independent response. If this can 
be achieved, we will be in a position to reconstruct both DAGLα− and 
DAGLβ−dependent eCB pathways for detailed structure/function studies and so 
disrupting DAGL would be the first step in eliminating eCB generation in these 
cells.  
 
We used the CRISPR/Cas9 system to mediate this intervention, as presented in the 
introduction, which can effectively be used to make precise genome modifications in 
mammalian cell lines (Jinek et al., 2013). This system is a cost effective and efficient 
method to disrupt the gene of interest. Cas9 is an endonuclease that is guided by a 
gRNA sequence to the target DNA. The resulting DSB can be repaired by indel-
forming NHEJ or by HDR using a donor template (Valerie & Povirk, 2003; Gaj et 
al., 2013). A mutant form of Cas9 allows single-strand cleavage capability to 
facilitate “nicking” and is termed Cas9 nickase (Cas9n). Using two Cas9ns can 
radically reduce off-target effects and is an effective method for HDR repair at the 
specific site (Jinek et al., 2012).  
 
In this chapter, I will report on the successful use of the novel CRISPR/Cas9 system 
to introduce mutations into both alleles in the DAGLα and DAGLβ genes that 
should disrupt correct protein translation and therefore eliminate DAGL activity in 
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the Tango cells. I will discuss the obstacles encountered in our initial strategy to 
target both the DAGLs simultaneously, highlighting the challenges associated with 
disrupting a relatively large gene. I will present on the use of Cas9n as an effective 
method to leverage HDR repair. Finally, I will present an alternative strategy to 
eliminate DAGL activity. We applied the CRISPR/Cas9 system to effectively target 
the catalytic domain of the DAGLs, thereby generating a Tango cell line that does 
not express functional variants of the DAGLs. This is the first step in eliminating 
eCB production in Tango cells. Next steps to disrupt other eCB-generating enzymes 





Targeting expression of the DAGLs using the site specific 
endonuclease, Cas9 
Design of strategy to target DAGLα by CRISPR/Cas9 
Our aim was to target both the DAGLs in CB1-Tango cells using the CRISPR/Cas9 
system. It is important to design gRNA sequences that target all predicted splice 
variants for the gene of interest. Splice variants for each enzyme were analysed using 
data available on Ensembl Genome Browser (ensembl.org). For DAGLα, there are 2 
predicted variants and for DAGLβ there are 7. We selected exon 3 for targeting 
DAGLα and exon 7 for targeting DAGLβ, with a view to targeting the most 
upstream exon to disrupt all potential splice variants. By targeting each gene towards 
the 5’ end, our aim was to stimulate NHEJ to disrupt translation of the rest of the 
sequence downstream from the target site. 
 
 
Construction of expression vectors and Generation of Tango KO cell 
lines 
In order to apply the CRISPR/Cas9 system to the Tango cells, we used Cas9 vectors 
that contained genes for all the essential components (Cong et al., 2013); Cas9 gene 
(4272 bp) with nuclear localization signal for eukaryotic expression, U6 promoter 
and tracrRNA, as well as vectors which also had the fluorescent markers GFP and 
mCherry – all of which were a kind gift from Marcello Maresca, Astra Zeneca (prior 
to any patent laws) (Mali et al., 2013b). We designed gRNAs specifically targeting 
DAGLα, as well as DAGLβ (Figure 6.1 & Figure 6.2). These sequences were 
ordered as two single oligonucleotide strands and were designed such that, once 
annealed, the double-stranded DNA had overhangs compatible with AarI restriction 
digest of our vectors. 20 nucleotide sequences were selected using software available 
on ww.zifit.org and in line with the criteria described previously (Hwang et al., 
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2013; Mali et al., 2013b). The sequences also began with G for U6 promoter 
recognition. For DAGLα, 4 sequences were chosen from exon 3 (Figure 6.1). For 
DAGLβ, 6 sequences were chosen from exon 7 and from the introns just upstream 
and downstream of this exon (Figure 6.2). To test the efficiency of each gRNA we 
designed, we first constructed these vectors to contain our custom oligonucleotides 
into the gRNA cassette.  
 
To do this, the Cas9 vector was digested with AarI and separated on agarose gel. The 
digested vector was purified from the gel, dephosphorylated and ligated with each of 
our gRNAs. Once each construct was generated, transient expression of each 
Cas9/gRNA construct for DAGLα and DAGLβ (double transfection) was achieved 
via Fugene HD, using the manufacturer’s protocol. After approximately 48 h, DNA 
from these heterogeneous cells was extracted and amplified by PCR, using primers 
flanking the CRISPR/Cas9 cutting site; for DAGLα, the forward primer was 5’– 
GCTAGTAGCATCTCGAGGTACAGG –3’ and the reverse primer was 5’– 
CGTAGAGCACGTACTGCATGG –3’, which amplified a 266 bp product for the 
wild type (WT) allele. For DAGLβ, the forward primer was 5’– CACCTT 
GTCATGGAAGCTGA –3’ and reverse primer was 5’– TCCTG 
AGAATTGTCCGCTCT –3’, amplifying a 262 bp product. The PCR products now 
contained a heterogeneous pool of WT DNA, as well as DNA containing 
insertions/deletions (indels) following Cas9 cutting and subsequent NHEJ repair. 
The PCR products were boiled and re-annealed to form mismatched heteroduplexes. 
Mismatched DNA is recognized and cleaved by the SURVEYOR Cel 1 mismatch-
specific endonuclease and can be visualized as a smaller band on an acrylamide gel 
(as described in the methods section, Chapter 2).  
 
Figure 6.3 shows the results from the different gRNA sequences tested. An empty 
Cas9 vector did not generate any fragment following Cel I digestion in either 
DAGLα or DAGLβ (‘ctrl’, Figure 6.3 A); a single larger dark band can be seen, 
indicating the presence of WT / matching DNA only. However, two smaller bands 
can clearly be seen in the presence of gRNA plasmids containing CRISPR sequences 
1 (cr 1) and 2 (cr 2) for DAGLα and also CRISPR sequence 2 (cr 2) for DAGLβ. Cr 
1 did not appear to result in efficient guiding of Cas9 to exon 7 of DAGLβ, indicated 
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by the lack of a smaller fragment in this column. We also tested digestion of AAVS1 
locus as a control, where two smaller bands can clearly be seen following Cas9 
activity (Figure 6.3 A, ‘cr’). We then tested the other sequences designed for the 
DAGLs (Figure 6.1 & 6.2) in the SURVEYOR Cel I assay. Figure 6.3 C shows that 
the sequences cr 3 and cr 4 for DAGLα were also efficient at guiding Cas9. 
Therefore any of these sequences could be used for future experiments. In the case of 
DAGLβ, sequence cr 6 resulted in a smaller fragment in the Cel I assay, but is less 
obvious than the fragment from cr 7. Therefore, cr 7 was selected as a backup for cr 










CRISPR 4 5’ – accgttcagggagcaggcctcgtg – 3’
5’ – aaccacgaggcctgctccctgaa– 3’
CRISPR 1 5’ – accgaccacggccgcggctacct – 3’
5’ – aaacaggtagccgcggccgtggt – 3’
CRISPR 2 5’ – accggccgaagagcaccacggac – 3’
5’ – aaacgtccgtggtgctcttcggc – 3’
CRISPR 3 5’ – accgcctggtctataacccgcacg – 3’






Figure 6.1 Design of gRNAs to guide Cas9 to cut DAGLα DNA sequence at 
Exon 3 
Schematic representation of the human DAGLα sequence, indicating exons 1 – 20 
(blue). Three sequences were selected using software available on ww.zifit.org. Each 
gRNA sequence selected was located in exon 3 of the hDAGLα gene and begin with 
G (bold) for U6 promotor recognition. Sequences show sense and antisense strands 
with overhangs present at the 5’-end (underlined), which are compatible with AarI 
restriction digest of the Cas9 vector. 
 
 








CRISPR 1 5’ – Accgcagcgtccacaccttgtca – 3’
5’ – Aaactgacaaggtgtggacgctg – 3’
CRISPR 5 5’ – Accgctgcttctgcagctaaaaag – 3’
5’ – Aaacctttttagctgcagaagcag – 3’
CRISPR 2 5’ – Accgctccatcctgcacaccaca – 3’
5’ – Aaactgtggtgtgcaggatggag – 3’
CRISPR 4 5’ – Accgccgaccaagtcatagtctg – 3’
5’ – Aaaccagactatgacttggtcgg – 3’
CRISPR 6 5’ – Aaacaagtgacagttgagctgat – 3’
5’ – Accgatcagctcaactgtcactt – 3’
CRISPR 7 5’ – Accgtccgaccaagtcatagtctg – 3’




Figure 6.2 Selection of oligonucleotide sequences for synthesis of gRNA for 
Cas9 recognition of the DAGLβ gene 
Schematic representation of the human DAGLβ sequence, indicating exons 1 – 12 
(blue). There are many predicted splice variants of DAGLβ with this diagram 
representing the longest predicted transcript. Sequences for gRNAs were selected 
from exon 7 which is the one predicted to cross all splice variants and begin with G 
(bold) for U6 promotor recognition. CRISPR 1 and 5 are partially outside the 
boundaries of exon 7. Sequences show sense and antisense strands with overhangs 
present at the 5’-end (underlined), which are compatible with AarI restriction digest 
of the Cas9 vector. 











Figure 6.3 SURVEYOR Cel I assay showing Cas9-mediated cleavage at the 
target locus in Tango cells using the different CRISPR sequences 
Tango cells were transfected with Cas9 nuclease vectors containing gRNA sequences 
detailed in figures 6.1 & 6.2 (CRISPR 1 = cr1, etc.). DNA from the transfected cells 
was extracted; DAGLα / DAGLβ DNA were PCR-amplified using primers flanking 
the gRNA recognition site. The PCR product contained a hetergenous population 
including modified as well as unmodified DNA, which were reannealed slowly to 
generate heteroduplexes. The reannealed heteroduplexes are cleaved by 
SURVEYOR Cel I nuclease, whereas homoduplexes are left intact.  
 
(A)  CRISPR 2 (cr2) is effective in guiding Cas9 to cleave the target DNA 
sequence in both for DAGLα and DAGLβ, as indicated by the prominent 
smaller bands (*).  
 
(B)  Cells were transfected with Cas9 vector containing a GFP marker. Cell pools 
were enriched for positive Cas9 transfection by FACs sorting for GFP, 
thereby increasing chances for selecting cell lines with indel formation (as 
seen here by a more prominent smaller band when compared to the same one 
seen in A). 
 
(C)  Identification of efficiency of the other CRISPR sequences designed, as 
highlighted in figure 6.1 and 6.2, through analysis in the Cel 1 assay. For 
DAGLα (top) CRISPR 5 and 6 both are effective at guiding Cas9 to cut the 
target sequence, but not as effciently as CRISPR 1 or 2 seen in A. DAGLβ 
CRISPR 7 is much more efficient than CRISPR 6 at cutting the target 
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Targeting the DAGLs using Cas9 endonuclease 
In order to enrich for Cas9 transfected cells and therefore cells with higher potential 
for DAGLα/β KO, we used the fluorescent markers GFP and mCherry. Vectors 
containing either of these fluorescent markers were digested and purified as 
described above. Our selected gRNAs, cr2 for DAGLα and cr2 for DAGLβ were 
cloned into Cas9-GFP and Cas9-mCherry, respectively. Cells expressing the 
fluorescent markers were selected from heterogeneous pools using fluorescence-
activated cell sorting (FACS). This allowed us to detect co-transfection of the two 
constructs. However, it was noted that cell viability following sorting was very poor 
and cell number was vastly reduced as a result.  
 
In order to determine if FACS had enriched for expressing cells, we performed the 
Cel I assay on fluorescent pools of cells to detect mutated DAGLα and DAGLβ 
DNA, as before. Figure 6.3 B shows the gRNA sequences cr2 for targeting DAGLα 
and DAGLβ resulted in a darker band than that seen in Figure 6.3 A. This selection 
process therefore resulted in enrichment of cells that had taken up the Cas9 vectors. 
Individual cell colonies were isolated by first diluting the fluorescent pools into a 
large 15 cm dish, allowing single cells to grow separately from each other. 




Sequencing of the CRISPR/Cas9 cell lines 
To detect small modifications (indels) in the sequence of either of the DAGLs’ 
alleles, DNA was analysed using Sanger Sequencing. To do this, DNA from each of 
the candidate KO cell lines was isolated using Puregene core kit. PCR was 
performed on each sample using Taq Polymerase (AmpliTaq Gold® DNA 
Polymerase). Taq polymerase has a nontemplate-dependent terminal transferase 
activity that adds a single deoxyadenosine (A) to the 3´ ends of PCR products. The 
primers flanking the targeted regions for both DAGLα and DAGLβ were used for 
the PCR, as described above. The PCR products were cloned into a TOPO-cloning 
vectors, which is already linerised with overhanging 3´ deoxythymidine (T) residues, 
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allowing our PCR inserts to be ligated efficiently into the TOPO-cloning vector at 
room temperature. The ligated PCR products were then transformed into DH5α 
competent E. coli cells. The next day, positive bacterial colonies were selected using 
blue/white screening and ten bacterial colonies were selected for each DAGL 
candidate KO cell line. DNA was isolated from each of the bacterial colonies using a 
miniprep kit (Qiagen) and sequencing analysis was performed using the BigDye 
terminator method (Sanger Sequencing). The sequencing results from each cell line 
are summarised in Table 6.1. From these results, cell lines 1, 3, 7 and 10 appeared to 
be a potential KO for both DAGLα and DAGLβ. (Note: As cell line 1 grew much 
more slowly and appeared less healthy than the other cell lines, this was not selected 
for further analysis). It was noted that cell line number 7 may contain a mixed 







Table 6.1 Summary of sequencing of DAGLα and DAGLβ double KO efforts 
using Cas9 endonuclease 
DNA from Tango cell KO cell lines was extracted, PCR-amplified using Taq 
Polymerase and cloned into a TOPO cloning vector. The vectors were then 
transformed into DH5α cells where positive cones were selected using blue/white 
screening. DNA was isolated from 10 bacterial colonies (for each cell line) and 
sequenced using Sanger Sequencing. Results were ‘blasted’ against WT DAGL 









qPCR on the CRISPR/Cas9 Cell lines  
To determine how the sequencing results related to the transcript level, we 
performed qPCR experiments on the cell lines 3, 7 and 10. To do this, RNA from 
each of the cell lines was extracted and reverse transcribed to cDNA. We used ‘best 
coverage’ Taqman assays for the DAGLs, which contain primers that span exon 3 
and therefore our CRISPR cutting sites, and so were deemed suitable assays for KO 
detection. PPIA was used as the endogenous control. Ct values for all assays were 
calculated using Bio-Rad CFX software. Fold change in transcript level was 
determined using the 2-ΔΔCt method, as described in Chapter 4 (Results II) (Livak & 
Schmittgen, 2001). The results from each cell line were compared to transcript levels 
in parental Tango cells and are presented in Figure 6.4 A-C.  
 
DAGLα transcripts appeared to be reduced by ~ 60 % in cells from lines 7 & 10, 
while being unaffected in cell line 3. DAGLβ transcripts were much more affected, 
being reduced by ~ 80% in cell line 3, by ~ 90% in 7 and by ~ 60% in 10. However, 
no cell line showed a complete KO of transcripts. Therefore, it was necessary to 
determine how this related to protein expression. In spite of the unreliability of the 
DAGLα antibody, we used it to determine if we could detect disurpted protein 
expression relative to WT Tango cells. However, no difference was seen in any of 
the selected cell lines (Figure 6.4). It was noted that the band detected in the western 
blot is smaller than that predicted for WT DAGLa (~ 120 kDa) and so this band 
appears to be non-specific (Bisogno, 2003).  
 
In conclusion, Cas9 is efficient at creating mutations within the DAGL sequence, as 
evident from the Cel I assay results (Figure 6.3). From the sequencing it looked as 
though these mutations would be sufficient to cause a frameshift in the sequence of 
the DAGLs, yet transcripts were not reduced by > 50% in our selected cell lines. The 
reason for this was unclear. While screening for successful transfection may be done 
through the fluorescent markers GFP and mCherry, FACS sorting appeared to be 
detrimental to cell viability. Furthermore, this may not be sufficient for detecting 
successful Cas9 cutting of the sequence, thereby resulting in a number of WT 
transcripts in our selected cell lines, especially in the case of DAGLα and we may 
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not have detected these transcripts in the sequence analysis. In addition, the double 
transfection of constructs to target both the DAGLs simultaneously may have 
interfered with one another, as co-transfection is known to reduce efficiency and can 
depend on the ratio of the DNA concentration between the two constructs (Hannig, 
2013). In our next step, we used Cas9n and initially focussed on disrupting DAGLα, 
with a view to subsequently disrupting DAGLβ. By using Cas9n we can insert a 
gene coding for a resistance marker, through introducing a donor DNA template, 








Figure 6.4 Analysis of the candidate KO cell lines 3, 7 and 10 using Taqman 
Assay and Western Blot. 
Tango cells as well as the candidate DAGL KO cell lines 3, 7 and 10 were grown to 
confluency in 2 x 10 cm dishes. 1 dish was using for RNA isolation, the other was 
used for membrane preparation. 
 
(A-C) RNA was isolated from cell lines 3, 7 and 10 and reverse transcribed to 
cDNA. The cDNA was used to perform real-time PCR reaction with a Taqman probe 
spanning the CRISPR cutting site for both DAGLα and DAGLβ. PPIA was used as a 
housekeeping gene. Data was analysed using the 2-ΔΔCt method previously described 
(Livak & Schmittgen, 2001). The Taqman assay revealed that line 3 is a possible KO 
of DAGLβ, but not of DAGLα (A). Cell line 7 is a knockdown of DAGLα and 
possible KO of DAGLβ (B) and cell line 10 has both DAGLα and DAGLβ knocked 
down (C).  
 
(D) Membranes were prepared from cell lines 3, 7 and 10. 20 µg of the membrane 
protein was analysed in a western blot using a DAGLα antibody, revealing a band at 
the predicted molecular weight (~120 kDa) for all three cell lines, indicating that 
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Double nicking strategy target the DAGLs and stimulate HDR 
repair in Tango cells  
Due to the difficulties experienced with our initial strategy to target both the DAGLs 
in Tango cells, our next approach was to use a pair of Cas9ns. An aspartate-to-
alanine (D10A) mutation in the RuvC catalytic domain allows Cas9n mutant to nick, 
rather than cleave DNA, yielding single-stranded breaks (Sapranauskas et al., 2011; 
Gasiunas et al., 2012; Jinek et al., 2012). Using a pair of Cas9ns greatly reduces off-
target effects, which we may have been picking up in the Cel1 assay. Following the 
DSB, the introduction of a donor repair template stimulates the HDR repair pathway 
(Ran et al., 2013a).  
 
 
Design of repair template  
Large modifications can be made at a target sequence by using plasmid-based donor 
repair templates that contain homology arms flanking the target sequence (Smithies 
et al., 1985; Thomas et al., 1986). The offset (distance) between our two gRNA 
sequences, cr2 and cr3 was -2 bp, which was well within the optimal range of -4 to 
20 bp (Figure 6.5 A) (Ran et al., 2013a; Ran et al., 2013b). We introduced plasmid 
DNA into our parental Tango cells containing a blasticidin-resistance gene (Life 
Technologies), with homology arms flanking the target sequence in exon 3 of the 
DAGLα sequence (Figure 6.5 B). This was transfected into the Tango cells alongside 
two Cas9n constructs, one containing gRNA sequence cr 2 and the other containing 
the sequence cr 3, which already had been functionally tested in the SURVEYOR 
Cel I assay (Figure 6.3). The blasticidin resistance gene had a promotor directing 
translation in the reverse to prevent translation of an unwanted protein, followed by a 
stop codon (Figure 6.5 C). Successful integration of our donor plasmid was detected 
by treating the Tango cells with blasticidin, which we viewed as toxic to parental 
Tango cells at 4 mg/ml. Blasticidin was kept in the media at this concentration 
following transfection. Single cell colonies were selected with a cloning disc, 













                          
 
Figure 6.5 Double nicking facilitates HDR and incorporation of blasticidin 
resistance gene 
 (A) Schematic illustrating DSBs caused by two Cas9ns with different gRNA 
sequences – one for the sense- (CRISPR 3) and antisense-strand (CRISPR 2). Below 
are the two gRNA sequences to target DAGLα (CRISPR 2, yellow; CRISPR 3, 
underlined) located in exon 3, highlighting offset of -2 bp. (B) Design of homology 
arms (HA) to flank the CRISPR cutting sites (highlighted in green on DAGLα 
sequence). (C) Design of donor template DNA, with blasticidin resistance gene (bsd) 
flanked by homology arm (HA) DNA. The promotor is in the reverse (arrow), 
followed by a stop codon. 
 
Figure A adapted from Ran et. al., 2013. 
B 
C 




Transcript levels in the nickase/ blasticidin resistant cell lines  
To determine the relative expression of DAGLα in our nickase cell lines compared to 
endogenous expression in the parental Tango cells, we performed Taqman analysis. 
To do this, our nickase cell lines were grown in the presence of blasticidin and lysed. 
RNA was extracted and converted to cDNA. Three housekeeping genes were used, 
PPIA, GAPDH and 18S. Relative fold change to WT Tango cells was analysed using 
the 2-ΔΔCt method, as described above. Relative transcript levels are presented in 
Figure 6.6 A. 
 
While none of the cell lines resulted in an apparent complete KO of DAGLα, B, C 
and X3 appeared to have a reduced level of transcripts and these cell lines were 
selected for further analysis (as indicated in Figure 6.6 A). Membrane protein from 
these cells was prepared and analysed in a western blot using the DAGLα antibody. 
As described above, this antibody is not entirely reliable, often resulting in non-
specific bands. However, we wanted to know if we could detect any changes when 
compared to parental Tango cells. However, no band that was detected in Tango cell 
membrane protein was absent or disrupted in these cells (Figure 6.6 B).  
 
The Taqman assay we used is a ‘best coverage’ assay from Life Technologies, as 
described before. This assay may have a variety of primers to cover the two 
predicted splice variants of DAGLα, but these may also be outside the locus of the 
blasticidin resistance gene. To gain a better understanding of what disruption had 
occurred followed treatment with our Cas9n constructs, we designed our own 
primers to perform RT-PCR. The forward primer selected was 5’– 
GCTAGTAGCATCTCGAGGTACAGG –3’ and the reverse primer was 5’– 
CGTAGAGCACGTACTGCATGG –3’; we used these primers to amplify the cDNA 
already extracted from our nickase cell lines, as described above. WT DAGLα 
cDNA would result in a band size of 266 bp. Insertion of our donor template would 
result in a band > 2 kb. The results from the RT-PCR are shown Figure 6.7. 
 
DNA from parental Tango cells (T) was at the predicted band size of 266 bp. This 
band is also present in some of the nickase cell lines, for example A and C, 
indicating that these cell lines still contain WT DAGLα transcripts. A large insert 
245 
 
can be seen in other cell lines, whose size corresponds to the blasticidin resistance 
gene. Where this is present and the ‘T’ band is absent, we predicted it to be 
successful disruption of the DAGLα gene in both alleles; this can be seen in the 
results from J. We selected this cell line for further analysis in a western blot with 
the DAGLα antibody, as described previously. The results can also be seen in Figure 
6.7 (below the RT-PCR results), where a clear, undisrupted band can be seen for J.  
 
It was unclear at this stage how these cells acquired blasticidin resistance without 
disruption to DAGLα transcription or translation. However, it may have been that 
one allele was undisrupted, while the other allele contained the blasticidin resistance 
gene, thereby affording them immunity to the antibiotic. However, this does not 
explain the results for cell line J. Bearing in mind the unreliability of the DAGLα 
antibody and the fact that cell line J clearly had a large insertion, we investigated the 
nickase disruption further by amplifying the catalytic domain. If the catalytic domain 
was still present, then DAGLα activity would be undisrupted.  
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Nickase / Blasticidin Resistant Clones














































          
Figure 6.6 Taqman and western blot analysis of DAGLα expression in 
blasticidin-resistant cell lines 
 (A) DAGLα RNA transcripts were analysed using a Taqman assay, as described 
previously, and compared to endogenous DAGLα expression in parental Tango cells. 
PPIA was used as a housekeeping gene. Data was analysed using the 2-ΔΔCt method 
previously described (Livak & Schmittgen, 2001). Cell lines B, C and X3 (red 
arrows) appeared to have fewer DAGLα RNA transcripts than Tango cells, and were 
selected for further investigation. (B) Membrane protein from B, C and X3 cells 
were analysed in a western blot using a DAGLα antibody, which indicated that 
DAGLα protein expression may still be translated in these cell lines, as all bands 
detected in Tango cell membranes were still present in our potential KO cell lines. 
However, we cannot exclude the possibility that the antibody picking up a protein 
other than DAGLα. 
















Figure 6.7 RT-PCR and western blot analysis of blasticidin-resistant cell lines 
PCR was performed on cDNA from each of our blasticidin-resistant cell lines using 
primers flanking the CRISPR cutting site and locus of blasticidin resistant gene 
insertion. Cell line J appeared to be the most likely disrupted candidate, as WT band 
was absent from the expected size (~200 bp) with a much larger insertion, 
corresponding to the blasticidin-resistance gene. Membrane preparations from J were 
subsequently analysed in a western blot using a DAGLα antibody, and compared to 
Tango and V5α11 cell membranes, revealing the presence of a band at the predicted 
size for DAGLα (~120 kDa); However, as discussed previously the specificity of the 
antibody is questionable.  




Amplification of DAGLα catalytic domain 
In order to determine whether the catalytic domain of DAGLα was disrupted in our 
nickase cell line J, we performed RT-PCR using primers designed within the 
catalytic domain. To do this, RNA was extracted from both parental Tango cells and 
from J cells and reverse transcribed to cDNA. The cDNA was PCR-amplified using 
two sets of primers. The first set of primers designed flanked the CRISPR cutting 
site and locus of the blasticidin resistance gene. The forward primer used was 5’– 
GCTAGTAGCATCTCGAGGTACAGG  –3’ and the reverse was 5’– 
CGTAGAGCACGTACTGCATGG –3’, which amplified a 266 bp product (as 
described previously). The second set of primers used were designed within the 
catalytic domain; the forward was located in exon 15 (5’– 
AGACAGCTCCTGGATGTCCT –3’) and the reverse in exon 18 (5’– 
GAGTCAGGTCCACCTCGGTA –3’) which amplified a 324 bp product. The 
results were analysed on an agarose gel and are shown in Figure 6.8. 
 
The disruption of DAGLα in exon 3 is clearly evident in the first gel (‘Primers 1 – 
spanning CRISPR site’), indicated by the lack of product at the predicted size, which 
can clearly be seen in parental Tango cells. Instead a much larger PCR product can 
be seen for J and this correlates with the predicted size of the blasticidin resistance 
gene (~ 2.8 kB), and our previous results seen in Figure 6.7. This confirmed insertion 
of our repair template via HDR at this locus. The second gel (‘Primers 2 – DAGLα 
catalytic domain’) is a repeat of the first, but using the second set of primers located 
within the catalytic domain. No difference was seen between the cDNA from 
parental Tango DNA and that from J; indicating that transcripts for the catalytic 
domain was still present in our J cell line. 
 
We were not sure at this point why the full DAGLα gene was not disrupted in our 
nickase cell line J. We hypothesised that there may have been a splicing event across 
the site of disruption by Cas9n (Black, 2003), especially considering the relatively 
large size of DAGLα transcript (~ 5,700 bp) and the fact that it contains 20 exons.  
The DAGLα has been raised against a peptide encoded within exon 20, the last exon 
in the sequence, and if there is splicing around the disrupted exon 3, this might 
explain why we still see a band in the western blot. However, we did not see an 
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expected shift in mw of the band recognised by the antibody, suggesting that the 
band might not be DAGLα. In any case, it was clear that whatever way the DNA had 
been repaired, transcripts encoding for the catalytic domain are still present, and on 
that basis active enzyme might still be expressed in these cells. As a result, we 
deemed it to be prudent to redesign our CRISPR strategy to directly target the 
catalytic domain of DAGLα. This strategy might result in the expression of a protein, 
but given our understanding of the catalytic triad, this protein would not be 
enzymatically active (Bisogno, 2003; Pedicord et al., 2011). However, we were 
concerned that the presence of a catalytically-dead DAGLα in the Tango cells may 





















Figure 6.8 RT-PCR using RNA from Tango and Clone J cells reveals the 
presence of DAGLα catalytic domain                                      
RNA from each cell line was extracted and reverse transcribed to cDNA. RT-PCR 
was performed on cDNA from both parental Tango cells and Clone J cells using two 
sets of primers. The first set of primers flank the CRISPR site and locus of 
blasticidin resistance gene, revealing the disruption of WT DAGLα DNA and 
presence of the gene at the expected locus (exon 3) (A) . The second set of primers 
used amplifies the catalytic domain, which is present in both cells types (B). 
A. Primers 1 – spanning CRISPR site 
site 











Expression of a catalytically-dead DAGLα and activity in the 
PNPB membrane assay 
A ‘dominant negative’ form of a protein can be a useful tool in testing the function 
of the native WT counterpart; this is enabled by proteins that need to assemble into 
multimers in order to function (Sheppard, 1994), or by competing for ligand binding. 
For example, a catalytically-dead version of the FGFR acts as a dominant negative 
by competing out ligand binding to the WT receptor (Saffell et al., 1997). It was 
important to determine if a catalytically-dead version of DAGLα interferes with the 
activity of WT or mutated DAGLα that is re-introduced back into the cells for 
mutagenesis studies. To this end, we used the PNPB membrane assay (described in 
results chapter II) to determine if the presence of a catalytically-dead version of the 
enzyme interferes with substrate hydrolysis driven by the WT enzyme. 
 
We first introduced a mutant, catalytically-dead version of DAGLα into our DAGLα 
overexpressing cells, V5α11 (see Chapter 4, Results II for details). V5α11 cells were 
transiently transfected with GFP alone (control), or with a second vector containing 
either an epitope-tagged DAGLα–V5 (wtDAGLα) or with an epitope-tagged 
catalytically-dead DAGLα-V5 (cdDAGLα), whereby a mutation within the catalytic 
domain has rendered it inactive. These constructs were introduced into the Tango 
cells via Fugene HD (as described before). After approximately 48 h, successful 
transfection was confirmed by examining the cells for GFP expression under a 
fluorescent microscope. Membrane protein from each transfection was then 
extracted. Equal expression of both wtDAGLα and cdDAGLα was confirmed by 
western blot and densitometry analysis using a V5 antibody and odyssey software, 
respectively. Results obtained were compared to V5α11 cells transfected with GFP 
alone (control), showing overexpression of each construct (Figure 6.9).  
 
We then tested the activity of the transfected V5α11 cells in the membrane protein 
PNPB assay. Membranes were plated at 12.5 µg/ml in a polypropylene 96-well plate, 
in the presence and absence of 1 µM THL. 250 µM of PNPB was then added per 
well and the plate was read immediately at 400 nM on the Spectramax, (as described 
in Chapter 4, Results II). Figure 6.10 shows there was clear hydrolysis of PNPB by 
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V5α11 cells, acting as a control for our assay. There was a much larger rate of PNPB 
hydrolysis when more DAGLα–V5 is present (wtDAGLα), which reached 
significance compared to the control. The presence of cdDAGLα does not reduce the 
rate of PNPB hydrolysis, and results were similar to V5α11 cells transfected with 
GFP alone, a comparison made much clearer when the responses are normalised to 
the THL response (Figure 6.10 B). It appeared that the presence of an inactive form 
of DAGLα does not interfere with the activity of the active form of the enzyme; 





                                         
 
                                        
                  






























                     
 
Figure 6.9 Expression of a catalytically dead DAGLα-V5 in the Tango cells 
compared with αV5 cells 
Stable V5α11 cells were transiently transfected with either GFP alone as control 
(V5α11), epitope-tagged DAGLα (wtDAGLα) and GFP, or with an epitope-tagged 
DAGLα whose catalytic domain is inactive (cdDAGLα) and GFP.  Transfection was 
deemed successful by viewing GFP expression under a fluorescent microscope. The 
cells were expanded, protein extracted and used at equal amounts for western blot 
analysis with a V5 antibody to confirm expression of both constructs (A) and actin 
was used as loading control (B). This was repeated in 3 independent experiments and 
the average intensity (normalised to actin) from three blots ± SEM is presented, 
which were not statistically different from each other (Student’s t-test) (C).
























































Figure 6.10 The catalytically dead version does not display different activity to 
that seen from DAGLα- in the PNPB membrane assay 
Stable V5α11 cells were transfected with either GFP alone (V5α11), with an epitope-
tagged DAGLα (wtDAGLα) and GFP, or with a catalytically-dead DAGLα 
(cdDAGLα) and GFP. Successful transfection was determined by examining GFP 
expression under a fluorescent microscope. Membrane protein from each 
transfection was extracted and plated at 12.5 µg/ml into a 96-well plate. Half of the 
membranes were treated with 1 µM THL and 250 µM PNPB was used as substrate. 
The absorbance was read at 400 nM for 10 min (A). Significance compared to 
V5α11 cells was established using the two-sided Student’s t-test (indicated below). 
The cdDAGLα response was not significantly different, indicating that DAGLα does 
not act as a multimer, as evident from the THL-sensitive response (B). Results 
presented are the mean of 3 wells from 3 independent experiments ± SEM.           





Targeting DAGLα catalytic domain with Cas9 endonuclease 
gRNA design to target DAGLα catalytic domain 
The DAGLs’ catalytic triad activity consists of a serine in exon 14, histidine in exon 
15 and aspartic acid in exon 18 (see Fig 3.3, Results I). As the serine is the most 
upstream of the amino acids, we took the sequence from exon 14 and designed 3 new 
gRNA sequences, as a frameshift downstream of this site would also disrupt the 
histidine and aspartic acid. However, a simple disruption of the serine would also 
render DAGLα catalytically dead, as a mutation in one member of the catalytic triad 
disrupts activity (Bisogno, 2003; Pedicord et al., 2011). CRISPR 2 therefore had a 
high probability of disrupting DAGLα activity, as this sequence cuts directly at the 
serine codon (Figure 6.11). We inserted our gRNA sequences into our Cas9 vectors, 
containing the necessary components for CRISPR/Cas9 system, as described 
previously. We used Cas9 vectors available from Addgene to allow our cells to have 
temporary puromycin antibiotic resistance following transfection (Ran et al., 2013b). 
We confirmed that our new gRNA sequences could effectively guide Cas9 to induce 







1 12 13 14 15 16 17 18 19 20
 
CRISPR 1 5’ –  GTGGGCCACTCCCTGGGCGC – 3’  
CRISPR 2 5’ – CGGAACCAAACACTACGGCC – 3’ 
CRISPR 3 5’ – CTCCCTGGGCGCGGGCACTG – 3’  
 
 
 CR1      CR2       CR3  
 
 
Figure 6.11 Custom gRNAs can effectively target DAGLα catalytic domain 
Schematic representation of the human DAGLα sequence, indicating exons 1, 12 – 
20 (A: blue). Three CRISPR sequences were selected using software on 
www.zifit.org. Each gRNA sequence is located in exon 14 of the hDAGLα gene, 
which contains the code for the catalytic serine. Tango cells were transfected with 
Cas9 nuclease vectors containing each of the 3 gRNA sequences and DNA from 
these cells was analyzed using the SURVEYOR Cel 1 nuclease assay, which detects 
indel formations, cleaving the DNA at this site. Agarose gel shows cutting at a 











Generation and genotyping of DAGLα-inactive Tango cell lines   
Following selection of cell lines transfected with our custom gRNA-Cas9 vectors, 
we wanted to determine any gross changes in transcript size via RT-PCR. To do this, 
we took our three custom gRNA sequences (CRISPR 1-3) inserted into the Cas9 
vector and transfected them into the Tango cells via Fugene HD. The cells were 
maintained for ~ 24 h before addition of 1mg/ml of puromycin to the media for a 
further 24 h, to enrich for cells containing our CRISPR/Cas9 constructs. The cells 
were then diluted and spread into a large 10 cm dish to allow individual cell colonies 
to grow before being selected and expanded. RNA was extracted from each of the 
cell lines, which was reverse transcribed to cDNA and amplified using primers 
spanning the CRISPR cutting site. The forward primer, located in exon 12 was 5’– 
GATGCCCTGACTGACCTGAC –3’ and the reverse, located in exon 15 was 5’–
GAGTCAGGTCCACCTCGG –3’, which amplified an 856 bp product. The PCR 
products were analysed in an agarose gel and the results from CRISPR sequences 1, 
2 and 3 are shown in Figure 6.12.  
 
The results from the three CRISPR sequences were very different. No major changes 
in transcript size were seen in cell lines treated with CRISPRs 1 and 3. Cell line 1A 
may have one disrupted allele, as indicated by a smaller band seen compared to the 
WT band, but there is also a band at the expected WT size. Similarly, cells from 3E 
and 3F resulted in a fainter band compared to the WT DNA. This may be a result of 
knockdown, or may simply be an issue with quantity of cDNA prior to PCR. 
Interestingly, CRISPR 2 resulted in a variety of disrupted transcripts. The cell line 
2B appeared to have a sizeable deletion, resulting in only one band that was much 
smaller than the WT transcript. RNA from 2I also appeared to contain less WT 
transcript. However, the lack of a clear band in the gel raises the possibility of an 
issue with the PCR reaction as opposed to major gene disruption. Other cell lines 
showed evidence for major disruptions to one transcript alongside a WT–sized 
transcript; for example 2D may have one allele with a deletion, while 2R could have 
an allele with an insertion. 2B appeared to have the largest deletion out of all the cell 
lines selected following CRISPR 2 treatment, while also missing a band at the 
expected WT size. As the results were much clearer for 2B, transcripts were 









Figure 6.12 RT-PCR analysis of DAGLα CRISPR cell lines highlights gross 
transcript changes following Cas9 targeting to the catalytic site 
RNA from the candidate DAGLα KO cell lines from each of the CRISPR sequences 
was extracted and reverse transcribed to cDNA. The cDNA was amplified using 
PCR with primers flanking the CRISPR cutting sites, and compared with non-
transfected Tango cell cDNA as a control. Cell lines isolated following treatment of 



























Tango     1A       1C       1D       1E        1F      1G 
 
Tango   2A     2B     2C     2D     2E     2F    2G     2H      2I      2J      2K      2L     2M 
 
2O      2P       2Q      2R      2S      2T    Tango 




Sequencing of  2B cells 
2B looked like the most promising cell line to follow up and it was important to 
obtain the sequence of both alleles. Therefore, we extracted RNA from 2B, reversed 
transcribed it to cDNA and PCR-amplified the catalytic domain using the primers 
above and Taq polymerase. The addition of an ‘A’ on the end of the sequence by 
Taq allowed us to TOPO clone and transform into E.Coli, as described previously 
(and in the methods section, Chapter 2). 48 colonies were selected and sent to GATC 
Biotech (Konstanz, Germany) for sequencing. The sequence of each allele was 
aligned with WT DAGLα sequence and the results are presented in Figures 6.13 & 
6.14. The two alleles are aligned to WT DAGLα in the diagram in Figure 6.15, 
showing the locus of the catalytic triad and the resulting disruptions. 
 
‘Allele 1’ had a 2 bp deletion within exon 14 and had the whole of exon 17 deleted; 
exon 17 harbours the histidine of the catalytic triad (Figure 6.13). The 2 bp deletion 
causes a frameshift in the rest of the sequence downstream, resulting in a KO of the 
catalytic triad. ‘Allele 2’ had exons 13-16 deleted, which is in frame but results in a 
KO of the serine and the aspartic acid of the catalytic triad (Figure 6.14). 
The translation of sequences from each allele were aligned to WT DAGLα and are 
shown in Figure 6.16 and Figure 6.17, highlighting the 3 amino acids of the catalytic 
triad (blue) and the disruption in each allele caused by Cas9 and NHEJ repair. The 
section of disrupted sequence that has been deleted is highlighted in yellow. In 
‘Allele 1’, the initial 2 bp deletion causes a frameshift in the downstream sequence; 
DAGLα protein translated from this sequence would be missing all three amino 
acids of the catalytic triad (Figure 6.16). In ‘Allele 2’, the translated sequence is 
lacking both the serine and aspartic acid of the catalytic triad (Figure 6.17). These 
two results indicated that in 2B, both DAGLα alleles have been seriously disrupted 
















Figure 6.13 Alignment of DAGLα catalytic domain in Tango cells with one 
allele of the DAGLα-inactive cell line, α2B 
RNA from Tango and DAGLα-inactive cell line, 2B was extracted and reverse 
transcribed to cDNA. The catalytic domain was amplified using primers (green) 
flanking the CRISPR cutting site (red) and the catalytic triad. Sequence analysis was 
performed using TOPO cloning and Sanger sequencing (Source Bioscience; 
accounted for 97% of results; 32% successful sequence results). Sequence alignment 
was performed using CLUSTAL W, highlighting a 2 bp deletion in exon 14 and 







DAGLa             --GATGCCCTGACTGACCTGACGGGTGATGCTGAGCGCCTCCCCGTGGAGGGGCACCACG 57 
14412695.seq      TTGATGCCCTGACTGACCTGACGGGTGATGCTGAGCGCCTCCCCGTGGAGGGGCACCACG 60 
                    ********************************************************** 
 
 
DAGLa             GCACCTGGCTGGGCCACAAGGGTATGGTCCTCTCAGCTGAGTACATCAAGAAGAAACTGG 117 
14412695.seq      GCACCTGGCTGGGCCACAAGGGTATGGTCCTCTCAGCTGAGTACATCAAGAAGAAACTGG 120 
                  ************************************************************ 
 
DAGLa             AGCAGGAGATGGTCCTGTCCCAGGCCTTTGGGCGAGACCTGGGCCGCGGAACCAAACACT 177 
14412695.seq      AGCAGGAGATGGTCCTGTCCCAGGCCTTTGGGCGAGACCTGGGCCGCGGA--CAAACACT 178 
                  **************************************************  ******** 
 
DAGLa             ACGGCCTGATTGTGGTGGGCCACTCCCTGGGCGCGGGCACTGCTGCCATCCTCTCCTTCC 237 
14412695.seq      ACGGCCTGATTGTGGTGGGCCACTCCCTGGGCGCGGGCACTGCTGCCATCCTCTCCTTCC 238 
                  ************************************************************ 
 
 
DAGLa             TTCTGCGCCCACAGTATCCGACCCTCAAGTGCTTTGCCTACTCCCCGCCAGGGGGCCTGC 297 
14412695.seq      TTCTGCGCCCACAGTATCCGACCCTCAAGTGCTTTGCCTACTCCCCGCCAGGGGGCCTGC 298 
                  ************************************************************ 
 
 
DAGLa             TGAGTGAGGATGCGATGGAGTATTCCAAGGAGTTCGTGACTGCTGTGGTTCTGGGCAAAG 357 
14412695.seq      TGAGTGAGGATGCAATGGAGTATTCCAAGGAGTTCGTGACTGCTGTGGTTCTGGGCAAAG 358 
                  ************* ********************************************** 
 
 
DAGLa             ACCTCGTCCCCAGGATTGGCCTCTCTCAGCTGGAAGGCTTCCGCAGACAGCTCCTGGATG 417 
14412695.seq      ACCTCGTCCCCAGGATTGGCCTCTCTCAGCTGGAAGGCTTCCGCAGACAGCTCCTGGATG 418 
                  ************************************************************ 
 
 
DAGLa             TCCTGCAGCGAAGCACCAAGCCCAAATGGCGGATCATCGTGGGGGCCACCAAATGCATCC 477 
14412695.seq      TCCTGCAGCGAAGCACCAAGCCCAAA---------------------------------- 444 
                  **************************                                   
 
 
DAGLa             CCAAGTCGGAGCTGCCTGAGGAGGTAGAGGTGACCACCCTGGCCAGCACGCGGCTCTGGA 537 
14412695.seq      ------------------------------------------------------------ 
 
                                                                               
DAGLa             CCCACCCCAGCGACCTAACTATAGCCCTCTCAGCCAGCACTCCACTCTACCCGCCCGGCC 597 
14412695.seq      ------------------------------------------------------------ 
 
                                                                               
DAGLa             GCATCATCCACGTGGTCCACAACCACCCTGCAGAGCAGTGCTGCTGCTGTGAGCAGGAGG 657 
14412695.seq      -------------------------------------------CTGCTGTGAGCAGGAGG 461 
                                                             ***************** 
 
DAGLa             AGCCCACATACTTTGCCATCTGGGGCGACAACAAGGCCTTCAATGAGGTGATCATCTCGC 717 
14412695.seq      AGCCCACATACTTTGCCATCTGGGGCGACAACAAGGCCTTCAATGAGGTGATCATCTCGC 521 
                  ************************************************************ 
 
 
DAGLa             CAGCCATGCTGCATGAGCACCTGCCCTATGTGGTCATGGAGGGGCTCAACAAGGTGCTGG 777 
14412695.seq      CAGCCATGCTGCATGAGCACCTGCCCTATGTGGTCATGGAGGGGCTCAACAAGGTGCTGG 581 
                  ************************************************************ 
 
DAGLa             AGAACTACAACAAGGGGAAGACCGCTCTGCTCTCTGCAGCCAAGGTCATGGTGAGCCCTA 837 
14412695.seq      AGAACTACAACAAGGGGAAGACCGCTCTGCTCTCTGCAGCCAAGGTCATGGTGAGCCCTA 641 
                  ************************************************************ 
 
 
DAGLa             CCGAGGTGGACCTGACTC------------------------------------------ 853 
14412695.seq      CCGAGGTGGACCTGACTCAAGGGCGAATTCGTTTAAACCTGCAGGACTAGTCCCTTTAGT 701 
                  ****************                                             
               


















Figure 6.14 Alignment of the nucleotide sequence of DAGLα catalytic domain 
in Tango cells with the second allele of the DAGLα-inactive cell line, α2B 
RNA from Tango and DAGLα-inactive cell line, 2B was extracted and reverse 
transcribed to cDNA. The catalytic domain was amplified using primers (green) 
flanking the CRISPR cutting site (red) and the catalytic triad. Sequence analysis was 
performed using TOPO cloning and Sanger sequencing (Source Bioscience; 
accounted for 6% of results; 32% successful sequence results). Sequence alignment 


















                
 Fwd  Primer 
 
DAGLa             GATGCCCTGACTGACCTGACGGGTGATGCTGAGCGCCTCCCCGTGGAGGGGCACCACGGC 59 
14412696.seq      GATGCCCTGACTGACCTGACGGGTGATGCTGAGCGCCTCCCCGTGGAGGGGCACCACGGC 60 
                  ************************************************************ 
 
 
DAGLa             ACCTGGCTGGGCCACAAGGGTATGGTCCTCTCAGCTGAGTACATCAAGAAGAAACTGGAG 119 
14412696.seq      ACCTGGCTGGGCCACAAG------------------------------------------ 78 
                  ******************                                           
 
 
DAGLa             CAGGAGATGGTCCTGTCCCAGGCCTTTGGGCGAGACCTGGGCCGCGGAACCAAACACTAC 179 
14412696.seq      ------------------------------------------------------------ 
                                                                              
 
DAGLa             GGCCTGATTGTGGTGGGCCACTCCCTGGGCGCGGGCACTGCTGCCATCCTCTCCTTCCTT 239 
14412696.seq      ------------------------------------------------------------ 
 
                                                                               
DAGLa             CTGCGCCCACAGTATCCGACCCTCAAGTGCTTTGCCTACTCCCCGCCAGGGGGCCTGCTG 299 
14412696.seq      ------------------------------------------------------------ 
 
                                                                               
DAGLa             AGTGAGGATGCGATGGAGTATTCCAAGGAGTTCGTGACTGCTGTGGTTCTGGGCAAAGAC 359 
14412696.seq      ------------------------------------------------------------ 
                                                                              
 
DAGLa             CTCGTCCCCAGGATTGGCCTCTCTCAGCTGGAAGGCTTCCGCAGACAGCTCCTGGATGTC 419 
14412696.seq      ------------------------------------------------------------ 
 
                                                                               
DAGLa             CTGCAGCGAAGCACCAAGCCCAAATGGCGGATCATCGTGGGGGCCACCAAATGCATCCCC 479 
14412696.seq      ------------------------TGGCGGATCATCGTGGGGGCCACCAAATGCATCCCC 114 
                                          ************************************ 
 
DAGLa             AAGTCGGAGCTGCCTGAGGAGGTAGAGGTGACCACCCTGGCCAGCACGCGGCTCTGGACC 539 
14412696.seq      AAGTCGGAGCTGCCTGAGGAGGTAGAGGTGACCACCCTGGCCAGCACGCGGCTCTGGACC 174 
                  ************************************************************ 
 
 
DAGLa             CACCCCAGCGACCTAACTATAGCCCTCTCAGCCAGCACTCCACTCTACCCGCCCGGCCGC 599 
14412696.seq      CACCCCAGCGACCTAACTATAGCCCTCTCAGCCAGCACTCCACTCTACCCGCCCGGCCGC 234 
                  ************************************************************ 
 
 
DAGLa             ATCATCCACGTGGTCCACAACCACCCTGCAGAGCAGTGCTGCTGCTGTGAGCAGGAGGAG 659 
14412696.seq      ATCATCCACGTGGTCCACAACCACCCTGCAGAGCAGTGCTGCTGCTGTGAGCAGGAGGAG 294 
                  ************************************************************ 
 
 
DAGLa             CCCACATACTTTGCCATCTGGGGCGACAACAAGGCCTTCAATGAGGTGATCATCTCGCCA 719 
14412696.seq      CCCACATACTTTGCCATCTGGGGCGACAACAAGGCCTTCAATGAGGTGATCATCTCGCCA 354 
                  ************************************************************ 
 
 
DAGLa             GCCATGCTGCATGAGCACCTGCCCTATGTGGTCATGGAGGGGCTCAACAAGGTGCTGGAG 779 
14412696.seq      GCCATGCTGCATGAGCACCTGCCCTATGTGGTCATGGAGGGGCTCAACAAGGTGCTGGAG 414 




DAGLa             AACTACAACAAGGGGAAGACCGCTCTGCTCTCTGCAGCCAAGGTCATGGTGAGCCCTACC 839 
14412696.seq      AACTACAACAAGGGGAAGACCGCTCTGCTCTCTGCAGCCAAGGTCATGGTGAGCCCTACC 474 
                  ************************************************************ 
 
 
DAGLa             GAGGTGGACCTGAC---------------------------------------------- 853 
14412696.seq      GAGGTGGACCTGACTCAAGGGCGAATTCGCGGCCGCTAAATTCAATTCGCCCTATAGTGA 534 
                  **************                                               
                 


















Figure 6.15 Diagrammatic representation of each allele from the DAGLα-
inactive cell line, α2B 
The amplified nucleotide sequence of each allele from α2B is compared to WT 
DAGLα sequence. Features highlighted include the gRNA sequence (‘CRISPR’, 
red), CRISPR cutting site (arrow), the catalytic residues (blue), missing exons 
following Cas9 treatment (yellow) and location of primers (purple), using software 









      
 
 
               
DAGLα  
Clone α2b 
Allele 1  
Cas9 cutting site 
2 bp Deletion  
Clone α2b 
Allele 2  
267 
 
DAGLa          DALTDLTGDAERLPVE  420 
C03             DALTDLTGDAERLPVE  16 
                **************** 
                                            
 Out of Frame 
 
DAGLa           GHHGTWLGHKGMVLSAEYIKKKLEQEMVLSQAFGRDLGRGTKHYGLIVVGHSLGAGTAAI 480 
C03             GHHGTWLGHKGMVLSAEYIKKKLEQEMVLSQAFGRDLGRGQTLRPDCGG----------- 65 
                **************************************** .                   
 
DAGLa           LSFLLRPQYPTLKCFAYSPPGGLLSEDAMEYSKEFVTAVVLGKDLVPRIGLSQLEGFRRQ 540 
C03             --------------------------------------------------------- 
                                                                             
DAGLa           LLDVLQRSTKPKWRIIVGATKCIPKSELPEEVEVTTLASTRLWTHPSDLTIALSASTPLY 600 
C03             ------------------------------------------------------------ 
                                                                             
DAGLa           PPGRIIHVVHNHPAEQCCCCEQEEPTYFAIWGDNKAFNEVIISPAMLHEHLPYVVMEGLN 660 
C03             --------------------------------------PLPGRGHCCHPLLPSAPTVSDP 87 
 
DAGLa           KVLENYNKGKTALLSAAKVMVSPTEVDLT 720 







Figure 6.16 Amino acid translation of ‘Allele 1’ from α2B cells 
The sequencing results from ‘allele 1’ of α2B cells following CRISPR (red) 
treatment were translated and aligned with the amino acid sequence of WT DAGLα. 
Allele 1 had a 2bp deletion, resulting in a frameshift of the amino acid sequence 
(highlighted in yellow). The frameshift disrupts all three amino acids of the catalytic 






DAGLa           DALTDLTGDAERLPVE   420 
D03             DALTDLTGDAERLPVE   16 
                **************** 
 
DAGLa           GHHGTWLGHKGMVLSAEYIKKKLEQEMVLSQAFGRDLGRGTKHYGLIVVGHSLGAGTAAI 480 
D03             GHHGTWLGHK-------------------------------------------------- 26 
                **********                                                   
 
DAGLa           LSFLLRPQYPTLKCFAYSPPGGLLSEDAMEYSKEFVTAVVLGKDLVPRIGLSQLEGFRRQ 540 
D03             ------------------------------------------------------------ 
                                                                             
DAGLa           LLDVLQRSTKPKWRIIVGATKCIPKSELPEEVEVTTLASTRLWTHPSDLTIALSASTPLY 600 
D03             ------------WRIIVGATKCIPKSELPEEVEVTTLASTRLWTHPSDLTIALSASTPLY 74 
                            ************************************************ 
 
DAGLa           PPGRIIHVVHNHPAEQCCCCEQEEPTYFAIWGDNKAFNEVIISPAMLHEHLPYVVMEGLN 660 
D03             PPGRIIHVVHNHPAEQCCCCEQEEPTYFAIWGDNKAFNEVIISPAMLHEHLPYVVMEGLN 134 
                ************************************************************ 
 
DAGLa           KVLENYNKGKTALLSAAKVMVSPTEVDLT 720 
D03             KVLENYNKGKTALLSAAKVMVSPTEVDLT 190 









Figure 6.17 Amino acid translation of ‘Allele 2’ from α2B cells 
The sequencing results from ‘allele 2’ of α2B cells following CRISPR (red) 
treatment were translated and aligned with the amino acid sequence of WT DAGLα. 
The primers used to amplify this sequence are in green. Allele 2 had a specific region 
deleted, which harbours the serine and aspartic acid of the catalytic triad, as 
highlighted in yellow in the figure below, rendering DAGLα translated from this 






Targeting DAGLβ catalytic activity in α2B cells   
gRNA design to target DAGLβ activity 
Having disrupted both DAGLα alleles in α2B cells, we next turned our attention to 
disrupting the DAGLβ alleles in the same cell line. To ensure we obtained a gRNA 
sequence that can effectively guide Cas9, we designed a total of 9 gRNAs to target 
exons 9, 10 and 11 of DAGLβ.  
 
To do this, we used software available on zifit.org and compared the results with 
those obtained from DNA 2.0 software (Figure 6.18 A). Each of the sequences were 
ordered as single nucleotide strands, with overhangs compatible with our vector and 
annealed to form double-stranded oligonucleotides, as described previously. We 
inserted our custom gRNA sequences into the Cas9 vector backbone (Ran et al., 
2013b). To test their efficiency, Tango cells were transfected with each of the 
vectors and treated with puromycin for 24 h, as described above. DNA from the 
transfected cells was extracted and amplified using primers flanking each of the 
CRISPR cutting sites and analysed in the SURVEYOR Cel I assay, as described 
previously. 
 
The results are shown in Figure 6.18 B. Sequence numbers 1, 2, 4, 6 and 8 appeared 
to have resulted in indel formations, as detected and cleaved by the Cel I 
endonuclease. Sequence number 2 resulted in two separate and darker bands and so 




1 5 6 7 8 9 10,11 12,13 14,15
CRISPR 1 5’ – GTCAGCGGAGAGTGAGGTGC –3’
CRISPR 2 5’ – GGTGCTGGACGTGGAGTGTG – 3’
CRISPR 3 5’ – GTGTGAGGTGCAGGACCGCC – 3’
CRISPR 4 5’ – GCACCTCACTCTCCGCTGAC –3’
Exon 9
CRISPR 5 5’ – GATACGTTTACCAACGACTC –3’
Exon 10
CRISPR 6 5’ – GAGCCGCCTACCCGCAGGTC –3’
CRISPR 7 5’ – GGGCGGGGCGGCCGCCCTGC –3’
CRISPR 8 5’ – GTAGCACCTGACCTGCGGGT –3’
CRISPR 9 5’ – GTCATAGTGGGCCACAGCCT –3’







                   1        2        3       4     5         6        7       8         9     Ctrl 
 
 
Figure 6.18 Design of gRNA sequences that target DAGLβ catalytic domain 
Schematic representation of the human DAGLβ sequence, indicating exons 1, 5 – 20 
(A: blue). 9 CRISPR (gRNA) sequences were selected using software on 
ww.zifit.org. The gRNA sequences are located in exons 9, 10 and 11 which harbour 
the residues encoding the catalytic triad of the enzyme (A). Tango cells were 
transfected with Cas9 vectors containing each of our custom gRNA sequences. DNA 
from these cell pools was analyzed using the SURVEYOR Cel I assay, which detects 
any mutations or indel formations, cleaving the DNA at this site. Agarose gel shows 
cutting at a particular locus (*) thereby confirming effective Cas9 guiding by the 
gRNA sequence (B). 
* 
* 





Generation and genotyping of DAGLβ-targeted Tango cell lines  
Next, we wanted to generate a double DAGLα and DAGLβ inactive cell line. We 
generated cell lines following transfection with our Cas9 vector containing our 
custom gRNA sequence 2 (located in exon 9) and determined any gross changes to 
the catalytic domain of DAGLβ via RT-PCR, as described before.  
 
To do this we transfected α2B cells with gRNA2/Cas9 vector via Fugene HD. The 
cells were maintained for ~ 24 h, before addition of 1mg/ml of puromycin to the 
media for a further 24 h, to enrich for cells containing our CRISPR/Cas9 construct. 
The cells were then diluted and spread into a large 10 cm dish and colonies picked ~ 
10 days later. Following this, individual cell lines were selected and expanded. RNA 
was extracted from each of the cell lines, which was reverse transcribed to cDNA 
and amplified using primers spanning the CRISPR cutting site. The forward primer 
used was 5’– AGTCTGTTGTGGTCGCTGTG – 3’ (exon 8) and the reverse primer 
was 5’ –  CGTCGTTGATGAGTCGTTGG – 3’ (exon 10). PCR products were 
analysed on an agarose gel and compared with cDNA from parental Tango cells 
(Figure 6.19). 
 
Disruptions can be seen in transcripts from a number of the cell lines generated 
following CRISPR/Cas9 treatment. Interestingly, there appeared to be a number of 
candidate cell lines with insertions (rather than deletions) at the target site; for 
example, B, P, R and most prominently in 1E. As we had a very reliable antibody for 
DAGLβ, we decided to analyse those cell lines with an apparent disruption to both 
transcripts for protein expression in a western blot. 
 
To do this, membrane protein was extracted from the cell lines B, P, R, V, U, 1B, 
1E, 1I, 1L, 1M, 1U, 1V and 1W. We also extracted parental Tango cell membranes 
to act as a control. We analysed for DAGLβ expression using a DAGLβ antibody 
(cell signalling) in a western blot. This antibody was raised against a peptide 
corresponding to the N-terminus of the enzyme, which is further downstream than 
the CRISPR target locus. Therefore, any disruption from NHEJ repair that leads to a 
frameshift in the sequence would result in an absent band in the western blot. As 
seen in Figure 6.20, there was a clear band at the expected size of ~ 74 kDa from 
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parental Tango cell membranes. None of the cell lines tested resulted in the WT 
band, or any band of a different size, indicating a high hit rate of DAGLβ disruption 
in these cell lines. Actin was used as a loading control, showing most of the 
membrane protein to be present (except clone 1M), albeit at different concentrations. 
However, none of the cell lines were loaded at concentrations lower than the control. 
 
These results point towards our selected DAGLβ-inactive cell lines having a gross 
mutation in their DAGLβ sequence, which has probably led to a frameshift 
downstream of the target site, as evident from the absent band in the western blot. It 
was important at this stage to understand what effect these mutations have in the 
CB1-Tango assay. We therefore selected 4 cell lines (1B, 1E, 1I and 1U) to 
determine if firstly they maintained a Tango assay response to ACEA and secondly, 
whether we could stimulate eCB production in response to forskolin treatment.  
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Figure 6.19 RT-PCR analysis of DAGLβ CRISPR cell lines highlights gross 
changes following Cas9 cutting at the targeted catalytic domain 
RNA from candidate DAGLβ KO cell lines from each of the CRISPR sequences was 
extracted and reverse transcribed to cDNA. The cDNA was amplified using PCR and 
primers flanking the CRISPR cutting sites (as indicated below) and compared with 
control cell cDNA (Tango) in an agarose gel. Selected cell lines were chosen for 
further analysis in a western blot (red).  
 
Tango   A     B    C     D    E     F     G     H     I      J      K     L    M    N    O     P     Q  
Tango    R       S       T        U       V      W       X       Y       Z  
 
  1A   1B   1C   1D   1E    1F  1G   1H    1I    1J    1K   1L  1M   1N   1O   1P   1Q  1R  Tango 
























Figure 6.20 The DAGLβ antibody highlights the disruption caused by Cas9 in 
our candidate DAGLβ KO cell lines  
Membrane protein was extracted from our candidate DAGLβ KO cell lines and from 
Tango cells as control. 20 µg of protein was analysed in a western blot and probed 
with a DAGLβ antibody (Cell Signalling). The blots were stripped and re-probed for 
actin to act as loading control (displayed under each blot). Control Tango 
membranes have a clear band at the expected size (~74 kDa), which is reduced or 
absent in all cell lines.  
 
 
Tango          B               P            R            V               U 
75 kDa 






The CB1-Tango assay in the CRISPR/Cas9-treated cell lines  
We had successfully disrupted the DAGLα catalytic triad in α2B cells. We also had 
apparently disrupted the catalytic domain of DAGLβ in these cells, as evident from 
the western blot. Therefore, we ensured that the Tango assay was still functional in 
these cell lines. To do this, 20,000 parental Tango, α2B and our candidate DAGLβ-
inactive cell lines (1B, 1E, 1I and 1U) were plated in McCoy’s medium containing 
1% FBS for 48 h. Compounds were made up in the same medium containing 100 
nM JZL195. Half the cells were treated with 10 µM AM251 for 30 minutes, before 
addition of 1 µM ACEA or media as control (+ JZL195) for a further 4 h. 
Fluorescence was detected using a FRET-enabled substrate, as described previously. 
The results were normalised to the control response in the presence of JZL195, set to 
100%. Significant difference between the response and that in the presence of 
AM251 is indicated in Figure 6.21. 
 
There was a substantial and highly significant response seen from ACEA in all cell 
lines. Importantly, the Tango assay response was maintained following disruption of 
both DAGLs. The background response in the presence of JZL195 appears greatly 
reduced in the case of the cell line 1B, which may indicate a reduction in eCB 
production. Therefore, how this affects eCB synthesis in response to forskolin 














Figure 6.21 The background and ACEA responses in the Tango assay from our 
DAGL KO cells 
20,000 cells (parental Tango, α2B and cells from 1B, 1E, 1I and 1U, as indicated) 
were plated in McCoy’s medium containing 1% FBS and maintained for 48 h. 
Compounds were diluted in the same medium containing 100 nM JZL195. Half the 
cells were treated with 10 µM AM251 for 30 min before addition of control medium 
or 1 µM ACEA for a further 4 h. Bla expression was detected using a FRET enabled 
substrate, as per manufacturer’s protocol. The results were normalised to the control 
response in the presence of JZL195, set to 100%. The data presented represents the 
mean of 8 replicate wells from 2 independent experiments ± SEM. Significant 
difference from the response in the presence of AM251 was established using the 
two-sided Student’s t-test, as indicated below.  
 




























































































































































Response of the candidate DAGL-inactive cell lines to PKA 
activation 
In order to determine the level of CB1 activation in response to PKA activation in 
our candidate cell lines, 20,000 Tango cells and cells from 1B, 1E, 1I and 1U were 
plated and maintained for 48 h, as described above. Compounds were diluted in 
McCoy’s 1% medium containing 100 nM JZL195. Half the cells were treated with 
10 µM AM251 for 30 minutes before addition of 10 µM forskolin to all wells for a 
further 4 h. Fluorescence was detected, as described above and the data was 
normalised to the control response, set to 100%.  
 
As expected, there was a clear and highly significant response seen from parental 
Tango cells to forskolin, in the presence of JZL195 (Figure 6.22). In comparison, the 
response from 1B, albeit significant above the control response, was markedly 
reduced. The responses seen from the other cell lines, 1E, 1I and 1U were still > 50% 
of that from parental Tango cells. This may be a variation of cell line selection, or it 
may be that these cell lines are not clonal and still contain WT DAGLα / DAGLβ. 
To determine if WT transcripts were still present in our candidate cell lines, we 















































Figure 6.22 The candidate double DAGL KO cell lines still respond to forskolin 
in the presence of JZL195 
20,000 cells (parental Tango cells and cell lines 1B, 1E, 1I and 1U, as indicated) 
were plated in McCoy’s medium containing 1% FBS and maintained for 48 h. 
Compounds were diluted in the same medium containing 100 nM JZL195. Half the 
cells were treated with 10 µM AM251 for 30 min before addition of 10 µM forskolin 
(FSK) for a further 4 h. Bla expression was detected using a FRET enabled substrate, 
as per manufacturer’s protocol. The results were normalised to the control response, 
set to 100%. The data presented represents the mean of 8 replicate wells from 2 
independent experiments ± SEM. Significance was established using the two-sided 
Student’s t-test, as indicated below.  
 
p<0.05*; p<0.01**; p<0.001 ***; Student’s t-test 
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Sequencing of the DAGL-inactive candidate cell lines 
To understand how the forskolin responses in the Tango assay related to the 
disruptions caused by Cas9, we sequenced the DNA from each of the candidate cell 
lines 1B, 1E, 1I and 1U. To do this, we extracted RNA from these cells, reverse 
transcribed to cDNA and PCR-amplified the catalytic domain using the forward 
primer 5’– GGCTCTGGATCACAGGAAAG–3’ (exon 8), the reverse primer 5’–
GGAGACCCCTTGTGCTGGAC– 3’ (exon 15) and Taq polymerase. The addition 
of a ‘A’ on the end of the sequence by Taq allowed us to TOPO clone and transform 
into E.Coli, as described previously (and in the methods section). 24 colonies were 
selected and sent to Source Bioscience for sequencing. The sequence of each allele 
was aligned with DAGLα WT sequence and the results are summarised in Table 6.2 
– 6.5.  
 
There were a large number of disruptions seen from treating the Tango cells with 
CRISPR/Cas9, demonstrating the efficiency of this genome editing technique. 
However, none of the cell lines we selected for sequencing were clonal, as each cell 
line had more than 2 sequencing results. Importantly, only clone 1I had results that 
aligned with WT DAGLβ (Table 6.4). Therefore, the response to forskolin in the 
other cell lines may have been due to the activity of eCB-producing enzymes other 
than the DAGLs.  
 
It was clear that clone 1B’s response to forskolin was greatly reduced in the Tango 
assay compared to parental Tango cells (Figure 6.22). From the sequencing results, it 
was apparent that this cell line did not contain any WT DAGLβ DNA (Table 6.2). 
Furthermore, most of the disruptions seen from the sequencing results caused 
frameshift mutations within the catalytic domain, except for the 78 bp deletion. This 
deletion is located in exon 9 of DAGLβ, which harbours the serine of the catalytic 
triad; therefore this disruption and all other disruptions seen render DAGLβ 
catalytically dead in these cells. As 1B showed a reduction in response to PKA 
activation, and had the least number of results from sequencing, this cell line will be 
subjected to further clonal selection. However, timeline for generating a clonal cell 




Table 6.2 Summary of sequencing results from 1B cells 
Clone 1B # Results 
1 bp insertion; 82 bp insertion 2 
4 bp deletion; 128 bp deletion 1 
4 bp deletion only 2 
78 bp deletion 5 
128 bp deletion 2 
1 bp deletion 8 





Table 6.3 Summary of sequencing results from 1E cells 
Clone 1E # Results 
6 bp Deletion 1 
120bp insertion 3 
120bp insertion; 128bp deletion 1 
94bp insertion 1 
1bp insertion; 128bp deletion 1 
1bp insertion 6 
128 bp deletion 1 
1bp insertion; 82bp insertion 1 
1bp insertion; 209bp insertion 1 
78bp deletion 2 






Table 6.4 Summary of sequencing results from 1I cells 
Clone 1I # Results 
Misalignment / 84 bp deletion 1 
1bp insertion; 128 bp deletion 4 
1bp insertion 8 
1bp insertion; 41 bp deletion 1 
14bp deletion; 128 bp deletion 2 
WT 4 





Table 6.5 Summary of sequencing results from 1X cells 
Clone 1X # Results 
No alignment at beginning (align with each other) 7 
78bp deletion 3 
1bp insertion 5 
40bp insertion 2 
1 bp insertion; 209 bp deletion 1 








6.3 Summary & Conclusions 
 
We have previously shown that we can report on eCB-dependent CB1 activation in 
the Tango assay. These cells express transcripts for both the DAGLs and are likely to 
also express other eCB-synthesising enzymes. The aim of this section therefore was 
to disrupt transcripts for each of the DAGL genes, with a view to also disrupting the 
non-DAGL component of the responses seen to forskolin, PMA and ionomycin in 
the Tango assay. Eliminating the activity of these enzymes and the DAGLs would 
provide us with a convenient method to study the structure-function relationship to 
DAGL activity and regulation. 
 
There a number of tools currently used to disrupt gene expression, which 
traditionally has been achieved in cultured cells through RNA interference (RNAi). 
RNAi represses gene expression through sequence-specific degradation of mRNA. 
However, RNAi is limited by its off-target effects and by the partial and / or transient 
nature of gene suppression, which is often insufficient to create noticeable changes 
in phenotype (Qiu et al., 2005; Gupta & Musunuru, 2014). Consequently, the ability 
to precisely edit DNA sequences specifically has obvious advantages.  
 
As presented in the general introduction, ‘precise genome editing’ or ‘genome 
engineering’ is currently achieved through one of three techniques; ZFNs, TALENs 
and CRISPR/Cas9. ZFNs and TALENs comprise chimeric nucleases, composed of 
sequence-specific DNA-binding modules linked to a nonspecific DNA cleavage 
(Fok1) domain (Gaj et al., 2013). In contrast, CRISPR/Cas9 is guided by small 
gRNAs to a specific target locus. This technology is derived from the type II 
CRISPR/Cas9 system, an adaptive immune response in bacteria which functions by 
Cas9 recognizing and cleaving foreign DNA through gRNAs (Horvath & Barrangou, 
2010; Jinek et al., 2012; Wiedenheft et al., 2012). The system has been manipulated 
to target mammalian genes (Cho et al., 2013; Mali et al., 2013b) and has 
successfully been used to disrupt specific DNA sequences, both in human and non-
human cell lines (Cho et al., 2013; Jinek et al., 2013; Yang et al., 2014) and more 
recently in U2OS cells (Feng et al., 2015). New CRISPR/Cas9 complexes can be 
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prepared simply by replacing the gRNA sequence; therefore this is a markedly easier 
and cheaper method than ZFNs or TALENs and is why we choose this method to 
disrupt DAGL activity in the Tango cells.  
 
Our initial approach was to use CRISPR/Cas9 to target both the DAGLs 
simultaneously. From the gRNA sequences we designed, cr2 was deemed the most 
successful to target both DAGLα and DAGLβ through examination in the 
SURVEYOR Cel I assay (Figure 6.3). Even though we stimulated NHEJ at the 5’ 
end of the sequence, none of the cell lines had complete KO of DAGL transcripts in 
the Taqman assay (Figure 6.4). 
 
At the time this study began, CRISPR/Cas9 was a relatively new genome editing 
technique and there was little evidence for the effective use of CRISPR/Cas9 in 
U20S cells, although at the time specific gene disruption had been achieved in 
Human Embryonic Kidney (HEK) cells (Cho et al., 2013; Cong et al., 2013; Jinek et 
al., 2013; Mali et al., 2013b). To explore the capabilities of CRISPR/Cas9 and 
stimulating the HDR DNA repair pathway, we did a parallel study using a ‘nickase’ 
strategy. This involved a ‘double-nicking’ approach, consisting of using a D10A 
mutant Cas9 (Cas9n) which renders it as a single-strand endonuclease. NHEJ can be 
stimulated using a pair of offset gRNAs, appropriately positioned at the target 
sequence (Jinek et al., 2012; Shen et al., 2014) and introduction of a repair template 
stimulates the HDR repair pathway (Smithies et al., 1985; Thomas et al., 1986; Ran 
et al., 2013b). Although WT Cas9 is more efficient at mediating homologous 
recombination than Cas9n, at the time of this study, HDR had only detected in 
HUES9 cells when using a pair of Cas9ns (and not WT Cas9) (Ran et al., 2013b). 
Due to the lack of literature and experience using CRISPR/Cas9 in U2OS cells, we 
used Cas9n to ensure stimulation of the HDR pathway and subsequent introduction 
of a resistance gene to the antibiotic, blasticidin. Therefore, our nickase strategy not 
only allowed us to disrupt DAGLα, it also allowed us to positively select cell lines 





Through analysis in the Taqman assay and western blot, we saw similar results to 
our initial strategy, whereby the selected cell lines that appeared to have reduced 
DAGLα transcripts (B, C and X3) still had apparent undisrupted protein translation, 
albeit with an unreliable DAGLα antibody (Figure 6.6 B).  
 
The Taqman assay provided by Life Technologies is a ‘best coverage’ assay. This is 
used to detect transcripts of all predicted splice variants of the gene of interest, and 
so the primer sequences for the real-time PCR reaction are not specified. To 
investigate our cell lines further, we designed primers flanking the insertion site of 
the blasticidin-resistance gene. The results from the RT-PCR on DNA from the cell 
line J gave us the most confidence. Firstly, there was a large insertion (corresponding 
to the blasticidin-resistance gene). Importantly, there was no resulting band at the 
predicted WT size, indicating both alleles had been disrupted in this cell line. 
However, analysis in a western blot revealed that all the bands detected in WT 
Tango cells were undisrupted in cell membranes from J (Figure 6.7). Furthermore, 
transcripts encoding for the catalytic domain were still present (Figure 6.8 B). We 
hypothesised that there may be a splicing event occurring across the site of the 
inserted gene, which would allow the downstream sequence to be translated.  
 
Considering the difficulties we were experiencing in disrupting the full length 
DAGL sequence downstream of the CRISPR targeting site, we re-focussed our 
efforts to target the catalytic domain. We proposed that if we targeted just one of the 
amino acids of the catalytic triad, then DAGL activity would be eliminated and this 
has been shown in previous reports (Bisogno, 2003; Pedicord et al., 2011). By using 
the PNPB membrane assay we confirmed that DAGLα is unaffected in the presence 
of a catalytically-dead version of DAGLα (Figure 6.10) and therefore this strategy 
should not interfere with future mutagenesis studies.   
 
We targeted DAGLα catalytic domain using 3 new gRNA sequences (Figure 6.11) 
and CRISPR 2 cuts directly at the serine of the catalytic triad. It may be that 
targeting Cas9 to a critical residue for a protein’s function results in more severe 
forms of NHEJ, as this gRNA resulted in the highest number of obvious disruptions 
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by Cas9 (Figure 6.12). As a result, we selected 2B (termed α2B) for sequencing, 
which had both alleles disrupted to eliminate DAGLα activity (Figure 6.13 – 6.16).  
 
To generate a DAGL-inactive cell line, we targeted the catalytic domain of DAGLβ 
in α2B cells. Through screening the selected cell lines treated with CRISPR/Cas9 
using RT-PCR (Figure 6.19) and subsequently western blot analysis (Figure 6.20), 
we selected 4 cell lines to test in the Tango assay. The eCB tone (as evident from a 
lack of reduction seen in the presence of AM251) seen in 1E, 1I and 1U cells 
appeared greater than that in parental Tango cells, which may be a result of cell line 
selection or possibly the presence of WT transcripts (Figure 6.21). While all cell 
lines maintained a robust response from ACEA, only 1B showed a reduction in eCB 
tone. 1B also resulted in a reduced response from PKA activation, which was ~ 50% 
of that seen in control Tango cells (Figure 6.22). This may indicate a lack of DAGL 
activity, with the forskolin response seen possibly being a result of the activity of 
other eCB-synthesising enzymes.  
 
The DNA from these cell lines was analysed by Sanger sequencing, which lead to a 
number of results for each, indicating none of the cell lines selected were clonal 
(Table 6.2 – Table 6.5). From these results, only 1I contained WT DAGLβ 
transcripts. Results from 1B indicated that these cells had the least number of 
transcripts, indicating that generating a clonal cell line from this pool may be 
achieved relatively easily. These cells also had the largest decrease in basal eCB tone 
and response to forskolin treatment in comparison to parental Tango cells. Therefore, 
next steps following this study would be to isolate a single clonal cell line from 1B 
for further investigations, with a view to disrupting the other aforementioned eCB-
producing enzymes to completely remove the eCB response (to forskolin, PMA and 
ionomycin) in CB1-Tango cells. This would provide us with a ‘parent’ cell line in 
order to study the structure of DAGL in relation to its function; these points are 








CHAPTER 7. DISCUSSION 
 
 
7.1 Therapeutic potential of the eCB system 
 
Until recently, research into the CB system was a relatively small field. The first 
breakthrough that opened the field was the discovery of the major psychoactive 
component of the cannabis plant, Δ9-THC about 50 years ago (Mechoulam & Gaoni, 
1965). However, it is only in the last two-three decades that great advances have 
been made, such as the identification and cloning of the receptors activated by Δ9-
THC, CB1 and CB2 (Matsuda et al., 1990; Munro et al., 1993), followed by the 
isolation of endogenous ligands that activate them, 2-AG and anandamide (Devane 
et al., 1992; Mechoulam et al., 1995). This has led to an increased interest in 
specifically targeting the eCB system for therapeutic purposes, particularly as 
cannabis was known to induce anti-nociception or analgesia. However, targeting the 
eCB system has proved difficult due to the widespread expression of the CB 
receptors throughout the body. For example, an anti-obesity drug SR141716A, a 
CB1 antagonist commercially known as Rimonabant (Pertwee, 2005; Le Foll et al., 
2009), was withdrawn from the market following links with anxiety and suicide, 
demonstrating the severity of undesired effects associated with targeting the CB1 
receptors in the CNS (Le Foll et al., 2009). However, the therapeutic potential of the 
eCB system is still generating a great deal of interest for areas such as neuropathic 
pain (Lau & Vaughan, 2014), liver disease (Basu et al., 2014) and for the eCB’s anti-
proliferative effects in cancer (Mimeault et al., 2003), with the idea of designing 
more specific drugs to minimize unwanted effects. 
 
The enzymes responsible for the synthesis of 2-AG, the DAGLs, have been cloned 
(Bisogno, 2003) and deleted in transgenic mice (Gao et al., 2010; Tanimura et al., 
2010), which has helped establish these enzymes as regulators within the eCB 
system. These efforts were also important in establishing DAGLα as being 
responsible for virtually all the 2-AG in the brain, as well as DAGLβ generating 
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more than 90% of 2-AG in the liver (Gao et al., 2010). The specificity of the 
individual DAGLs over the control of 2-AG synthesis is in vast contrast to 
anandamide, as identifying a specific enzyme for anandamide’s production has 
remained elusive; no significant reduction in anandamide was seen in animals 
lacking enzymes thought to be responsible for anandamide synthesis, such as 
knockouts of NAPE-PLD, GDE1 or both (Leung et al., 2006; Simon & Cravatt, 
2010b).  
 
2-AG is produced following elevations in calcium in the postsynaptic neuron by 
hydrolysis of DAG by the action of the DAGLs. The released 2-AG acts retrogradely 
to activate the presynaptic CB1 receptor to suppress further neurotransmitter (NT) 
release. DAGL-generated 2-AG also plays a role in fasciculated axonal growth in the 
developing brain (Berghuis et al., 2007; Keimpema et al., 2010; Wu et al., 2010), as 
well as in adult neurogenesis (Goncalves et al., 2008; Gao et al., 2010). 2-AG is then 
degraded by the action of MAGL, although the action of COX-2 may also play a role 
(Beltramo & Piomelli, 2000; Kozak et al., 2000; Piomelli et al., 2000; Dinh et al., 
2002; Muccioli et al., 2007; Long et al., 2009a; Schlosburg et al., 2010). FAAH and 
ABHD12 have also been shown to have 2-AG hydrolytic activity (Long et al., 
2009a; Long et al., 2009b). However, there remains stronger evidence for a role for 
ABHD6 alongside that of MAGL. For example, ABHD6 knockdown has been 
shown to increase the efficacy of 2-AG to stimulate CB2-mediated cell migration in 
a microglial cell line. Immunohistochemical studies revealed ABHD6 localizes to 
sites of 2-AG generation, including post-synaptic dendrites of glutamatergic 
neurones and some GABAergic interneurones (Marrs et al., 2010). Being a member 
of the α/β-hydrolase fold family, the active site of ABHD6 is predicted to face the 
cell interior and is therefore well suited to guard the intracellular pool of 2-AG. This 
been suggested to provide the eCB system with a greater capacity to control the 
duration and magnitude of 2-AG signalling (Savinainen et al., 2012). 
 
In DAGL KO animals, there was a parallel reduction in AA alongside 2-AG. AA 
acts as a precursor for the production of the major eicosanoids (prostaglandins, 
leukotrienes, thromboxanes), which are potent inducers of inflammation (Srinivasan 
& Kulkarni, 1989; Tilley et al., 2001; Kozak et al., 2002). MAGL hydrolysis of 2-
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AG generates an arachidonate precursor pool for neuroinflammatory prostaglandins 
which have been shown to promote neuroinflammation (Nomura et al., 2011), a 
process associated with a number of neurodegenerative diseases, including 
Alzheimer's disease (AD), Parkinson's disease (PD) and multiple sclerosis (MS) 
(reviewed in (Glass et al., 2010)). In fact, activation of CB receptors has been 
associated with anti-inflammatory and neuroprotective effects on the level of 
neurodegeneration that occurs as a result of the inflammatory insults seen in MS 
(Baker & Pryce, 2008). Furthermore, pharmacological or genetic inhibition of 
MAGL that increases 2-AG, with parallel reductions in AA and eicosanoid 
production, has highlighted non-eCB roles for the DAGLs in the context of 
neuroinflammation (Schlosburg et al., 2010; Nomura et al., 2011). For example, in 
mouse models of AD, MAGL KO animals had decreased AA and eicosanoid levels, 
as well as a reduction in microglia and astrocyte activation, inflammatory cytokines 
and amyloid plaques (the latter being one of the hallmarks of the disease), where 
MAGL inhibition exhibited its effects through a reduction in prostaglandin 
production, rather than through enhanced eCB signalling (Piro et al., 2012).  
 
Similarly in PD, genetic or pharmacological inhibition of MAGL prevents MPTP 
increases in AA and eicosanoids as well as neuronal loss, showing that in the brain, 
the production of pro-inflammatory prostaglandins is controlled by hydrolysis of 2-
AG by MAGL (Nomura et al., 2011). However, prolonged MAGL inactivation 
causes profound alterations to the brain eCB system, including physical dependence, 
impaired eCB-dependent synaptic plasticity and desensitised brain CB1 receptors 
(Schlosburg et al., 2010). Genetic or pharmacological DAGLβ inactivation resulted 
in elevated 2-AG and corresponding reductions in AA, demonstrating 2-AG 
synthesis as a major precursor pro-inflammatory eicosanoids in the brain and 
peritoneal macrophages (Hsu et al., 2012). Therefore, the DAGLs may be better 
targets for therapeutic intervention.  
 
The potential benefit of enhancing DAGL activity was highlighted in a study 
examining Fragile X retardation protein, which has linked the eCB system to autism. 
2-AG, enhanced by MAGL inhibition, repaired synaptic defects seen in Fragile X 
KO mice (Jung et al., 2012). Beyond the nervous system, increased CB1 and 
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DAGLβ expression, alongside 2-AG levels were seen in the liver of mice in a model 
of alcohol-induced liver steatosis, also known as fatty liver disease. When the CB1 
receptor was disrupted either pharmacologically or genetically, these effects were 
reduced (Jeong et al., 2008). As DAGLβ activity accounts for the majority of 2-AG 
produced in the liver (Gao et al., 2010), targeting DAGLβ may have therapeutic 
benefit in fatty acid liver disease. 
 
These studies have highlighted the role of the DAGLs in regulating eCB function 
and also AA and eicosanoid production. However, very little is known about the 
regulatory mechanisms that affect their ability to hydrolyse DAG in order to provide 
2-AG as a precursor for AA synthesis, as well as the endogenous ligand for CB1 
activation. Studying regulation of the DAGLs will further our knowledge of their 
physiological and possible patho-physiological roles in both the CNS and the 
periphery. As the DAGLs demonstrate different tissue contributions towards 2-AG 
production (Gao et al., 2010), targeting them individually may be ideal to alter their 
activity in a specific tissue relating to a disease. Recently, a compound was 
developed known as KT109, which displays more than 50 times greater potency for 
DAGLβ over DAGLα, highlighting that differences between the two enzymes could 
be exploited for a therapeutic strategy (Hsu et al., 2012). Therefore, understanding 
how their structure relates to their function and whether/how they are regulated, 
could allow design of specific therapeutics. 
 
 
7.2 Identifying structural features of the DAGLs and 
their functions 
 
As presented in this thesis, we examined the structure of the DAGLs in order to 
determine the role of a post-translational modification (PTM) in regulating activity. 
We took a bioinformatics approach to assess the wealth of information freely 
available online. We gathered this information together to determine if there is 
sufficient evidence for a regulatory role of phosphorylation (or other type of PTM) in 




Through homology modelling of the crystallised fungal DAGL to drosophila, and 
drosophila to the human DAGL, our group identified 4 TM domains, linked by 
helices (2 intracellular and 2 extracellular). The TM domains lead onto an 
intracellular catalytic domain, whose structure is a member of the α/β hydrolase fold 
family of enzymes (Reisenberg et al., 2012). Common structural features of this 
enzyme family can tolerate considerable-sized inserts at certain locations (Nardini & 
Dijkstra, 1999). In the case of the DAGLs, two substantial inserts were identified; a 
cysteine-rich insert and a lid-like structure that we have termed the ‘regulatory loop’.  
 
The cysteine rich insert is a potential palmitoylation site and evidence for 
palmitoylation of the DAGLs was provided in rat brain synaptosomes, rat cortical 
neurons and Jurkat cells (Kang et al., 2008; Martin & Cravatt, 2009). This insert 
therefore may act to regulate DAGL activity by affecting its localization at the 
membrane, and subsequent access to the substrate. The second insert, the regulatory 
loop, may constitute a common lid-like feature that is seen in many lipases of the α/β 
hydrolase fold family of enzymes, where it is responsible for interfacial activation, a 
process whereby activity of lipases is enhanced upon contact with a lipid–water 
interface and is believed to trigger the opening of the lid (Nardini & Dijkstra, 1999; 
Holmquist, 2000). The regulatory loop is in the right position to shield DAG access 
to the catalytic site and also harbours a highly conserved ‘signature motif’ 
(Reisenberg et al., 2012).  
 
 
7.3 Regulatory mechanisms for the DAGLs 
 
We have proposed phosphorylation as a regulator of DAGL activity that determines 
the position of the regulatory loop in the ‘open’ or ‘closed’ conformation. The 
activity of many lipases is controlled by phosphorylation (Kurat et al., 2009; Gresset 
et al., 2010; Lampidonis et al., 2011) by increasing/decreasing an enzyme’s activity, 
or affecting protein-protein interactions (Johnson & Lewis, 2001; Salazar & Hofer, 
2009). For example, HSL is phosphorylated by PKA, resulting in ~ 2-fold increase in 
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activity and all phospho-sites are located within the regulatory lid. This has led to the 
model whereby, at least in vitro, HSL is phosphorylated by PKA in response to 
certain stimuli (Holm et al., 1994; Krintel et al., 2009; Lampidonis et al., 2011). 
 
The evidence for the role of phosphorylation in regulating the activity of HSL gives 
us a working model for studying possible regulatory mechanisms of the DAGLs, 
based on its key structural features. Furthermore, there is ample evidence for the role 
of PKA and PKC in 2-AG generation. For example, DAGL from brain microsomes 
was shown to be phosphorylated by PKA (Rosenberger et al., 2007) and 
phosphorylation of bovine rod membranes by PKA resulted in a ~70% increase in 
DAGL activity (Perez Roque et al., 1998). Similarly, PKA and PKC activation 
stimulated 2-AG synthesis (Vellani et al., 2008).  
 
We have identified key phospho-sites through cross-examination of the DAGLs’ 
sequences between different online databases. All of those identified in DAGLβ are 
within the catalytic domain and are therefore well positioned to regulate activity. 
Surprisingly, these sites are not conserved in the sequence of DAGLα. However, 5 of 
the 15 amino acids in the corresponding region are serine/threonine and so this does 
not rule out identification of phosphorylation sites within this region in the future. In 
the case of DAGLα, only one site was identified within the regulatory loop (T560), 
while the rest are located within the tail domain. While the tail is dispensable in 
terms of activity, it may still serve to regulate positioning of the regulatory loop, as 
one report showed that phosphorylation by CaMKII decreased DAGLα activity by ~ 
40% (Shonesy et al., 2013). This is surprising considering that previous reports have 
shown phosphorylation to increase DAGLα activity. However, CaMKII signalling 
has been shown to allow stimuli-specific spatiotemporal patterns, which may be 
important for synapse-specificity of synaptic plasticity. CaMKII therefore may exert 
its activity to control DAGLα activity at specific synapses (Lee et al., 2009). 
However, the role of CaMKII in the regulation of DAGLα in a more physiological 
context remains to be seen.  
 
The DAGLs are therefore potentially phosphorylated at a number of sites, and this 
may be important for regulation. Furthermore, stimuli observed to increase 
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production of 2-AG levels in cells/tissues can also activate various kinases, as 
discussed below.  
 
 
7.4 2-AG levels increase following stimuli that activate 
protein kinases 
 
There have been numerous reports demonstrating an increase in 2-AG production 
following various stimuli. For example, cerebellar granular neurons increased their 
2-AG synthesis in response to ethanol, ionomycin and glutamate (Basavarajappa et 
al., 2000). 2-AG synthesis was enhanced in astrocytes by endothelin 1, ionomycin 
and ATP (Walter & Stella, 2003; Walter et al., 2004). Stimulation was also seen in 
cortical neurons in response to glutamate and NMDA (Stella et al., 1997; Stella & 
Piomelli, 2001), as well as by ionomycin in neuroblastoma cells (Bisogno et al., 
1997a). The DAGLs are the principle enzymes responsible for 2-AG synthesis (Gao 
et al., 2010; Tanimura et al., 2010) and are therefore the likely enzymes to be 
responsible for this increase in 2-AG.  
 
The calcium ionophore, ionomycin (and other stimuli) is likely to be mimicking the 
increase in intracellular calcium seen as a result of specific signals which open 
calcium channels either in the cell membrane or in the endoplasmic reticulum. 
Activated GPCRs, such group 1 and 5 mGluRs, form GTP-Gαq complexes (Willard 
& Koochekpour, 2013). The canonical effector of Gαq signalling is the activation of 
PLCβ, although the βγ subunits of G proteins can also stimulate PLCβ (Rozengurt, 
2007). Active PLCβ catalyses the hydrolysis of PIP2 to produce inositol 1,4,5-
triphosphate (IP3) and DAG. DAG activates PKC, while IP3 triggers 
calcium mobilization from endoplasmic reticulum stores leading to an increase of 
intracellular calcium concentration (Parekh & Putney, 2005; Cattaneo et al., 2014) 
However, a recent review has commented on there being one or more Gαq-
dependent, PLCβ-independent effectors (Sanchez-Fernandez et al., 2014). For 
example, the activation of the glycogen synthase kinase-3 (GSK-3) has been shown 
to be promoted by Gαq independently of PLCβ (Fan et al., 2003). However, other 
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PLCβ-independent effectors have yet to be identified (Sanchez-Fernandez et al., 
2014). Gαq signalling might stimulate these other effectors as well as increase 
intracellular calcium in tandem to mediate its effects. This PLCβ-independent 
element of Gαq signalling may encompass the unidentified signalling pathway that 
results in phosphorylation of the DAGLs. 
 
 
7.5 Establishing CB1-Tango cell lines stably expressing 
DAGLα and DAGLβ  
 
The eCB system is regulated at the level of synthesis and degradation of the eCBs, 
and our aim was to study the regulatory mechanisms of the DAGLs. Activity of the 
DAGLs is commonly assessed by measuring the production of 2-AG. However, this 
is challenging for a few reasons; for example, 2-AG isomerizes spontaneously to its 
biologically inactive analogue 1-arachidonoyl glycerol (1-AG) (Zoerner et al., 2012; 
Balgoma et al., 2013). It also requires an expensive and elaborate laboratory setup 
for LC/MS, as well as user expertise (Balgoma et al., 2013). Other groups have 
shown that, in general, to be able to measure robust activity there is a requirement to 
overexpress the DAGLs (Bisogno, 2003; Shonesy et al., 2013; van der Wel et al., 
2015). These assays have generally been limited to studies that aim to directly 
measure DAGL activity for the purpose of developing new inhibitors (Hoover et al., 
2008; Ortar et al., 2008; Bisogno et al., 2009; Hsu et al., 2012; Bisogno et al., 2013) 
 
As described in the thesis, we have developed a CB1-Tango (U2OS) cell line to over 
express DAGLα and DAGLβ. The Tango cells harbour a recombinant assay system 
to measure CB1 activation. Using the Tango cells allows us to try to develop an 
assay to measure DAGL-dependent CB1 activation. Provided an appropriate 
stimulus is given, theoretically DAGLα/β hydrolysis of DAG would produce 2-AG 
thereby activating the CB1 receptor. The overexpressed DAGLα/β may or may not 
be required to measure this response as there are endogenous DAGLs expressed in 
the cells and enzyme levels may not be rate-limiting. However, given that this in 




Previous attempts to reconstitute eCB-mediated CB1 activation was shown in 
isolated rat sympathetic neurons. Transfected mGluR5a and CB1 produced modest, 
but variable intracellular calcium inhibition (in the same neuron) following L-
glutamate application. However, when DAGLα was recombinantly expressed, L-
glutamate resulted in robust intracellular calcium influx inhibition, consistent with 
mGluR5-mediated 2-AG biosynthesis, transport, and subsequent activation of CB1 
receptor (Won et al., 2009). This study demonstrated a gain of function assay, 
whereby the transfected DAGLα resulted in a larger and more robust response to L-
glutamate compared to control cells. Similarly, we generated a Tango cell line 
overexpressing DAGLα (V5α11) and a cell line overexpressing DAGLβ (V5β4) to 
determine if we could measure a gain of function response in the Tango assay.  
 
The natural substrate, DAG is generally found associated to the membrane (Goni & 
Alonso, 1999). Consequently, the DAGLs are likely to orientate themselves at the 
membrane to increase accessibility of their substrate to the catalytic domain. When 
assessing expression patterns of the transfected DAGLs, DAGLα staining revealed 
expression throughout the cell surface. Surprisingly, DAGLβ expression appeared 
punctated and perinuclear. This observation was also made by Piomelli’s group, 
where overexpression in mouse neuroblastoma cells showed DAGLβ to be 
associated to intracellular structures, rather than at the plasma membrane (Jung et al., 
2007). We confirmed the location of DAGLβ in our V5β4 cells to be localised to the 
Golgi (thesis of Praveen Singh, Prof. Doherty lab). The functional significance of 
this, and relevance to 2-AG mobilisation, is unknown. However, DAGLβ 
localisation in V5β4 cells may also be due to an artefact of overexpressing the 
enzyme.  
 
When confirming DAGLα and DAGLβ expression at the membrane, the bands 
detected in a western blot were at slightly larger molecular weights than is predicted 
for each DAGL (~120 kDa for DAGLα, ~75 kDa for DAGLβ) (Bisogno, 2003), 
perhaps owing to their V5 tag. However, a previous study using a V5-tagged version 
of DAGLα revealed a band at ~ 116 kDa, albeit in HEK293 cells (Shonesy et al., 
2013). Although the DAGLα antibody did not reliably detect endogenous 
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expression, we concluded that the Tango cells express DAGLβ as well as RNA 
transcripts for both the DAGLs.  
 
Previously, a membrane assay was developed as a convenient method to screen for 
inhibitors of DAGLα (Pedicord et al., 2011). Using the reported surrogate substrates, 
PNPB and DiFMUO, we showed we could measure activity from the transfected 
DAGLα and that this could be inhibited by the DAGL inhibitors THL, OMDM and 
RHC-80267, with the only target these inhibitors compounds having in common 
being DAGL (Ortar et al., 2003; Hoover et al., 2008; Ortar et al., 2008). Although 
these substrates did not report on activity of the transfected DAGLβ, another 
surrogate substrate, Enzchek has been reported that may detect activity of this 
enzyme (Basu et al., 2011). Further development of the membrane assay would be to 
determine whether these substrates could report on DAGL in the context of a live 
cell. This would enable direct measurement of DAGL activity in both live cells as 
well as in membrane preparations, allowing aspects such as membrane permeability 
to be factored into kinetics of the different synthetic substrates. Work on developing 
this assay in our lab is ongoing. 
 
Although we could measure activity from the transfected DAGLα, the size of the 
substrates meant they might not report on the position of the regulatory loop. The 
surrogate substrates are substantially smaller than DAG and may be able to access 
the active site irrespective of the loop’s conformational position. In support of this, 
treatments aimed at phosphorylating the DAGLs, such as kinase activation, did not 
alter hydrolysis of either substrate in a live cell assay (data not shown; work 
completed with Dr. Praveen Singh, unpublished data). Therefore it appears that the 
catalytic site of DAGLα is consistently active, and shielding by the regulatory loop is 
what regulates DAG hydrolysis, akin to the active catalytic site of GL, where 
substrate access is limited by the position of the regulatory lid (Miled et al., 2003). 
 
The fact that no transgenic DAGLβ activity could be detected using these substrates 
was surprising considering that DAGLβ is more highly expressed in V5β4 cells than 
DAGLα is in V5α11 cells. This might demonstrate different kinetics between the 
two enzymes, whereby DAGLα is capable of hydrolysing these substrates and 
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DAGLβ is not. If this were the case then there is certainly potential for specific 
therapeutic intervention of one DAGL over the other. This potential was highlighted 
by the discovery of two compounds, KT109 and KT172. These compounds were 
shown to lower 2-AG, as well as AA and eicosanoids, in mouse peritoneal 
macrophages. IC50 values of 2.3 and 0.14 μM were reported for inhibition of 
recombinant DAGLα by KT109 and KT172, respectively. In comparison, IC50 
values of 0.04 and 0.06 μM for KT109 and KT172 respectively were reported for 
DAGLβ inhibition. KT109 can therefore be considered an isoform-selective inhibitor 
of DAGLβ, whereas KT172 exhibits similar activity against both DAGLα and 
DAGLβ (Hsu et al., 2012). As the DAGLs are expressed at different levels by 
different tissues, developing specific compounds could lead to therapeutic 
intervention with less undesired effects.  
 
As discussed, there is substantial evidence that phosphorylation can change the 
activity of the DAGLs and that this results in an increase in 2-AG production. The 
limitations of using the surrogate substrates means we were unlikely to detect any 
changes in DAGL activity in the membrane assays. However, by establishing their 
overexpression in the Tango cells, we intend to develop a DAGL-dependent CB1 
activation assay using these cell lines in the future.  
 
 
7.6 Detecting eCB activation of CB1 
 
At the outset of the project we recognised that eCBs other than 2-AG might be active 
in the CB1-Tango assay. Based on this our strategy was to try to establish a robust 
eCB-dependent response in the cells with a view to then determining which (if any) 
of the known eCB synthesising enzymes mediated the response.  In this context, the 
relationship between 2-AG synthesis and CB receptor activation is not well 
established and might be governed by other factors, such as rapid 2-AG hydrolysis 




Recently a natural substrate assay has been developed, whereby 2-AG production is 
measured as a result of DAGLα hydrolysis of SAG (van der Wel et al., 2015). At the 
outset of this study we wanted to develop an assay that measures eCB-dependent 
activation of the CB1 receptor, rather than eCB production per se. This is because it 
is likely that there are metabolic as well as signalling pools of the eCBs, and we 
wanted to focus on the signalling pools. For this purpose, we used the CB1-Tango 
assay. This assay uses U2OS cells (osteosarcoma cell line) overexpressing the CB1 
receptor, which has been fused to a non-native transcription factor at its C-terminus. 
This is separated from the receptor by a linker containing a protease cleavage site. 
Upon receptor activation, β-Arrestin 2, fused to a non-native protease, is recruited. 
The protease acts on the cleavage site releasing the transcription factor, activating a 
mammalian-optimised β-lactamase (bla) reporter gene in the nucleus (Barnea et al., 
2008; van der Lee et al., 2009). β-lactamase activity is then monitored using a 
FRET–enabled substrate (Zlokarnik et al., 1998), thereby directly reporting on CB1 
activation.  
 
By establishing CB1-Tango cell lines that stably and robustly express the DAGL 
transgenes (V5α11 and V5β4), our aim was not only to increase our chances of being 
able to measure DAGL-dependent CB1 activation, but to also address the question as 
to whether the enzyme level is rate limiting. This is similar to an approach described 
previously, where reconstitution of DAGLα provided a gain-of-function assay, 
thereby demonstrating eCB-mediated signalling in rat neurons (Won et al., 2009). 
However, reconstituting the pathway in primary neurons is not amenable to moderate 
throughput assays, which we developed to evaluate various stimuli that could 
potentially induce eCB-CB1 activation.  
 
PKA and PKC are two kinases implicated in stimulating 2-AG synthesis in cells   
and they can be activated synthetically through treatment with forskolin and PMA 
respectively. 2-AG levels increased approximately 3-fold when HEK293 cells were 
treated with forskolin or PMA, a response that was blocked when these kinases were 
inhibited (Vellani et al., 2008). However, these stimuli can also result in production 
of anandamide. For example, glucocorticoids cause rapid synthesis of both 
anandamide and 2-AG in neuroendocrine cells of the hypothalamus (Di et al., 2003; 
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Malcher-Lopes et al., 2006). Moreover, anandamide synthesis can also be stimulated 
by calcium (Di Marzo et al., 1994; Cadas et al., 1997; Schmid, 2000; Leung et al., 
2006). We therefore sought to determine whether we could stimulate eCB activation 
of CB1, with a view to extrapolating the DAGL-dependent portion of the response.  
 
No basal eCB tone was detected in this assay, nor was one revealed when MAGL 
was inhibited by JZL184. The lack of eCB tone observed in these cells might reflect 
a lack of substrate, or perhaps substrate is available but unable to access the active 
site of the enzyme due to steric hindrance by the regulatory loop. However, the 
forskolin response, although significant at certain concentrations, was not 
concentration-dependent and was relatively small; this could be due to lack of 
substrate or possibly another limiting factor such as lack of enzyme, or enzyme not 
being active. However, even the relatively large overexpression of enzyme did not 
reveal tone, showing that enzyme level is not limiting.  
 
The failure to detect a substantial basal eCB tone, in cells that overexpress DAGLα 
in media containing JZL184 and in the presence and absence forskolin, was 
surprising given the report that PKA activation leads to 2-AG synthesis (Vellani et 
al., 2008). Due to constraints of the assay format, whereby the full contents of 
Freestyle starvation medium were undisclosed, we optimised the assay in McCoy’s 
medium supplemented with 1% FBS. This ensured that all factors that are likely to 
be required for the synthesis of 2-AG (and perhaps other eCBs), including calcium, 
were present in the culture media.  
 
JZL195 is a dual MAGL/FAAH inhibitor that also displays some activity against 
ABHD6 (Long et al., 2009b). We included this inhibitor in the assay as a previous 
report demonstrated cross talk between MAGL and FAAH pathways, where one 
enzyme had the ability to compensate when the other was inhibited (Long et al., 
2009b). Furthermore, JZL184 has not been reported to have activity against ABHD6 
(Long et al., 2009b). A small eCB tone was detected in the presence of JZL195, 
which was absent when JZL195 was not present. The lack of eCB tone when JZL195 
is absent might reflect MAGL/FAAH/ABHD6 acting as ‘gate-keeping’ enzymes, 
which hydrolyse 2-AG (or other eCBs) thereby preventing it from stimulating the 
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CB1 receptor. Once these enzymes are inhibited by JZL195, β-lactamase activity 
increases after both 4 h and 18 h by ~ 15% and ~ 30%, respectively. This response 
was fully inhibited by AM251, providing evidence it is dependent on CB1 
activation. This ‘gate-keeping’ activity is similar to that seen in developing axon, 
whereby MAGL is restricted from the motile tip of the growth cone, being confined 
further back along the axon, thereby allowing 2-AG to be available to activate CB1 
in a highly restricted manner and this is required for axonal growth (Keimpema et 
al., 2010). In adult synapses, MAGL is expressed on the presynaptic neuron (with 
DAGL expressed on the postsynaptic neuron), which is in keeping with MAGL’s 
function to terminate the signal, rather than preventing the DAGL-produced 2-AG to 
reach the presynaptic CB1 receptor (Bisogno, 2003; Yoshida et al., 2006; 
Hashimotodani et al., 2007).  
 
By allowing calcium to be present in the culture medium, we found that forskolin 
alone could stimulate an eCB tone to a similar extent as JZL195 alone, in both 4 h 
and 18 h assays. The response to these agents together is greater than that seen from 
either one of them on their own and were inhibited by AM251. This indicated that 
the forskolin-stimulated response was much greater when MAGL and FAAH, and 
perhaps ABHD6 are inhibited, indicating that possibly one or both of the 
endogenous DAGLs could be active. Following a 48 h starvation period, no response 
was detected in the presence of forskolin alone and was only revealed in the presence 
of JZL195. Similarly, stimulation of PKC with PMA stimulated eCB signalling and 
this again was only convincingly seen when JZL195 limited the breakdown of 2-AG 
and/or anadamide (and possibly some other eCB).  
 
A clear and concentration-dependent increase in response was seen in the presence 
of ionomycin alone. This response was significantly reduced in the presence of either 
5 or 10 µM THL. However, this only reached  15-20% inhibition, indicating that 
~80% of the ionomycin response may not be due to DAGL activity. (It was noted 
that THL on its own did not reduce basal tone in these cells.) The fact that 
ionomycin could stimulate a response in the absence of JZL195 might be a result of 
the activation of more than one component necessary for eCB production. In the case 
of the DAGLs, it might be that more than one kinase is important for regualtion of 
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activity. In the presence of JZL195, the level of the ionomycin-simulated CB1 
activation is much greater, with the response from 2 µM being increased by ~ 50% . 
In contrast, neither JZL184 nor URB597 increased basal eCB tone or potentiated the 
ionomycin response, indicating that inhibiting either MAGL or FAAH alone is not 
sufficient to potentiate the eCB response in CB1-Tango cells; the response is greater 
only when the hydrolytic activity of both of these enzymes (and possibly ABHD6) is 
inhibited, thereby allowing eCBs being produced to signal through the CB1 receptor. 
Again this may have been that FAAH was compensating for the lack of activity of 
MAGL, and vice versa. Dual blockade of FAAH/MAGL (and not when MAGL was 
inhibited alone) has been shown to produce THC-like responses that were reversed 
by a CB1 antagonist, indicating these pathways display a degree of crosstalk and 
may not be mutually exclusive (Long et al., 2009b). Furthermore, JZL195 can also 
inhibit ABHD6, an enzyme previously shown to contribute to 2-AG hydrolysis in 
mouse brain which also appears to play a role in efficacy of 2-AG to activate CB1, 
being suggested as a rate-limiting step for 2-AG signalling (Blankman et al., 2007; 
Marrs et al., 2010). 
 
Our overexpressing cell lines did not show an obvious ‘gain of function’ phenotype. 
However, this may be possible in the future by further optimising assay conditions, 
but as yet we have not seen substantive evidence; although it may also be an 
indication that substrate is a limiting factor. DAGL (as well as other eCB producing 
enzymes) activity may be controlled at the level of substrate availability as well as 
phosphorylation and as such, the availability of DAG has been implicated as another 
regulatory mechanism for the activity of the enzymes. For example, an increase in 
PLCγ activity is likely to hydrolyse phospholipids and DAG levels, thereby 
upregulating DAGL activity, 2-AG and subsequent CB1 activation. This pathway 
has been suggested in FGFR driven neurite outgrowth in cerebellar neurons in 
culture (Saffell et al., 1997; Bisogno, 2003; Williams et al., 2003). Furthermore, 
increased PLCβ activity has been shown to upregulate DAGL-dependent 2-AG 
synaptic signalling (Hashimotodani et al., 2005; Tanimura et al., 2010). 
Consequently, post-synaptic receptor activation, resulting in an increase in 
intracellular calcium, activates PLCβ and increases DAG levels, DAGL activity and 
2-AG production. Nonetheless, it was essential to eliminate eCB production in the 
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Tango cells to accommodate future structure-function studies of the DAGLs and also 
study the non-DAGL component of the responses seen. As at the outset of this study, 
there were no specific inhibitors for the enzymes and so it was apparent that a 
genetic intervention tool was required.  
 
 
7.7 Precise genome editing with CRISPR/Cas9 
 
The above results have started to give us clear insights into some of the factors 
governing eCB signalling, and there is no doubt that much more could be learned by 
utilising simple pharmacological approaches. In a recent commentary, the late Alan 
Hall discussed several reasons for the increase in irreproducibility seen across the 
field of science. One such explanation was that small molecules described as 
‘specific’ are never truly so and one should exploit the power of genetics to target 
the specific protein in question (Yamada & Hall, 2015). However, there is also a 
high degree of irreproducibility associated with the use of RNA interference (RNAi), 
a technique used to repress gene expression through sequence-specific degradation 
of mRNA. RNAi is limited by its off-target effects and by the partial and / or 
transient nature of gene suppression, which is often insufficient to create noticeable 
changes in phenotype (Qiu et al., 2005; Gupta & Musunuru, 2014). Consequently, 
the ability to precisely edit specific DNA sequences has obvious advantages. Until 
recently, this was typically achieved through ZFNs or TALENs. These technologies 
comprise chimeric nucleases, composed of sequence-specific DNA-binding modules 
linked to a nonspecific DNA cleavage (Fok1) domain (Gaj et al., 2013); because a 
new chimeric protein needs to be generated for each new target, both of these 
methodologies are time-consuming and expensive.  
 
Three years ago, CRISPR hit the radar screen (Jinek et al., 2012). This gave us the 
opportunity to explore this technology in the context of DAGL function. This 
technique was derived from the type II CRISPR-Cas9 system, an adaptive immune 
response in bacteria and archaea, which functions by Cas9 recognizing and cleaving 
foreign DNA (viruses or plasmids) through gRNAs, whose sequences are partially 
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derived from the invaders (Horvath & Barrangou, 2010; Jinek et al., 2012; 
Wiedenheft et al., 2012). The system has been manipulated to target mammalian 
genes (Cho et al., 2013; Mali et al., 2013b) and has successfully been used to disrupt 
specific DNA sequences, both in human and non-human cell lines (Cho et al., 2013; 
Cong et al., 2013; Mali et al., 2013a; Yang et al., 2014) and more recently, in U2OS 
cells (Feng et al., 2015). New CRISPR/Cas9 complexes can be prepared simply by 
replacing the gRNA sequence; therefore it is a markedly easier and cheaper method 
than ZFNs or TALENs and is the method we chose to KO the DAGLs.  
 
We used three different approaches to target DAGL activity in the Tango cells with 
CRISPR/Cas9. Initially we attempted to disrupt the most upstream exon to hit any 
predicted splice variants of each enzyme; we targeted exon 3 in DAGLα and exon 7 
in DAGLβ. At the same time, we exploited the D10A mutant version of Cas9, Cas9 
nickase to limit off-target effects and introduce a blasticidin resistance gene through 
the HDR DNA repair pathway (at the same locus in each gene). Although we were 
aware of the unreliability of the DAGLα antibody, neither method gave us 
confidence that we were disrupting the full length gene downstream of the CRISPR 
targeting site. Inducing a DSB in a DNA sequence has been known to effectively 
create a frameshift or premature stop codon in the downstream sequence (Perez et 
al., 2008) and from the sequencing it looked as though the mutations in our selected 
cell lines would be sufficient to cause a frameshift in the DAGLs’ sequences; yet 
transcripts were not reduced by > 50% in our selected cell lines.  
 
We questioned whether the relatively large length of the DAGL genes was providing 
a mechanism to splice across the CRISPR cutting site. More recently, a report has 
demonstrated that by using two gRNAs coupled with Cas9 efficiently generates 
DNA deletions of up to 10 kb in human cells through introduction of a repair 
template, thereby stimulating HDR repair pathway (Zheng et al., 2014). 
Furthermore, a single Cas9-gRNA complex was used to effectively disrupt CDK11 
gene (~20 kb) in U2OS cells (Feng et al., 2015). However, the DAGLα gene consists 
of ~ 67 kb and DAGLβ gene ~ 65 kb and there are no reports to date on using 
CRISPR/Cas9 to disrupt a gene of a similar size. Therefore, it is unclear if one Cas9-
gRNA complex alone (or two in the case of our nickase strategy) can efficiently 
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disrupt this size without pairing it with another complex. More than one gene can be 
disrupted by ‘multiplexing’ two Cas9-gRNA complexes simultaneously (Cong et al., 
2013; Yan et al., 2014). Using two or more Cas9-gRNA complexes to target 
different loci on the DAGL sequence could be a more effective method to disrupt the 
full length gene. 
 
When using CRISPR/Cas9 technology, it is important to have appropriate screening 
methods for selecting a knockout cell line. For this purpose, we targeted DAGLα and 
DAGLβ simultaneously, with vectors containing GFP and mCherry, respectively. 
While screening for successful transfection may be done through these fluorescent 
markers, FACS sorting appeared to be detrimental to cell viability. Furthermore, this 
may not be sufficient for detecting successful Cas9 cutting of the sequence, thereby 
resulting in a number of WT transcripts in our selected cell lines. This was especially 
true in the case of DAGLα, where we may not have detected these WT transcripts in 
the sequence analysis. In addition, the double transfection of constructs to target both 
the DAGLs simultaneously may have interfered with one another, as co-transfection 
is known to reduce efficiency and can depend on the ratio of the DNA concentration 
between the two constructs (Hannig, 2013). In deciphering whether WT transcripts 
for DAGLα’s catalytic domain were still present, we screened the blasticidin-
resistant cell line J using RT-PCR. This provided a much more efficient and higher 
throughput method to detect WT or disrupted DAGL transcripts. 
 
One clearly has to consider the limitations of CRISPR, such as mosaicism seen in 
mice, whereby a mutant allele in only some of their cells may be produced (Long et 
al., 2014). This has been one issue we encountered when attempting to generate a 
clonal DAGL-inactive cell line. Furthermore, earlier reports of the aforementioned 
off-targeting events reported a number of tolerated mismatches between the gRNA 
sequence and the target locus (Fu et al., 2013). However, off-target effects are only a 
concern for us if they interfere with the Tango assay system, and to this end we have 
very clear controls in place; for example, ensuring the Tango cells maintained 
maximal ACEA responses that can be inhibited by AM251. As we could show that 
DAGLα activity is not interfered by the presence of a catalytically-dead version of 
the enzyme, by re-focussing our efforts to disrupt the catalytic domain and therefore 
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activity of the DAGLs, we could show the efficiency of Cas9 in disrupting a target 
DNA locus. The simplicity of the technology allowed us to generate cell lines with 
various disruptions within catalytic domain of each of the DAGLs  and these may be 
of interest in future studies. As a result, our Tango cell lines contained disruptions to 
both genes that should eliminate DAGLα and DAGLβ activity in the same cell line. 
However, as expected these cells responded significantly to PKA activation, 
indicating other eCBs are likely to be contributing to the response.  
 
More than 1,000 reports have been published since the explosion of CRISPR/Cas9 
onto the genome modifying market and the genomes of virtually all model animals 
and plants have been successfully edited by the technology (Sternberg & Doudna, 
2015). However researchers are continuing to adapt the CRISPR/Cas9 system to suit 
their needs. For example, it has been used to generate chromosomal rearrangements, 
similar to those found in tumours, in both human and primary cell lines (Choi & 
Meyerson, 2014; Torres et al., 2014). In addition, a catalytically-dead version of 
Cas9 (dCas9) has been used to study gene regulation, by fusing dCas9 to 
transcription activators or repressors, which are guided to a specific genomic locus 
via the gRNA (Gilbert et al., 2013; Maeder et al., 2013; Perez-Pinera et al., 2013), 
which could of interest in studying DAGL phosphorylation and regulation in the 
future.  
 
Although many hurdles still exist for clinical use, the therapeutic potential of 
CRISPR/Cas9 is becoming more evident for treatment of genetic disease. For 
example, CRISPR/Cas9-mediated correction of a Fah mutation seen in the metabolic 
hereditary disorder, tyrosinemia resulted in rescue of the body weight loss phenotype 
in a mouse model of the disease, demonstrating that genome editing is possible in 
adult animals (Yin et al., 2014). In addition, Duchenne muscular dystrophy was 
prevented by injection of CRISPR/Cas9 components directly into the mouse 
germline (Long et al., 2014). These examples highlight the potential of 





7.8 Future Directions 
 
Before continuing with disruption of other eCB synthetic pathways, it would be 
prudent to isolate a clonal cell line from the DAGL-inactive Tango cells, in order to 
study the non-DAGL pathway. In designing a strategy to KO anandamide 
biosynthesis, one has to take into account the numerous pathways that have been 
described. For example, in NAPE-PLD KO mouse (Leung et al., 2006), GDE1 KO 
mouse or mice lacking both GDE1 and NAPE-PLD activity (Simon & Cravatt, 
2010b) there were no significant reductions in anandamide levels, indicating that 
more than one synthetic pathway can account for anandamide synthesis in vivo. 
However, one could eliminate one pathway at a time in the Tango cells and therefore 
decipher the most important pathway or combination of pathways for anandamide 
biosynthesis, at least in vitro.  
 
A cell line lacking eCB synthesis would act as a ‘parent’ cell line for the generation 
of cells that have a single gain-of-function pathway, e.g. DAGLα, DAGLβ and 
possibly an anandamide pathway for detailed studies on factors that can stimulate 
their activity. Another advantage to obtaining a cell line that in itself cannot mount 
an eCB response would be to use it as a reporter in co-culture assays with, for 
example, neurons, to monitor their ability to release eCBs via CB1 activation in our 
parent cell line. Co-cultures have previously been used to demonstrate that 
developing acetylcholinergic basal forebrain neurons are attracted to COS-7 cells 
overexpressing DAGLα, termed “2-AG hotspots” 
  
We would then perform structure-function studies on each of the DAGL enzymes, 
for example mutagenesis, to determine which phospho-sites that we have identified 
are important for their function. One such method to re-introduce a mutated version 
of DAGL would be CRISPR/Cas9, which has previously been shown to be an 
effective method to insert DNA at a target locus in mammalian cells via the HDR 
pathway (Lee et al., 2015).  
 
Following on from this study, it would be interesting to see the effects of knocking 
out the DAGLs in induced pluripotent stem (iPS) cells, a type of cell that can be 
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generated from adult cells. One caveat of researching in cell lines or in animal 
models is translating the information into human; therefore, if we could determine 
the effects resulting from a lack of DAGL activity in human cells, especially those 
that can differentiate into different cell types, this may give us a better understanding 
of the different functions between DAGLα and DAGLβ that occur in the human. For 
example, we could reintroduce DAGLβ back into these cells followed by 
differentiation into neurons and determine whether DAGLβ is located in post-
synaptic densities, a function associated to the tail in DAGLα. In addition, DAGLα 
could be reintroduced before differentiation into immune cells and determine 
whether they retain anti-inflammatory properties. For example, would DAGLα 
expression in these cells, or a lack of 2-AG production (double KO) result in an 
increase in cytokines, or result in an increase in microglial activation? These 
processes have previously been shown to be suppressed by an increase in 2-AG 
production, via MAGL inhibition (Ramirez et al., 2005; Nomura et al., 2011). 
Similarly, if they were differentiated into macrophages, how would they compare to 
a mouse (RAW 264.7) or human (U937) macrophage cell line, or primary 
animal/human macrophage cells? If one could extrapolate the exact reason for the 
difference in expression and function between DAGLα and DAGLβ then this would 
allow a greater understanding of how the eCB system in regulated, as well as more 
selective therapeutic targeting. 
 
Understanding the different functions as well as their regulatory mechanisms is 
crucial if these enzymes are to become attractive drug targets in the future. If the 
activity of these enzymes can be targeted therapeutically, there is great potential for 
treatment of disease associated with synaptic dysfunction, such as depression or 
obesity. Furthermore, if the elusive cure is discovered for neurodegenerative diseases 
such as Alzheimer’s or Parkinson’s, there will still be a need to repair the damage 
caused in time to diagnosis. The role of the DAGLs in neurogenesis may prove 
crucial in order to generate new neurons to innervate the damaged areas. Finally, as 
they also appear to play a crucial role in regulation of inflammatory processes, the 
DAGLs may also be a target for treatment of diseases where inflammation plays a 
major role, such as in autoimmune disease, or in diseases that contain an 
inflammatory component, such as MS or AD.  
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